<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00853385</url>
  </required_header>
  <id_info>
    <org_study_id>A3921064</org_study_id>
    <nct_id>NCT00853385</nct_id>
  </id_info>
  <brief_title>A Phase 3 Study Comparing 2 Doses Of CP-690,550 And The Active Comparator, Humira (Adalimumab) Vs. Placebo For Treatment Of Rheumatoid Arthritis</brief_title>
  <official_title>Phase 3 Randomized, Double-Blind, Active Comparator, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of CP 690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a comparative study of CP 690,550, Humira (adalimumab) and placebo on background
      methotrexate in patients with Rheumatoid Arthritis. The study is intended to provide evidence
      of the efficacy and safety of CP 690,550 when dosed 5 mg and 10 mg twice a day on background
      methotrexate in adult patients with moderate to severe Rheumatoid Arthritis. It is intended
      to confirm the benefits of CP-690,550 in improving signs and symptoms and physical function
      that were observed in Rheumatoid Arthritis. An active comparator, adalimumab, is also
      included.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Month 6</measure>
    <time_frame>Month 6</time_frame>
    <description>ACR20 response: greater than or equal to (&gt;=) 20% improvement in tender joint count (TJC); &gt;= 20% improvement in swollen joint count (SJC); and &gt;= 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP). For comparison of CP-690,550 with placebo, placebo sequences were combined into single reporting group for Month 6 analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI) at Month 3</measure>
    <time_frame>Baseline, Month 3</time_frame>
    <description>HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; common activities over past week. Each item scored on 4-point scale from 0-3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as sum of domain scores and divided by number of domains answered. Total possible score range 0-3: 0=least difficulty and 3=extreme difficulty. For comparison of CP-690,550 with placebo, placebo sequences were combined into single reporting group for Month 3 analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Disease Activity Score Using 28-Joint Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) Less Than 2.6 at Month 6</measure>
    <time_frame>Month 6</time_frame>
    <description>DAS28-4 (ESR) calculated from SJC and TJC using 28-joint count, erythrocyte sedimentation rate (ESR) (millimeters per hour [mm/hour]) and patient's global assessment (PtGA) of disease activity (transformed score ranging 0 to 10; higher score indicated greater affectation due to disease activity). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-4 (ESR) less than or equal to (&lt;=) 3.2 implied low disease activity and &gt; 3.2 to 5.1 implied moderate to high disease activity, and &lt; 2.6 = remission. For comparison of CP-690,550 with placebo, placebo sequences were combined into single reporting group for Month 6 analysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Month 1 and 3</measure>
    <time_frame>Month 1, 3</time_frame>
    <description>ACR20 response: &gt;=20% improvement in TJC; &gt;= 20% improvement in SJC; and &gt;= 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Month 9 and 12</measure>
    <time_frame>Month 9, 12</time_frame>
    <description>ACR20 response: &gt;=20% improvement in tender joint count; &gt;=20% improvement in swollen joint count; and &gt;=20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response at Month 1, 3 and 6</measure>
    <time_frame>Month 1, 3, 6</time_frame>
    <description>ACR50 response: &gt;=50% improvement in tender joint count; &gt;=50% improvement in swollen joint count; and 50% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response at Month 9 and 12</measure>
    <time_frame>Month 9, 12</time_frame>
    <description>ACR50 response: &gt;=50% improvement in tender joint count; &gt;=50% improvement in swollen joint count; and 50% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response at Month 1, 3 and 6</measure>
    <time_frame>Month 1, 3, 6</time_frame>
    <description>ACR70 response: &gt;=70% improvement in tender joint count; &gt;=70% improvement in swollen joint count; and 70% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response at Month 9 and 12</measure>
    <time_frame>Month 9, 12</time_frame>
    <description>ACR70 response: &gt;=70% improvement in tender joint count; &gt;=70% improvement in swollen joint count; and 70% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Activity Score Using 28-Joint Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Baseline, Month 1, 3 and 6</measure>
    <time_frame>Baseline, Month 1, 3, 6</time_frame>
    <description>DAS28-3 (CRP) was calculated from SJC and TJC using 28 joint count and CRP (milligram per liter [mg/L]). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) =&lt;3.2 implied low disease activity, &gt;3.2 to 5.1 implied moderate to high disease activity and &lt;2.6 implied remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Activity Score Using 28-Joint Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Month 9 and 12</measure>
    <time_frame>Month 9, 12</time_frame>
    <description>DAS28-3 (CRP) was calculated from SJC and TJC using 28 joint count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) =&lt;3.2 implied low disease activity, &gt;3.2 to 5.1 implied moderate to high disease activity and &lt;2.6 implied remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Activity Score Using 28-Joint Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Baseline, Month 1, 3 and 6</measure>
    <time_frame>Baseline, Month 1, 3, 6</time_frame>
    <description>DAS28-4 (ESR) calculated from SJC and TJC using 28 joint count, ESR (mm/hour) and PGA of disease activity (participant rated arthritis activity assessment with transformed score ranging 0 to 10; higher score indicated greater affectation due to disease activity). Total score range:0 to 9.4, higher score indicated more disease activity. DAS28-4 (ESR) =&lt;3.2 implied low disease activity, &gt;3.2 to 5.1 implied moderate to high disease activity and &lt;2.6 implied remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Activity Score Using 28-Joint Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Month 9 and 12</measure>
    <time_frame>Month 9, 12</time_frame>
    <description>DAS28-4 (ESR) calculated from SJC and TJC using 28 joint count, ESR (mm/hour) and PGA of disease activity (participant rated arthritis activity assessment with transformed score ranging 0 to 10; higher score indicated greater affectation due to disease activity). Total score range:0 to 9.4, higher score indicated more disease activity. DAS28-4 (ESR) =&lt;3.2 implied low disease activity, &gt;3.2 to 5.1 implied moderate to high disease activity and &lt;2.6 implied remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Activity Score Using 28-Joint Count and C-Reactive Protein (4 Variables) (DAS28-4 [CRP])</measure>
    <time_frame>Baseline, Month 1, 3, 6, 9, 12</time_frame>
    <description>DAS28-4 [CRP] calculated from SJC and TJC using 28 joint count, CRP (mg/L) and PGA of disease activity (participant rated arthritis activity assessment with transformed score ranging 0 to 10; higher score indicated greater affectation due to disease activity). Total score range:0 to 9.4, higher score indicated more disease activity. DAS28-4 (CRP) =&lt;3.2 implied low disease activity, &gt;3.2 to 5.1 implied moderate to high disease activity and &lt;2.6 implied remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Activity Score Using 28-Joint Count and Erythrocyte Sedimentation Rate (3 Variables) (DAS28-3 [ESR])</measure>
    <time_frame>Baseline, Month 1, 3, 6, 9, 12</time_frame>
    <description>DAS28-3 (ESR) was calculated from SJC and TJC using 28 joint count and ESR (mm/hour). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (ESR) =&lt;3.2 implied low disease activity, &gt;3.2 to 5.1 implied moderate to high disease activity and &lt;2.6 implied remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Assessment Questionnaire-Disability Index (HAQ-DI) at Month 1, 3 and 6</measure>
    <time_frame>Month 1, 3, 6</time_frame>
    <description>HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; common activities over past week. Each item scored on 4-point scale from 0-3:0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as sum of domain scores and divided by number of domains answered. Total possible score range 0-3: 0=least difficulty and 3=extreme difficulty.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Assessment Questionnaire-Disability Index (HAQ-DI) at Month 9 and 12</measure>
    <time_frame>Month 9, 12</time_frame>
    <description>HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; common activities over past week. Each item scored on 4-point scale from 0-3:0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as sum of domain scores and divided by number of domains answered. Total possible score range 0-3: 0=least difficulty and 3=extreme difficulty.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Assessment of Arthritis Pain at Baseline, Month 1, 3 and 6</measure>
    <time_frame>Baseline, Month 1, 3, 6</time_frame>
    <description>Participants rated the severity of arthritis pain on a 0 to 100 millimeter (mm) visual analogue scale (VAS), where 0 mm = no pain and 100 mm = most severe pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Assessment of Arthritis Pain at Month 9 and 12</measure>
    <time_frame>Month 9, 12</time_frame>
    <description>Participants rated the severity of arthritis pain on a 0 to 100 mm VAS, where 0 mm = no pain and 100 mm = most severe pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Assessment (PtGA) of Arthritis Pain at Baseline, Month 1, 3 and 6</measure>
    <time_frame>Baseline, Month 1, 3, 6</time_frame>
    <description>Participants answered: &quot;Considering all the ways your arthritis affects you, how are you feeling today?&quot; Participants responded by using a 0 - 100 mm VAS, where 0 mm = very well and 100 mm = very poorly.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Assessment (PtGA) of Arthritis Pain at Month 9 and 12</measure>
    <time_frame>Month 9, 12</time_frame>
    <description>Participants answered: &quot;Considering all the ways your arthritis affects you, how are you feeling today?&quot; Participants responded by using a 0 - 100 mm VAS, where 0 mm = very well and 100 mm = very poorly.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician Global Assessment (PGA) of Arthritis Pain at Baseline, Month 1, 3 and 6</measure>
    <time_frame>Baseline, Month 1, 3, 6</time_frame>
    <description>Physician global assessment of arthritis was measured on a 0 to 100 mm VAS, where 0 mm = very good and 100 mm = very bad.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician Global Assessment (PGA) of Arthritis Pain at Month 9 and 12</measure>
    <time_frame>Month 9, 12</time_frame>
    <description>Physician Global Assessment of Arthritis was measured on a 0 to 100 mm VAS, where 0 mm = very good and 100 mm = very bad.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>36-Item Short-Form Health Survey (SF-36) at Baseline, Month 1, 3 and 6</measure>
    <time_frame>Baseline, Month 1, 3, 6</time_frame>
    <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and was reported as 2 summary scores; Physical Component Score and Mental Component Score. Total score range for the summary scores = 0-100 where higher scores represented higher level of functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>36-Item Short-Form Health Survey (SF-36) at Month 9 and 12</measure>
    <time_frame>Month 9, 12</time_frame>
    <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and was reported as 2 summary scores; Physical Component Score and Mental Component Score. Total score range for the summary scores = 0-100 where higher scores represented higher level of functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT)-Fatigue Scale at Baseline, Month 1, 3 and 6</measure>
    <time_frame>Baseline, Month 1, 3, 6</time_frame>
    <description>FACIT-Fatigue scale is a 13-item questionnaire. Participant scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as 4 minus the participant's response. The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). A higher score reflected an improvement in the participant's health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT)-Fatigue Scale at Month 12</measure>
    <time_frame>Month 12</time_frame>
    <description>FACIT-Fatigue scale is a 13-item questionnaire. Participant scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as 4 minus the participant's response. The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). A higher score reflected an improvement in the participant's health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medical Outcomes Study-Sleep Scale (MOS-SS) at Baseline, Month 1, 3 and 6</measure>
    <time_frame>Baseline, Month 1, 3, 6</time_frame>
    <description>Participant-rated questionnaire to assess key constructs of sleep over the past week. Consists of a 12-item based on 7 sub scales: sleep disturbance (SD), snoring (Sno), awakened short of breath (ASOB) or with headache, sleep adequacy (Ade), and somnolence (Som) (range:0-100); sleep quantity (Qua)(range:0-24), and optimal (Opt) sleep (yes: 1, no: 0) and nine item index measures of sleep disturbance were constructed to provide composite scores: sleep problem summary (SPS) and overall sleep problems (OSP). Except sleep adequacy, optimal sleep and quantity, higher scores=greater impairment. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range* 100); total score range: 0 to 100; higher score = greater intensity of attribute.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medical Outcomes Study-Sleep Scale (MOS-SS) at Month 12</measure>
    <time_frame>Month 12</time_frame>
    <description>Participant-rated questionnaire to assess key constructs of sleep over the past week. Consists of a 12-item based on 7 sub scales: sleep disturbance (SD), snoring (Sno), awakened short of breath (ASOB) or with headache, sleep adequacy (Ade), and somnolence (Som) (range:0-100); sleep quantity (Qua)(range:0-24), and optimal (Opt) sleep (yes: 1, no: 0) and nine item index measures of sleep disturbance were constructed to provide composite scores: sleep problem summary (SPS) and overall sleep problems (OSP). Except sleep adequacy, optimal sleep and quantity, higher scores=greater impairment. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range* 100); total score range: 0 to 100; higher score = greater intensity of attribute.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Optimal Sleep Assessed Using Medical Outcomes Study-Sleep Scale (MOS-SS) at Baseline, Month 1, 3 and 6</measure>
    <time_frame>Baseline, Month 1, 3, 6</time_frame>
    <description>MOS-SS: participant-rated 12 item questionnaire to assess constructs of sleep over past week. It included 7 subscales: sleep disturbance, snoring, awakened short of breath, sleep adequacy, somnolence, sleep quantity and optimal sleep. Participants responded whether their sleep was optimal or not by choosing yes or no. Number of participants with optimal sleep are reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Optimal Sleep Assessed Using Medical Outcomes Study-Sleep Scale (MOS-SS) at Month 12</measure>
    <time_frame>Month 12</time_frame>
    <description>MOS-SS: participant-rated 12 item questionnaire to assess constructs of sleep over past week. It included 7 subscales: sleep disturbance, snoring, awakened short of breath, sleep adequacy, somnolence, sleep quantity and optimal sleep. Participants responded whether their sleep was optimal or not by choosing yes or no. Number of participants with optimal sleep are reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Euro Quality of Life-5 Dimension (EQ-5D) Health State Profile Utility Score at Baseline, Month 1, 3 and 6</measure>
    <time_frame>Baseline, Month 1, 3, 6</time_frame>
    <description>EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (&quot;confined to bed&quot;). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Euro Quality of Life-5 Dimension (EQ-5D) Health State Profile Utility Score at Month 12</measure>
    <time_frame>Month 12</time_frame>
    <description>EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (&quot;confined to bed&quot;). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Work Limitations Questionnaire (WLQ) Score at Month 3 and 6</measure>
    <time_frame>Month 3, 6</time_frame>
    <description>WLQ: participant-reported 25-item scale to evaluate degree to which health problems interfere with an ability to perform job roles along 4 dimensions: 5-items Time Management scale (TMS); 6-items Physical Demands scale (PDS); 9-items Mental-Interpersonal Demands Scale (MIDS); 5-items Output Demands scale (ODS). All the scales ranged from 0 (limited none of the time) to 100 (limited all of the time). Work Loss Index (WLI), which represented percentage of lost work over time period relative to a normative population, was derived (total score: 0 [no loss] to 100 [complete loss of work]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Work Limitations Questionnaire (WLQ) Score at Baseline and Month 12</measure>
    <time_frame>Baseline, Month 12</time_frame>
    <description>WLQ: participant-reported 25-item scale to evaluate degree to which health problems interfere with an ability to perform job roles along 4 dimensions: 5-items Time Management scale (TMS); 6-items Physical Demands scale (PDS); 9-items Mental-Interpersonal Demands Scale (MIDS); 5-items Output Demands scale (ODS). All the scales ranged from 0 (limited none of the time) to 100 (limited all of the time). Work Loss Index (WLI), which represented percentage of lost work over time period relative to a normative population, was derived (total score: 0 [no loss] to 100 [complete loss of work]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Work Productivity and Healthcare Resource Utilization (HCRU) at Baseline, Month 3 and 6</measure>
    <time_frame>Baseline, Month 3, 6</time_frame>
    <description>Rheumatoid Arthritis (RA)-HCRU assessed healthcare usage during last 3 months for direct, indirect medical cost domains. Direct cost: any RA/non-RA related medical/non-medical (NM) practitioner visit, nursing home, hospital, surgery, emergency room (ER) treatment, diagnostic tests, over-night stay, home healthcare (HC) services, aids/devices used. Indirect costs associated with functional disability: employment status, willingness to work, work disability due to RA, sick leave, part time work, ability to perform chores, chores done by family/friends/housekeeper. Assessment was based on 0 to 2-point scale; higher score indicated higher medical cost.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Work Productivity and Healthcare Resource Utilization (HCRU) at Month 12</measure>
    <time_frame>Month 12</time_frame>
    <description>RA-HCRU assessed healthcare usage during last 3 months for direct, indirect medical cost domains. Direct cost: visit to doctor, NM practitioner, nursing home, hospital, surgery, ER treatment, diagnostic tests, over-night stay, home HC services, and aids/devices used. Indirect costs associated with functional disability: employment status, willingness to work, work disability due to RA, sick leave, part time work, ability to perform chores, chores done by family/friends/housekeeper. Assessment was based on 0 to 2-point scale; higher score indicated higher medical cost.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Events Including Visits, Surgeries, Tests or Devices as Assessed Using RA-HCRU at Baseline, Month 3 and 6</measure>
    <time_frame>Baseline, Month 3, 6</time_frame>
    <description>RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains. Any RA/non-RA related number of events including visits to doctor, non-medical practitioner, hospital ER treatment, hospitalizations, number of surgeries, diagnostic tests, and devices/aids used were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Events Including Visits, Surgeries, Tests or Devices as Assessed Using RA-HCRU at Month 12</measure>
    <time_frame>Month 12</time_frame>
    <description>RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains. Any RA/non-RA related number of events including visits to doctor, non-medical practitioner, hospital ER treatment, hospitalizations, number of surgeries, diagnostic tests, and devices/aids used were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days as Assessed Using RA-HCRU at Baseline, Month 3 and 6</measure>
    <time_frame>Baseline, Month 3, 6</time_frame>
    <description>RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains. Any RA or non-RA related number of days spent in hospital, nursing home, aids/devices used, on sick leave, work per week, performed part time work, performed paid work, chores done by housekeeper and chores done by family/friends.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days as Assessed Using RA-HCRU at Month 12</measure>
    <time_frame>Month 12</time_frame>
    <description>RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains. Any RA or non-RA related number of days spent in hospital, nursing home, aids/devices used, on sick leave, work per week, performed part time work, performed paid work, chores done by housekeeper and chores done by family/friends.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Hours Per Day as Assessed RA-HCRU at Baseline, Month 3 and 6</measure>
    <time_frame>Baseline, Month 3, 6</time_frame>
    <description>RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains. Any RA or non-RA related number of hours spent per day for home healthcare services, chores done by housekeeper, chores done by family or friends, hours affected per day and average number of hours missed work per day were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Hours Per Day as Assessed RA-HCRU at Month 12</measure>
    <time_frame>Month 12</time_frame>
    <description>RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains. Any RA or non-RA related number of hours spent per day for home healthcare services, chores done by housekeeper, chores done by family or friends, hours affected per day and average number of hours missed work per day were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Work Performance in Past 3 Months on Days Bothered as Assessed Using RA-HCRU at Baseline, Month 3 and 6</measure>
    <time_frame>Baseline, Month 3, 6</time_frame>
    <description>Work performance of participants on number of days bothered was based on 10-point scale, where higher score indicated lower work performance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Work Performance in Past 3 Months on Days Bothered as Assessed Using RA-HCRU at Month 12</measure>
    <time_frame>Month 12</time_frame>
    <description>Work performance of participants on number of days bothered was based on 10-point scale, where higher score indicated lower work performance.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">717</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Sequence 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Sequence 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>adalimumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CP 690,550</intervention_name>
    <description>tablets 5 mg BID PO plus q2 week placebo SC injections for 12 months</description>
    <arm_group_label>5mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CP-690,550</intervention_name>
    <description>tablets 10 mg BID PO plus q2 week placebo SC injections for 12 months</description>
    <arm_group_label>10 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo tablets BID PO advance to 5mg CP 690,550 BID at Month 3 or 6 visit plus q2 week placebo SC injections for 12 months</description>
    <arm_group_label>Placebo Sequence 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>tablets BID PO advance tablets to10mg CP 690,550 BID at Month 3 or 6 visit plus q2 week placebo SC injections for 12 months</description>
    <arm_group_label>Placebo Sequence 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Biologic TNFi</intervention_name>
    <description>placebo tablets BID PO plus adalimumab 40 mg q2 week SC injections for 12 months</description>
    <arm_group_label>adalimumab</arm_group_label>
    <other_name>Humira (Adalimumab)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient has a diagnosis of RA based upon the American College of Rheumatology
             (ACR) 1987 Revised Criteria.

          -  The patient must have had an inadequate response to methotrexate and have active
             disease, as defined by both: ≥6 joints tender or painful on motion; and ≥6 joints
             swollen; and fulfills 1 of the following 2 criteria at Screening: 1.ESR (Westergren
             method) &gt;28 mm in the local laboratory. 2. CRP &gt;7 mg/L in the central laboratory.

          -  No evidence of active or latent or inadequately treated infection with Mycobacterium
             tuberculosis.

          -  The patient must have been on a stable dose of 7.5 mg to 25 mg weekly of methotrexate
             and washed out of all other DMARDs.

        Exclusion Criteria:

          -  Blood dyscrasias including confirmed: 1. Hemoglobin &lt;9 g/dL or Hematocrit &lt;30%; 2.
             White blood cell count &lt;3,000 cu.mm. Absolute neutrophil count &lt;1,200 cu.mm; 4.
             Platelet count &lt;100,000/L

          -  History of any other autoimmune rheumatic disease other than Sjogren's syndrome

          -  No malignancy or history of malignancy.

          -  History of infection requiring hospitalization, parenteral antimicrobial therapy, or
             as otherwise judged clinically significant by the investigator, within the 6 months
             prior to the first dose of study drug

          -  Patients who have failed any TNFi for either lack of efficacy or a TNFi mechanism
             related adverse event.

          -  Patients who have previously received adalimumab therapy for any reason.

          -  Patients who are contraindicated for treatment with adalimumab in accordance with the
             approved local label.

          -  Patients meeting the New York Heart Association Class III and Class IV Congestive
             Heart failure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Paradise Valley</city>
        <state>Arizona</state>
        <zip>85253</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <zip>72401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Fair Oaks</city>
        <state>California</state>
        <zip>95628</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <zip>80304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Largo</city>
        <state>Florida</state>
        <zip>33777</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <zip>34102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <zip>34684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Pinellas Park</city>
        <state>Florida</state>
        <zip>33782</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <state>Florida</state>
        <zip>33710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Rockford</city>
        <state>Illinois</state>
        <zip>61107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40515</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Haverhill</city>
        <state>Massachusetts</state>
        <zip>01830</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49546</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79424</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Mesquite</city>
        <state>Texas</state>
        <zip>75150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Clarksburg</city>
        <state>West Virginia</state>
        <zip>26301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>St Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cairns</city>
        <state>Queensland</state>
        <zip>4870</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Maroochydore</city>
        <state>Queensland</state>
        <zip>4558</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Malvern East</city>
        <state>Victoria</state>
        <zip>3145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sarajevo</city>
        <zip>71000</zip>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Plovdiv</city>
        <zip>4000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Plovdiv</city>
        <zip>4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sevlievo</city>
        <zip>5400</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sofia</city>
        <zip>1709</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1L7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lunenburg</city>
        <state>Nova Scotia</state>
        <zip>B0J 2C0</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4V2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L5M 2V8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Trois-Rivieres</city>
        <state>Quebec</state>
        <zip>G8Z 1Y2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 0W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Quebec</city>
        <zip>G1W 4R4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Santiago</city>
        <state>RM</state>
        <zip>7510186</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Santiago</city>
        <state>RM</state>
        <zip>8360156</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Providencia</city>
        <state>Santiago, RM</state>
        <zip>7530206</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Rancagua</city>
        <state>VI Region</state>
        <zip>2841959</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cartago</city>
        <country>Costa Rica</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>San Jose</city>
        <zip>00</zip>
        <country>Costa Rica</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>San Jose</city>
        <country>Costa Rica</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Osijek</city>
        <zip>31000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Split</city>
        <zip>21000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Brno - Zidenice</city>
        <zip>615 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Brno</city>
        <zip>60200</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Brno</city>
        <zip>656 91</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Brno</city>
        <zip>65691</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hlucin</city>
        <zip>748 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Pardubice</city>
        <zip>530 02</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Praha 11 - Chodov</city>
        <zip>148 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Praha 11</city>
        <zip>14800</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Praha 2</city>
        <zip>128 50</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Praha 4</city>
        <zip>140 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Zlin</city>
        <zip>760 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Frederiksberg</city>
        <zip>2000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Randers NOE</city>
        <zip>8930</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Santo Domingo</city>
        <zip>00000</zip>
        <country>Dominican Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hyvinkaa</city>
        <zip>05800</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Aachen</city>
        <zip>52064</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>14059</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Halle</city>
        <zip>06108</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Halle</city>
        <zip>06128</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Herne</city>
        <zip>44652</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Ratingen</city>
        <zip>40882</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Wuerzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Daegu</city>
        <zip>705-718</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Gwangju</city>
        <zip>501-757</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>133-792</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Mexico</city>
        <state>DF</state>
        <zip>10700</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44620</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Morelia</city>
        <state>Michoacan</state>
        <zip>58249</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>San Luis Potosi</city>
        <state>SLP</state>
        <zip>78240</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lipa City</city>
        <state>Batangas</state>
        <zip>4217</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Angeles City</city>
        <state>Pampanga</state>
        <zip>2009</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cebu City</city>
        <zip>6000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bialystok</city>
        <zip>15-337</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cieszyn</city>
        <zip>43-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Koscian</city>
        <zip>64-000</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Krakow</city>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sopot</city>
        <zip>81-759</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Torun</city>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02-118</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bratislava</city>
        <zip>82606</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dunajska Streda</city>
        <zip>92901</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kosice</city>
        <zip>040 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Nove Zamky</city>
        <zip>94001</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Povazska Dystrica</city>
        <zip>017 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Zilina</city>
        <zip>010 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>A Coruña</state>
        <zip>15705</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Vigo</city>
        <state>Pontevedra</state>
        <zip>36200</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>A Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Rajathevee</city>
        <state>Bangkok</state>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Amphoe Muang</city>
        <state>Chiang Mai</state>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Wirral</city>
        <state>Merseyside</state>
        <zip>CH49 5PE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cannock</city>
        <state>Staffs</state>
        <zip>WS11 2XY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dudley, West Midlands</city>
        <zip>DY1 2HQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Bosnia and Herzegovina</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Costa Rica</country>
    <country>Croatia</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Dominican Republic</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Thailand</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3921064&amp;StudyName=A%20Phase%203%20Study%20Comparing%202%20Doses%20Of%20CP-690%2C550%20And%20The%20Active%20Comparator%2C%20Humira%20%28adalimumab%29%20Vs.%20Placebo%20For%20Treatment%20Of%20Rh</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 27, 2009</study_first_submitted>
  <study_first_submitted_qc>February 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2009</study_first_posted>
  <results_first_submitted>December 4, 2012</results_first_submitted>
  <results_first_submitted_qc>December 4, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 9, 2013</results_first_posted>
  <disposition_first_submitted>November 5, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>November 5, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">November 7, 2012</disposition_first_posted>
  <last_update_submitted>January 10, 2013</last_update_submitted>
  <last_update_submitted_qc>January 10, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>oral DMARD</keyword>
  <keyword>JAK inhibitor</keyword>
  <keyword>clinical trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
    <mesh_term>Tofacitinib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>CP-690,550 5 mg</title>
          <description>CP-690,550 5 milligram (mg) tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
        </group>
        <group group_id="P2">
          <title>CP-690,550 10 mg</title>
          <description>CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
        </group>
        <group group_id="P3">
          <title>Placebo, Then CP-690,550 5 mg</title>
          <description>Placebo matched to CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week, for 3 to 6 months. Response was assessed at Month 3 and participants who failed to achieve a minimum improvement of at least 20 percent (%) reduction in both swollen and tender joint counts from baseline, received CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12. At Month 6, remaining participants advanced to CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
        </group>
        <group group_id="P4">
          <title>Placebo, Then CP-690,550 10 mg</title>
          <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week, for 3 to 6 months. Response was assessed at Month 3 and participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts from baseline, received CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12. At Month 6, remaining participants advanced to CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
        </group>
        <group group_id="P5">
          <title>Adalimumab</title>
          <description>Adalimumab 40 mg injection subcutaneously once every other week along with placebo matched to CP-690,550 5 mg tablet orally twice daily up to Month 12.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="204"/>
                <participants group_id="P2" count="201"/>
                <participants group_id="P3" count="56"/>
                <participants group_id="P4" count="52"/>
                <participants group_id="P5" count="204"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="150"/>
                <participants group_id="P2" count="158"/>
                <participants group_id="P3" count="47"/>
                <participants group_id="P4" count="39"/>
                <participants group_id="P5" count="162"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="43"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="13"/>
                <participants group_id="P5" count="42"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CP-690,550 5 mg</title>
          <description>CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
        </group>
        <group group_id="B2">
          <title>CP-690,550 10 mg</title>
          <description>CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
        </group>
        <group group_id="B3">
          <title>Placebo, Then CP-690,550 5 mg</title>
          <description>Placebo matched to CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week, for 3 to 6 months. Response was assessed at Month 3 and participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts from baseline, received CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12. At Month 6, remaining participants advanced to CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
        </group>
        <group group_id="B4">
          <title>Placebo, Then CP-690,550 10 mg</title>
          <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week, for 3 to 6 months. Response was assessed at Month 3 and participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts from baseline, received CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12. At Month 6, remaining participants advanced to CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
        </group>
        <group group_id="B5">
          <title>Adalimumab</title>
          <description>Adalimumab 40 mg injection subcutaneously once every other week along with placebo matched to CP-690,550 5 mg tablet orally twice daily up to Month 12.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="204"/>
            <count group_id="B2" value="201"/>
            <count group_id="B3" value="56"/>
            <count group_id="B4" value="52"/>
            <count group_id="B5" value="204"/>
            <count group_id="B6" value="717"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.0" spread="11.9"/>
                    <measurement group_id="B2" value="52.9" spread="11.8"/>
                    <measurement group_id="B3" value="55.5" spread="13.7"/>
                    <measurement group_id="B4" value="51.9" spread="13.7"/>
                    <measurement group_id="B5" value="52.5" spread="11.7"/>
                    <measurement group_id="B6" value="52.9" spread="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="174"/>
                    <measurement group_id="B2" value="168"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="39"/>
                    <measurement group_id="B5" value="162"/>
                    <measurement group_id="B6" value="586"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="42"/>
                    <measurement group_id="B6" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Month 6</title>
        <description>ACR20 response: greater than or equal to (&gt;=) 20% improvement in tender joint count (TJC); &gt;= 20% improvement in swollen joint count (SJC); and &gt;= 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP). For comparison of CP-690,550 with placebo, placebo sequences were combined into single reporting group for Month 6 analysis.</description>
        <time_frame>Month 6</time_frame>
        <population>Full analysis set: all randomized participants who received &gt;=1 dose and had &gt;=1 post-baseline and baseline measurement (change from baseline endpoint). N(number of participants analyzed)=participants evaluable for this measure. Missing values due to withdrawal advancement to active treatment before Month 6 were imputed by non-responder imputation.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week for 3 to 6 months. Response was assessed at Month 3 and participants who failed to achieve at least 20% reduction from baseline in both swollen and tender joint counts, received CP-690,550 5 mg or 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12. At Month 6, remaining participants received CP-690,550 5 mg or 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O4">
            <title>Adalimumab</title>
            <description>Adalimumab 40 mg injection subcutaneously once every other week along with placebo matched to CP-690,550 5 mg tablet orally twice daily up to Month 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Month 6</title>
          <description>ACR20 response: greater than or equal to (&gt;=) 20% improvement in tender joint count (TJC); &gt;= 20% improvement in swollen joint count (SJC); and &gt;= 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP). For comparison of CP-690,550 with placebo, placebo sequences were combined into single reporting group for Month 6 analysis.</description>
          <population>Full analysis set: all randomized participants who received &gt;=1 dose and had &gt;=1 post-baseline and baseline measurement (change from baseline endpoint). N(number of participants analyzed)=participants evaluable for this measure. Missing values due to withdrawal advancement to active treatment before Month 6 were imputed by non-responder imputation.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="196"/>
                <count group_id="O2" value="196"/>
                <count group_id="O3" value="106"/>
                <count group_id="O4" value="199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.53"/>
                    <measurement group_id="O2" value="52.55"/>
                    <measurement group_id="O3" value="28.30"/>
                    <measurement group_id="O4" value="47.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Normal approximation for the difference in binomial proportions was used to test the superiority of CP-690,550 10 mg to placebo and 2-sided 95% confidence interval (CI) was evaluated for the difference in percentages.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>A step-down procedure was used to control for multiple comparisons. In order for the comparison to 5 mg to be statistically significant, the comparison to 10 mg had to be statistically significant.</p_value_desc>
            <method>Normal approximation</method>
            <param_type>Percent difference</param_type>
            <param_value>24.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>13.18</ci_lower_limit>
            <ci_upper_limit>35.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Normal approximation for the difference in binomial proportions was used to test the superiority of CP-690,550 5 mg to placebo and 2-sided 95% CI was evaluated for the difference in percentages.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>A step-down procedure was used to control for multiple comparisons. In order for the comparison to 5 mg to be statistically significant, the comparison to 10 mg had to be statistically significant.</p_value_desc>
            <method>Normal approximation</method>
            <param_type>Percent difference</param_type>
            <param_value>23.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>12.16</ci_lower_limit>
            <ci_upper_limit>34.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Normal approximation for the difference in binomial proportions was used to test the superiority of adalimumab to placebo and 2-sided 95% CI was evaluated for the difference in percentages.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0007</p_value>
            <p_value_desc>Statistical testing was done at 5% significance level (2-sided).</p_value_desc>
            <method>Normal approximation</method>
            <param_type>Percent difference</param_type>
            <param_value>18.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.90</ci_lower_limit>
            <ci_upper_limit>29.96</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI) at Month 3</title>
        <description>HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; common activities over past week. Each item scored on 4-point scale from 0-3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as sum of domain scores and divided by number of domains answered. Total possible score range 0-3: 0=least difficulty and 3=extreme difficulty. For comparison of CP-690,550 with placebo, placebo sequences were combined into single reporting group for Month 3 analysis.</description>
        <time_frame>Baseline, Month 3</time_frame>
        <population>Full analysis set (FAS): all randomized participants who received at least 1 dose of study drug and had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). n=number of participants evaluable at specific time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week for 3 to 6 months. Response was assessed at Month 3 and participants who failed to achieve at least 20% reduction from baseline in both swollen and tender joint counts, received CP-690,550 5 mg or 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12. At Month 6, remaining participants received CP-690,550 5 mg or 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O4">
            <title>Adalimumab</title>
            <description>Adalimumab 40 mg injection subcutaneously once every other week along with placebo matched to CP-690,550 5 mg tablet orally twice daily up to Month 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI) at Month 3</title>
          <description>HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; common activities over past week. Each item scored on 4-point scale from 0-3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as sum of domain scores and divided by number of domains answered. Total possible score range 0-3: 0=least difficulty and 3=extreme difficulty. For comparison of CP-690,550 with placebo, placebo sequences were combined into single reporting group for Month 3 analysis.</description>
          <population>Full analysis set (FAS): all randomized participants who received at least 1 dose of study drug and had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). n=number of participants evaluable at specific time points for each arm group, respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="199"/>
                <count group_id="O3" value="106"/>
                <count group_id="O4" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=201, 199, 106, 201)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" spread="0.64"/>
                    <measurement group_id="O2" value="1.53" spread="0.63"/>
                    <measurement group_id="O3" value="1.42" spread="0.68"/>
                    <measurement group_id="O4" value="1.50" spread="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 (n=188, 185, 98, 190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.49" spread="0.59"/>
                    <measurement group_id="O2" value="-0.59" spread="0.58"/>
                    <measurement group_id="O3" value="-0.17" spread="0.56"/>
                    <measurement group_id="O4" value="-0.45" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Least squares (LS) mean difference and corresponding 95% CI was calculated using a mixed-effect repeated measure model with treatment, visit and treatment-by-visit interaction as fixed effect and participant as random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>A step-down procedure was used to control for multiple comparisons. For the comparison of 10 mg to placebo to be statistically significant in this measure, the comparison of 10 mg to placebo in ACR20 had to be significant.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LS mean difference</param_type>
            <param_value>-0.38</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.06</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.50</ci_lower_limit>
            <ci_upper_limit>-0.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>LS mean difference and corresponding 95% CI was calculated using a mixed-effect repeated measure model with treatment, visit and treatment-by-visit interaction as fixed effect and participant as random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Step-down procedure: For the comparison of 5 mg to placebo to be statistically significant in this measure, the comparison of 10 mg to placebo as well as the comparison of 5 mg to placebo in ACR20 had to be statistically significant.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LS mean difference</param_type>
            <param_value>-0.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.43</ci_lower_limit>
            <ci_upper_limit>-0.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>LS mean difference and corresponding 95% CI was calculated using a mixed-effect repeated measure model with treatment, visit and treatment-by-visit interaction as fixed effect and participant as random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Statistical testing was done at 5% significance level (2-sided).</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LS mean difference</param_type>
            <param_value>-0.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.37</ci_lower_limit>
            <ci_upper_limit>-0.13</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Disease Activity Score Using 28-Joint Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) Less Than 2.6 at Month 6</title>
        <description>DAS28-4 (ESR) calculated from SJC and TJC using 28-joint count, erythrocyte sedimentation rate (ESR) (millimeters per hour [mm/hour]) and patient's global assessment (PtGA) of disease activity (transformed score ranging 0 to 10; higher score indicated greater affectation due to disease activity). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-4 (ESR) less than or equal to (&lt;=) 3.2 implied low disease activity and &gt; 3.2 to 5.1 implied moderate to high disease activity, and &lt; 2.6 = remission. For comparison of CP-690,550 with placebo, placebo sequences were combined into single reporting group for Month 6 analysis.</description>
        <time_frame>Month 6</time_frame>
        <population>FAS: all randomized participants who received at least 1 dose of study drug and had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). N=participants evaluable for this measure. Missing values due to withdrawal advancement to active treatment before Month 6 were imputed using non-responder imputation (NRI).</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week for 3 to 6 months. Response was assessed at Month 3 and participants who failed to achieve at least 20% reduction from baseline in both swollen and tender joint counts, received CP-690,550 5 mg or 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12. At Month 6, remaining participants received CP-690,550 5 mg or 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O4">
            <title>Adalimumab</title>
            <description>Adalimumab 40 mg injection subcutaneously once every other week along with placebo matched to CP-690,550 5 mg tablet orally twice daily up to Month 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Disease Activity Score Using 28-Joint Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) Less Than 2.6 at Month 6</title>
          <description>DAS28-4 (ESR) calculated from SJC and TJC using 28-joint count, erythrocyte sedimentation rate (ESR) (millimeters per hour [mm/hour]) and patient's global assessment (PtGA) of disease activity (transformed score ranging 0 to 10; higher score indicated greater affectation due to disease activity). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-4 (ESR) less than or equal to (&lt;=) 3.2 implied low disease activity and &gt; 3.2 to 5.1 implied moderate to high disease activity, and &lt; 2.6 = remission. For comparison of CP-690,550 with placebo, placebo sequences were combined into single reporting group for Month 6 analysis.</description>
          <population>FAS: all randomized participants who received at least 1 dose of study drug and had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). N=participants evaluable for this measure. Missing values due to withdrawal advancement to active treatment before Month 6 were imputed using non-responder imputation (NRI).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
                <count group_id="O2" value="176"/>
                <count group_id="O3" value="92"/>
                <count group_id="O4" value="178"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.21"/>
                    <measurement group_id="O2" value="12.50"/>
                    <measurement group_id="O3" value="1.09"/>
                    <measurement group_id="O4" value="6.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Normal approximation to the binomial distribution was used to test the superiority of CP-690,550 10 mg to placebo and two-sided 95% CI was evaluated for the difference in percentages.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>A step-down procedure was used to control for multiple comparisons. For comparison of 10 mg to placebo to be statistically significant in this measure, comparison of 10 mg to placebo in HAQ-DI had to be significant.</p_value_desc>
            <method>Normal approximation</method>
            <param_type>Percent difference</param_type>
            <param_value>11.41</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.08</ci_lower_limit>
            <ci_upper_limit>16.73</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Normal approximation for the difference in binomial proportions was used to test the superiority of CP-690,550 5 mg to placebo and 2-sided 95% CI was evaluated for the difference in percentages.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0151</p_value>
            <p_value_desc>Step-down procedure: For the comparison of 5 mg to placebo to be statistically significant in this measure, the comparison of 10 mg to placebo as well as comparison of 5 mg to placebo in HAQ-DI had to be statistically significant.</p_value_desc>
            <method>Normal approximation</method>
            <param_type>Percent difference</param_type>
            <param_value>5.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.98</ci_lower_limit>
            <ci_upper_limit>9.26</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Normal approximation for the difference in binomial proportions was used to test the superiority of adalimumab to placebo and 2-sided 95% CI was evaluated for the difference in percentages.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0091</p_value>
            <p_value_desc>Statistical testing was done at 5% significance level (2-sided).</p_value_desc>
            <method>Normal approximation</method>
            <param_type>Percent difference</param_type>
            <param_value>5.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.40</ci_lower_limit>
            <ci_upper_limit>9.90</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Month 1 and 3</title>
        <description>ACR20 response: &gt;=20% improvement in TJC; &gt;= 20% improvement in SJC; and &gt;= 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.</description>
        <time_frame>Month 1, 3</time_frame>
        <population>FAS: all randomized participants who received at least 1 dose of study drug and had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). N=participants evaluable for this measure. Missing values due to withdrawal advancement to active treatment before Month 6 were imputed using NRI.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week for 3 to 6 months. Response was assessed at Month 3 and participants who failed to achieve at least 20% reduction from baseline in both swollen and tender joint counts, received CP-690,550 5 mg or 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12. At Month 6, remaining participants received CP-690,550 5 mg or 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O4">
            <title>Adalimumab</title>
            <description>Adalimumab 40 mg injection subcutaneously once every other week along with placebo matched to CP-690,550 5 mg tablet orally twice daily up to Month 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Month 1 and 3</title>
          <description>ACR20 response: &gt;=20% improvement in TJC; &gt;= 20% improvement in SJC; and &gt;= 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.</description>
          <population>FAS: all randomized participants who received at least 1 dose of study drug and had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). N=participants evaluable for this measure. Missing values due to withdrawal advancement to active treatment before Month 6 were imputed using NRI.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="196"/>
                <count group_id="O2" value="196"/>
                <count group_id="O3" value="106"/>
                <count group_id="O4" value="199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.24"/>
                    <measurement group_id="O2" value="45.92"/>
                    <measurement group_id="O3" value="16.04"/>
                    <measurement group_id="O4" value="37.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.71"/>
                    <measurement group_id="O2" value="58.67"/>
                    <measurement group_id="O3" value="26.42"/>
                    <measurement group_id="O4" value="56.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Month 9 and 12</title>
        <description>ACR20 response: &gt;=20% improvement in tender joint count; &gt;=20% improvement in swollen joint count; and &gt;=20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.</description>
        <time_frame>Month 9, 12</time_frame>
        <population>FAS: all randomized participants who received at least 1 dose of study drug and had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). N=participants evaluable for this measure. Missing values due to withdrawal advancement to active treatment before Month 6 were imputed using NRI.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Then CP-690,550 5 mg</title>
            <description>Placebo matched to CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week, for 3 to 6 months. Response was assessed at Month 3 and participants who failed to achieve a minimum improvement of at least 20 percent (%) reduction in both swollen and tender joint counts from baseline, received CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12. At Month 6, remaining participants advanced to CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, Then CP-690,550 10 mg</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week, for 3 to 6 months. Response was assessed at Month 3 and participants who failed to achieve a minimum improvement of at least 20 percent (%) reduction in both swollen and tender joint counts from baseline, received CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12. At Month 6, remaining participants advanced to CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O5">
            <title>Adalimumab</title>
            <description>Adalimumab 40 mg injection subcutaneously once every other week along with placebo matched to CP-690,550 5 mg tablet orally twice daily up to Month 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Month 9 and 12</title>
          <description>ACR20 response: &gt;=20% improvement in tender joint count; &gt;=20% improvement in swollen joint count; and &gt;=20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.</description>
          <population>FAS: all randomized participants who received at least 1 dose of study drug and had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). N=participants evaluable for this measure. Missing values due to withdrawal advancement to active treatment before Month 6 were imputed using NRI.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="196"/>
                <count group_id="O2" value="196"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.49"/>
                    <measurement group_id="O2" value="50.51"/>
                    <measurement group_id="O3" value="30.36"/>
                    <measurement group_id="O4" value="36.00"/>
                    <measurement group_id="O5" value="47.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.49"/>
                    <measurement group_id="O2" value="49.49"/>
                    <measurement group_id="O3" value="33.93"/>
                    <measurement group_id="O4" value="34.00"/>
                    <measurement group_id="O5" value="49.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response at Month 1, 3 and 6</title>
        <description>ACR50 response: &gt;=50% improvement in tender joint count; &gt;=50% improvement in swollen joint count; and 50% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.</description>
        <time_frame>Month 1, 3, 6</time_frame>
        <population>FAS: all randomized participants who received at least 1 dose of study drug and had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). N=participants evaluable for this measure. Missing values due to withdrawal advancement to active treatment before Month 6 were imputed using NRI.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week for 3 to 6 months. Response was assessed at Month 3 and participants who failed to achieve at least 20% reduction from baseline in both swollen and tender joint counts, received CP-690,550 5 mg or 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12. At Month 6, remaining participants received CP-690,550 5 mg or 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O4">
            <title>Adalimumab</title>
            <description>Adalimumab 40 mg injection subcutaneously once every other week along with placebo matched to CP-690,550 5 mg tablet orally twice daily up to Month 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response at Month 1, 3 and 6</title>
          <description>ACR50 response: &gt;=50% improvement in tender joint count; &gt;=50% improvement in swollen joint count; and 50% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.</description>
          <population>FAS: all randomized participants who received at least 1 dose of study drug and had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). N=participants evaluable for this measure. Missing values due to withdrawal advancement to active treatment before Month 6 were imputed using NRI.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="196"/>
                <count group_id="O2" value="196"/>
                <count group_id="O3" value="106"/>
                <count group_id="O4" value="199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.95"/>
                    <measurement group_id="O2" value="16.33"/>
                    <measurement group_id="O3" value="4.72"/>
                    <measurement group_id="O4" value="12.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.18"/>
                    <measurement group_id="O2" value="27.55"/>
                    <measurement group_id="O3" value="6.60"/>
                    <measurement group_id="O4" value="23.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.73"/>
                    <measurement group_id="O2" value="34.69"/>
                    <measurement group_id="O3" value="12.26"/>
                    <measurement group_id="O4" value="27.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response at Month 9 and 12</title>
        <description>ACR50 response: &gt;=50% improvement in tender joint count; &gt;=50% improvement in swollen joint count; and 50% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.</description>
        <time_frame>Month 9, 12</time_frame>
        <population>FAS: all randomized participants who received at least 1 dose of study drug and had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). N=participants evaluable for this measure. Missing values due to withdrawal advancement to active treatment before Month 6 were imputed using NRI.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Then CP-690,550 5 mg</title>
            <description>Placebo matched to CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week, for 3 to 6 months. Response was assessed at Month 3 and participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts from baseline, received CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12. At Month 6, remaining participants advanced to CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, Then CP-690,550 10 mg</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week, for 3 to 6 months. Response was assessed at Month 3 and participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts from baseline, received CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12. At Month 6, remaining participants advanced to CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O5">
            <title>Adalimumab</title>
            <description>Adalimumab 40 mg injection subcutaneously once every other week along with placebo matched to CP-690,550 5 mg tablet orally twice daily up to Month 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response at Month 9 and 12</title>
          <description>ACR50 response: &gt;=50% improvement in tender joint count; &gt;=50% improvement in swollen joint count; and 50% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.</description>
          <population>FAS: all randomized participants who received at least 1 dose of study drug and had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). N=participants evaluable for this measure. Missing values due to withdrawal advancement to active treatment before Month 6 were imputed using NRI.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="196"/>
                <count group_id="O2" value="196"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.71"/>
                    <measurement group_id="O2" value="37.24"/>
                    <measurement group_id="O3" value="17.86"/>
                    <measurement group_id="O4" value="26.00"/>
                    <measurement group_id="O5" value="29.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.73"/>
                    <measurement group_id="O2" value="35.71"/>
                    <measurement group_id="O3" value="21.43"/>
                    <measurement group_id="O4" value="28.00"/>
                    <measurement group_id="O5" value="33.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response at Month 1, 3 and 6</title>
        <description>ACR70 response: &gt;=70% improvement in tender joint count; &gt;=70% improvement in swollen joint count; and 70% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.</description>
        <time_frame>Month 1, 3, 6</time_frame>
        <population>FAS: all randomized participants who received at least 1 dose of study drug and had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). N=participants evaluable for this measure. Missing values due to withdrawal advancement to active treatment before Month 6 were imputed using NRI.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week for 3 to 6 months. Response was assessed at Month 3 and participants who failed to achieve at least 20% reduction from baseline in both swollen and tender joint counts, received CP-690,550 5 mg or 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12. At Month 6, remaining participants received CP-690,550 5 mg or 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O4">
            <title>Adalimumab</title>
            <description>Adalimumab 40 mg injection subcutaneously once every other week along with placebo matched to CP-690,550 5 mg tablet orally twice daily up to Month 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response at Month 1, 3 and 6</title>
          <description>ACR70 response: &gt;=70% improvement in tender joint count; &gt;=70% improvement in swollen joint count; and 70% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.</description>
          <population>FAS: all randomized participants who received at least 1 dose of study drug and had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). N=participants evaluable for this measure. Missing values due to withdrawal advancement to active treatment before Month 6 were imputed using NRI.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="196"/>
                <count group_id="O2" value="196"/>
                <count group_id="O3" value="106"/>
                <count group_id="O4" value="199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.58"/>
                    <measurement group_id="O2" value="4.08"/>
                    <measurement group_id="O3" value="0.94"/>
                    <measurement group_id="O4" value="3.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.24"/>
                    <measurement group_id="O2" value="14.80"/>
                    <measurement group_id="O3" value="1.89"/>
                    <measurement group_id="O4" value="8.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.90"/>
                    <measurement group_id="O2" value="21.94"/>
                    <measurement group_id="O3" value="1.89"/>
                    <measurement group_id="O4" value="9.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response at Month 9 and 12</title>
        <description>ACR70 response: &gt;=70% improvement in tender joint count; &gt;=70% improvement in swollen joint count; and 70% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.</description>
        <time_frame>Month 9, 12</time_frame>
        <population>FAS: all randomized participants who received at least 1 dose of study drug and had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). N=participants evaluable for this measure. Missing values due to withdrawal advancement to active treatment before Month 6 were imputed using NRI.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Then CP-690,550 5 mg</title>
            <description>Placebo matched to CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week, for 3 to 6 months. Response was assessed at Month 3 and participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts from baseline, received CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12. At Month 6, remaining participants advanced to CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, Then CP-690,550 10 mg</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week, for 3 to 6 months. Response was assessed at Month 3 and participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts from baseline, received CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12. At Month 6, remaining participants advanced to CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O5">
            <title>Adalimumab</title>
            <description>Adalimumab 40 mg injection subcutaneously once every other week along with placebo matched to CP-690,550 5 mg tablet orally twice daily up to Month 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response at Month 9 and 12</title>
          <description>ACR70 response: &gt;=70% improvement in tender joint count; &gt;=70% improvement in swollen joint count; and 70% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.</description>
          <population>FAS: all randomized participants who received at least 1 dose of study drug and had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). N=participants evaluable for this measure. Missing values due to withdrawal advancement to active treatment before Month 6 were imputed using NRI.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="196"/>
                <count group_id="O2" value="196"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.37"/>
                    <measurement group_id="O2" value="21.94"/>
                    <measurement group_id="O3" value="8.93"/>
                    <measurement group_id="O4" value="10.00"/>
                    <measurement group_id="O5" value="11.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.96"/>
                    <measurement group_id="O2" value="23.47"/>
                    <measurement group_id="O3" value="10.71"/>
                    <measurement group_id="O4" value="14.00"/>
                    <measurement group_id="O5" value="16.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Activity Score Using 28-Joint Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Baseline, Month 1, 3 and 6</title>
        <description>DAS28-3 (CRP) was calculated from SJC and TJC using 28 joint count and CRP (milligram per liter [mg/L]). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) =&lt;3.2 implied low disease activity, &gt;3.2 to 5.1 implied moderate to high disease activity and &lt;2.6 implied remission.</description>
        <time_frame>Baseline, Month 1, 3, 6</time_frame>
        <population>FAS: all randomized participants who received at least 1 dose of study drug and had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). N=participants evaluable for this measure. n=number of participants evaluable at specific time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week for 3 to 6 months. Response was assessed at Month 3 and participants who failed to achieve at least 20% reduction from baseline in both swollen and tender joint counts, received CP-690,550 5 mg or 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12. At Month 6, remaining participants received CP-690,550 5 mg or 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O4">
            <title>Adalimumab</title>
            <description>Adalimumab 40 mg injection subcutaneously once every other week along with placebo matched to CP-690,550 5 mg tablet orally twice daily up to Month 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Activity Score Using 28-Joint Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Baseline, Month 1, 3 and 6</title>
          <description>DAS28-3 (CRP) was calculated from SJC and TJC using 28 joint count and CRP (milligram per liter [mg/L]). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) =&lt;3.2 implied low disease activity, &gt;3.2 to 5.1 implied moderate to high disease activity and &lt;2.6 implied remission.</description>
          <population>FAS: all randomized participants who received at least 1 dose of study drug and had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). N=participants evaluable for this measure. n=number of participants evaluable at specific time points for each arm group, respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
                <count group_id="O2" value="199"/>
                <count group_id="O3" value="106"/>
                <count group_id="O4" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=200, 199, 106, 201)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.43" spread="0.89"/>
                    <measurement group_id="O2" value="5.43" spread="0.83"/>
                    <measurement group_id="O3" value="5.44" spread="0.88"/>
                    <measurement group_id="O4" value="5.33" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 1 (n=193, 196, 104, 197)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.26" spread="1.09"/>
                    <measurement group_id="O2" value="4.21" spread="1.05"/>
                    <measurement group_id="O3" value="5.09" spread="1.15"/>
                    <measurement group_id="O4" value="4.27" spread="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 (n=187, 184, 99, 190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.78" spread="1.21"/>
                    <measurement group_id="O2" value="3.77" spread="1.21"/>
                    <measurement group_id="O3" value="4.83" spread="1.25"/>
                    <measurement group_id="O4" value="3.88" spread="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (n=174, 180, 46, 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.51" spread="1.27"/>
                    <measurement group_id="O2" value="3.29" spread="1.22"/>
                    <measurement group_id="O3" value="3.85" spread="1.14"/>
                    <measurement group_id="O4" value="3.63" spread="1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Activity Score Using 28-Joint Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Month 9 and 12</title>
        <description>DAS28-3 (CRP) was calculated from SJC and TJC using 28 joint count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) =&lt;3.2 implied low disease activity, &gt;3.2 to 5.1 implied moderate to high disease activity and &lt;2.6 implied remission.</description>
        <time_frame>Month 9, 12</time_frame>
        <population>FAS: all randomized participants who received at least 1 dose of study drug and had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). N=participants evaluable for this measure. n=number of participants evaluable at specific time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Then CP-690,550 5 mg</title>
            <description>Placebo matched to CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week, for 3 to 6 months. Response was assessed at Month 3 and participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts from baseline, received CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12. At Month 6, remaining participants advanced to CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, Then CP-690,550 10 mg</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week, for 3 to 6 months. Response was assessed at Month 3 and participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts from baseline, received CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12. At Month 6, remaining participants advanced to CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O5">
            <title>Adalimumab</title>
            <description>Adalimumab 40 mg injection subcutaneously once every other week along with placebo matched to CP-690,550 5 mg tablet orally twice daily up to Month 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Activity Score Using 28-Joint Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Month 9 and 12</title>
          <description>DAS28-3 (CRP) was calculated from SJC and TJC using 28 joint count and CRP (mg/L). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (CRP) =&lt;3.2 implied low disease activity, &gt;3.2 to 5.1 implied moderate to high disease activity and &lt;2.6 implied remission.</description>
          <population>FAS: all randomized participants who received at least 1 dose of study drug and had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). N=participants evaluable for this measure. n=number of participants evaluable at specific time points for each arm group, respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="160"/>
                <count group_id="O2" value="167"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="41"/>
                <count group_id="O5" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 9 (n=160, 167, 49, 41, 171)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.13" spread="1.11"/>
                    <measurement group_id="O2" value="3.20" spread="1.20"/>
                    <measurement group_id="O3" value="3.11" spread="1.11"/>
                    <measurement group_id="O4" value="3.03" spread="1.10"/>
                    <measurement group_id="O5" value="3.46" spread="1.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (n=149, 150, 48, 37, 160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.05" spread="1.13"/>
                    <measurement group_id="O2" value="3.00" spread="1.18"/>
                    <measurement group_id="O3" value="3.12" spread="0.96"/>
                    <measurement group_id="O4" value="3.02" spread="1.28"/>
                    <measurement group_id="O5" value="3.18" spread="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Activity Score Using 28-Joint Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Baseline, Month 1, 3 and 6</title>
        <description>DAS28-4 (ESR) calculated from SJC and TJC using 28 joint count, ESR (mm/hour) and PGA of disease activity (participant rated arthritis activity assessment with transformed score ranging 0 to 10; higher score indicated greater affectation due to disease activity). Total score range:0 to 9.4, higher score indicated more disease activity. DAS28-4 (ESR) =&lt;3.2 implied low disease activity, &gt;3.2 to 5.1 implied moderate to high disease activity and &lt;2.6 implied remission.</description>
        <time_frame>Baseline, Month 1, 3, 6</time_frame>
        <population>FAS: all randomized participants who received at least 1 dose of study drug and had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). N=participants evaluable for this measure. n=number of participants evaluable at specific time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week for 3 to 6 months. Response was assessed at Month 3 and participants who failed to achieve at least 20% reduction from baseline in both swollen and tender joint counts, received CP-690,550 5 mg or 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12. At Month 6, remaining participants received CP-690,550 5 mg or 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O4">
            <title>Adalimumab</title>
            <description>Adalimumab 40 mg injection subcutaneously once every other week along with placebo matched to CP-690,550 5 mg tablet orally twice daily up to Month 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Activity Score Using 28-Joint Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Baseline, Month 1, 3 and 6</title>
          <description>DAS28-4 (ESR) calculated from SJC and TJC using 28 joint count, ESR (mm/hour) and PGA of disease activity (participant rated arthritis activity assessment with transformed score ranging 0 to 10; higher score indicated greater affectation due to disease activity). Total score range:0 to 9.4, higher score indicated more disease activity. DAS28-4 (ESR) =&lt;3.2 implied low disease activity, &gt;3.2 to 5.1 implied moderate to high disease activity and &lt;2.6 implied remission.</description>
          <population>FAS: all randomized participants who received at least 1 dose of study drug and had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). N=participants evaluable for this measure. n=number of participants evaluable at specific time points for each arm group, respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
                <count group_id="O2" value="194"/>
                <count group_id="O3" value="103"/>
                <count group_id="O4" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=195, 194, 103, 194)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.56" spread="0.93"/>
                    <measurement group_id="O2" value="6.48" spread="0.89"/>
                    <measurement group_id="O3" value="6.45" spread="0.90"/>
                    <measurement group_id="O4" value="6.36" spread="0.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 1 (n=172, 175, 90, 176)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.23" spread="1.19"/>
                    <measurement group_id="O2" value="5.14" spread="1.26"/>
                    <measurement group_id="O3" value="5.93" spread="1.22"/>
                    <measurement group_id="O4" value="5.13" spread="1.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 (n=170, 166, 87, 167)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.64" spread="1.33"/>
                    <measurement group_id="O2" value="4.66" spread="1.39"/>
                    <measurement group_id="O3" value="5.60" spread="1.31"/>
                    <measurement group_id="O4" value="4.66" spread="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (n=155, 162, 41, 158)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.40" spread="1.38"/>
                    <measurement group_id="O2" value="4.21" spread="1.38"/>
                    <measurement group_id="O3" value="4.61" spread="1.17"/>
                    <measurement group_id="O4" value="4.37" spread="1.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Activity Score Using 28-Joint Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Month 9 and 12</title>
        <description>DAS28-4 (ESR) calculated from SJC and TJC using 28 joint count, ESR (mm/hour) and PGA of disease activity (participant rated arthritis activity assessment with transformed score ranging 0 to 10; higher score indicated greater affectation due to disease activity). Total score range:0 to 9.4, higher score indicated more disease activity. DAS28-4 (ESR) =&lt;3.2 implied low disease activity, &gt;3.2 to 5.1 implied moderate to high disease activity and &lt;2.6 implied remission.</description>
        <time_frame>Month 9, 12</time_frame>
        <population>FAS: all randomized participants who received at least 1 dose of study drug and had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). N=participants evaluable for this measure. n=number of participants evaluable at specific time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Then CP-690,550 5 mg</title>
            <description>Placebo matched to CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week, for 3 to 6 months. Response was assessed at Month 3 and participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts from baseline, received CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12. At Month 6, remaining participants advanced to CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, Then CP-690,550 10 mg</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week, for 3 to 6 months. Response was assessed at Month 3 and participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts from baseline, received CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12. At Month 6, remaining participants advanced to CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O5">
            <title>Adalimumab</title>
            <description>Adalimumab 40 mg injection subcutaneously once every other week along with placebo matched to CP-690,550 5 mg tablet orally twice daily up to Month 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Activity Score Using 28-Joint Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) at Month 9 and 12</title>
          <description>DAS28-4 (ESR) calculated from SJC and TJC using 28 joint count, ESR (mm/hour) and PGA of disease activity (participant rated arthritis activity assessment with transformed score ranging 0 to 10; higher score indicated greater affectation due to disease activity). Total score range:0 to 9.4, higher score indicated more disease activity. DAS28-4 (ESR) =&lt;3.2 implied low disease activity, &gt;3.2 to 5.1 implied moderate to high disease activity and &lt;2.6 implied remission.</description>
          <population>FAS: all randomized participants who received at least 1 dose of study drug and had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). N=participants evaluable for this measure. n=number of participants evaluable at specific time points for each arm group, respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="151"/>
                <count group_id="O3" value="45"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 9 (n=140, 151, 45, 35, 149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.00" spread="1.21"/>
                    <measurement group_id="O2" value="4.08" spread="1.33"/>
                    <measurement group_id="O3" value="3.99" spread="1.25"/>
                    <measurement group_id="O4" value="3.93" spread="1.17"/>
                    <measurement group_id="O5" value="4.20" spread="1.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (n=134, 136, 44, 32, 139)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.85" spread="1.22"/>
                    <measurement group_id="O2" value="3.88" spread="1.35"/>
                    <measurement group_id="O3" value="4.00" spread="0.95"/>
                    <measurement group_id="O4" value="3.70" spread="1.24"/>
                    <measurement group_id="O5" value="3.95" spread="1.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Activity Score Using 28-Joint Count and C-Reactive Protein (4 Variables) (DAS28-4 [CRP])</title>
        <description>DAS28-4 [CRP] calculated from SJC and TJC using 28 joint count, CRP (mg/L) and PGA of disease activity (participant rated arthritis activity assessment with transformed score ranging 0 to 10; higher score indicated greater affectation due to disease activity). Total score range:0 to 9.4, higher score indicated more disease activity. DAS28-4 (CRP) =&lt;3.2 implied low disease activity, &gt;3.2 to 5.1 implied moderate to high disease activity and &lt;2.6 implied remission.</description>
        <time_frame>Baseline, Month 1, 3, 6, 9, 12</time_frame>
        <population>Data was not analyzed for DAS28-4 (CRP) due to change in planned analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week for 3 to 6 months. Response was assessed at Month 3 and participants who failed to achieve at least 20% reduction from baseline in both swollen and tender joint counts, received CP-690,550 5 mg or 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12. At Month 6, remaining participants received CP-690,550 5 mg or 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O4">
            <title>Adalimumab</title>
            <description>Adalimumab 40 mg injection subcutaneously once every other week along with placebo matched to CP-690,550 5 mg tablet orally twice daily up to Month 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Activity Score Using 28-Joint Count and C-Reactive Protein (4 Variables) (DAS28-4 [CRP])</title>
          <description>DAS28-4 [CRP] calculated from SJC and TJC using 28 joint count, CRP (mg/L) and PGA of disease activity (participant rated arthritis activity assessment with transformed score ranging 0 to 10; higher score indicated greater affectation due to disease activity). Total score range:0 to 9.4, higher score indicated more disease activity. DAS28-4 (CRP) =&lt;3.2 implied low disease activity, &gt;3.2 to 5.1 implied moderate to high disease activity and &lt;2.6 implied remission.</description>
          <population>Data was not analyzed for DAS28-4 (CRP) due to change in planned analyses.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Activity Score Using 28-Joint Count and Erythrocyte Sedimentation Rate (3 Variables) (DAS28-3 [ESR])</title>
        <description>DAS28-3 (ESR) was calculated from SJC and TJC using 28 joint count and ESR (mm/hour). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (ESR) =&lt;3.2 implied low disease activity, &gt;3.2 to 5.1 implied moderate to high disease activity and &lt;2.6 implied remission.</description>
        <time_frame>Baseline, Month 1, 3, 6, 9, 12</time_frame>
        <population>Data was not analyzed for DAS28-3 (ESR) due to change in planned analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week for 3 to 6 months. Response was assessed at Month 3 and participants who failed to achieve at least 20% reduction from baseline in both swollen and tender joint counts, received CP-690,550 5 mg or 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12. At Month 6, remaining participants received CP-690,550 5 mg or 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O4">
            <title>Adalimumab</title>
            <description>Adalimumab 40 mg injection subcutaneously once every other week along with placebo matched to CP-690,550 5 mg tablet orally twice daily up to Month 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Activity Score Using 28-Joint Count and Erythrocyte Sedimentation Rate (3 Variables) (DAS28-3 [ESR])</title>
          <description>DAS28-3 (ESR) was calculated from SJC and TJC using 28 joint count and ESR (mm/hour). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28-3 (ESR) =&lt;3.2 implied low disease activity, &gt;3.2 to 5.1 implied moderate to high disease activity and &lt;2.6 implied remission.</description>
          <population>Data was not analyzed for DAS28-3 (ESR) due to change in planned analyses.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health Assessment Questionnaire-Disability Index (HAQ-DI) at Month 1, 3 and 6</title>
        <description>HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; common activities over past week. Each item scored on 4-point scale from 0-3:0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as sum of domain scores and divided by number of domains answered. Total possible score range 0-3: 0=least difficulty and 3=extreme difficulty.</description>
        <time_frame>Month 1, 3, 6</time_frame>
        <population>FAS: all randomized participants who received at least 1 dose of study drug and had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). N=participants evaluable for this measure. n=number of participants evaluable at specific time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week for 3 to 6 months. Response was assessed at Month 3 and participants who failed to achieve at least 20% reduction from baseline in both swollen and tender joint counts, received CP-690,550 5 mg or 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12. At Month 6, remaining participants received CP-690,550 5 mg or 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O4">
            <title>Adalimumab</title>
            <description>Adalimumab 40 mg injection subcutaneously once every other week along with placebo matched to CP-690,550 5 mg tablet orally twice daily up to Month 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Health Assessment Questionnaire-Disability Index (HAQ-DI) at Month 1, 3 and 6</title>
          <description>HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; common activities over past week. Each item scored on 4-point scale from 0-3:0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as sum of domain scores and divided by number of domains answered. Total possible score range 0-3: 0=least difficulty and 3=extreme difficulty.</description>
          <population>FAS: all randomized participants who received at least 1 dose of study drug and had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). N=participants evaluable for this measure. n=number of participants evaluable at specific time points for each arm group, respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="196"/>
                <count group_id="O3" value="106"/>
                <count group_id="O4" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 1 (n=194, 196, 106, 198)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.15" spread="0.66"/>
                    <measurement group_id="O2" value="1.11" spread="0.67"/>
                    <measurement group_id="O3" value="1.32" spread="0.69"/>
                    <measurement group_id="O4" value="1.12" spread="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 (n=188, 185, 99, 190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" spread="0.72"/>
                    <measurement group_id="O2" value="0.94" spread="0.75"/>
                    <measurement group_id="O3" value="1.25" spread="0.67"/>
                    <measurement group_id="O4" value="1.05" spread="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (n=174, 181, 46, 180)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.92" spread="0.72"/>
                    <measurement group_id="O2" value="0.89" spread="0.69"/>
                    <measurement group_id="O3" value="1.15" spread="0.71"/>
                    <measurement group_id="O4" value="0.98" spread="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health Assessment Questionnaire-Disability Index (HAQ-DI) at Month 9 and 12</title>
        <description>HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; common activities over past week. Each item scored on 4-point scale from 0-3:0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as sum of domain scores and divided by number of domains answered. Total possible score range 0-3: 0=least difficulty and 3=extreme difficulty.</description>
        <time_frame>Month 9, 12</time_frame>
        <population>FAS: all randomized participants who received at least 1 dose of study drug and had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). N=participants evaluable for this measure. n=number of participants evaluable at specific time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Then CP-690,550 5 mg</title>
            <description>Placebo matched to CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week, for 3 to 6 months. Response was assessed at Month 3 and participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts from baseline, received CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12. At Month 6, remaining participants advanced to CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, Then CP-690,550 10 mg</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week, for 3 to 6 months. Response was assessed at Month 3 and participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts from baseline, received CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12. At Month 6, remaining participants advanced to CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O5">
            <title>Adalimumab</title>
            <description>Adalimumab 40 mg injection subcutaneously once every other week along with placebo matched to CP-690,550 5 mg tablet orally twice daily up to Month 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Health Assessment Questionnaire-Disability Index (HAQ-DI) at Month 9 and 12</title>
          <description>HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; common activities over past week. Each item scored on 4-point scale from 0-3:0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as sum of domain scores and divided by number of domains answered. Total possible score range 0-3: 0=least difficulty and 3=extreme difficulty.</description>
          <population>FAS: all randomized participants who received at least 1 dose of study drug and had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). N=participants evaluable for this measure. n=number of participants evaluable at specific time points for each arm group, respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="167"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="41"/>
                <count group_id="O5" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 9 (n=158, 167, 49, 41, 171)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.86" spread="0.66"/>
                    <measurement group_id="O2" value="0.85" spread="0.66"/>
                    <measurement group_id="O3" value="0.89" spread="0.69"/>
                    <measurement group_id="O4" value="0.90" spread="0.64"/>
                    <measurement group_id="O5" value="0.97" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (n=149, 149, 49, 38, 159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.83" spread="0.68"/>
                    <measurement group_id="O2" value="0.81" spread="0.71"/>
                    <measurement group_id="O3" value="0.88" spread="0.71"/>
                    <measurement group_id="O4" value="0.91" spread="0.72"/>
                    <measurement group_id="O5" value="0.90" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Assessment of Arthritis Pain at Baseline, Month 1, 3 and 6</title>
        <description>Participants rated the severity of arthritis pain on a 0 to 100 millimeter (mm) visual analogue scale (VAS), where 0 mm = no pain and 100 mm = most severe pain.</description>
        <time_frame>Baseline, Month 1, 3, 6</time_frame>
        <population>FAS: all randomized participants who received at least 1 dose of study drug and had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). n=number of participants evaluable at specific time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week for 3 to 6 months. Response was assessed at Month 3 and participants who failed to achieve at least 20% reduction from baseline in both swollen and tender joint counts, received CP-690,550 5 mg or 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12. At Month 6, remaining participants received CP-690,550 5 mg or 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O4">
            <title>Adalimumab</title>
            <description>Adalimumab 40 mg injection subcutaneously once every other week along with placebo matched to CP-690,550 5 mg tablet orally twice daily up to Month 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Assessment of Arthritis Pain at Baseline, Month 1, 3 and 6</title>
          <description>Participants rated the severity of arthritis pain on a 0 to 100 millimeter (mm) visual analogue scale (VAS), where 0 mm = no pain and 100 mm = most severe pain.</description>
          <population>FAS: all randomized participants who received at least 1 dose of study drug and had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). n=number of participants evaluable at specific time points for each arm group, respectively.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="199"/>
                <count group_id="O3" value="106"/>
                <count group_id="O4" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=201, 199, 106, 201)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.29" spread="20.95"/>
                    <measurement group_id="O2" value="59.01" spread="22.18"/>
                    <measurement group_id="O3" value="55.20" spread="21.27"/>
                    <measurement group_id="O4" value="56.46" spread="21.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 1 (n=194, 196, 106, 198)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.71" spread="22.60"/>
                    <measurement group_id="O2" value="36.77" spread="22.63"/>
                    <measurement group_id="O3" value="49.92" spread="23.94"/>
                    <measurement group_id="O4" value="39.27" spread="24.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 (n=188, 185, 99, 190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.98" spread="23.09"/>
                    <measurement group_id="O2" value="31.27" spread="22.39"/>
                    <measurement group_id="O3" value="48.53" spread="23.42"/>
                    <measurement group_id="O4" value="36.27" spread="25.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (n=174, 181, 46, 179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.40" spread="23.26"/>
                    <measurement group_id="O2" value="28.36" spread="22.52"/>
                    <measurement group_id="O3" value="35.04" spread="20.95"/>
                    <measurement group_id="O4" value="32.78" spread="22.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Assessment of Arthritis Pain at Month 9 and 12</title>
        <description>Participants rated the severity of arthritis pain on a 0 to 100 mm VAS, where 0 mm = no pain and 100 mm = most severe pain.</description>
        <time_frame>Month 9, 12</time_frame>
        <population>FAS: all randomized participants who received at least 1 dose of study drug and had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). N=participants evaluable for this measure. n=number of participants evaluable at specific time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Then CP-690,550 5 mg</title>
            <description>Placebo matched to CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week, for 3 to 6 months. Response was assessed at Month 3 and participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts from baseline, received CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12. At Month 6, remaining participants advanced to CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, Then CP-690,550 10 mg</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week, for 3 to 6 months. Response was assessed at Month 3 and participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts from baseline, received CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12. At Month 6, remaining participants advanced to CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O5">
            <title>Adalimumab</title>
            <description>Adalimumab 40 mg injection subcutaneously once every other week along with placebo matched to CP-690,550 5 mg tablet orally twice daily up to Month 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Assessment of Arthritis Pain at Month 9 and 12</title>
          <description>Participants rated the severity of arthritis pain on a 0 to 100 mm VAS, where 0 mm = no pain and 100 mm = most severe pain.</description>
          <population>FAS: all randomized participants who received at least 1 dose of study drug and had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). N=participants evaluable for this measure. n=number of participants evaluable at specific time points for each arm group, respectively.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="167"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="41"/>
                <count group_id="O5" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 9 (n=158, 167, 49, 41, 171)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.04" spread="21.35"/>
                    <measurement group_id="O2" value="27.99" spread="22.97"/>
                    <measurement group_id="O3" value="31.31" spread="22.66"/>
                    <measurement group_id="O4" value="24.93" spread="19.38"/>
                    <measurement group_id="O5" value="32.70" spread="24.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (n=150, 150, 49, 38, 160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.99" spread="21.97"/>
                    <measurement group_id="O2" value="24.55" spread="20.68"/>
                    <measurement group_id="O3" value="28.23" spread="17.86"/>
                    <measurement group_id="O4" value="29.37" spread="20.57"/>
                    <measurement group_id="O5" value="27.94" spread="22.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Global Assessment (PtGA) of Arthritis Pain at Baseline, Month 1, 3 and 6</title>
        <description>Participants answered: &quot;Considering all the ways your arthritis affects you, how are you feeling today?&quot; Participants responded by using a 0 - 100 mm VAS, where 0 mm = very well and 100 mm = very poorly.</description>
        <time_frame>Baseline, Month 1, 3, 6</time_frame>
        <population>FAS: all randomized participants who received at least 1 dose of study drug and had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). n=number of participants evaluable at specific time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week for 3 to 6 months. Response was assessed at Month 3 and participants who failed to achieve at least 20% reduction from baseline in both swollen and tender joint counts, received CP-690,550 5 mg or 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12. At Month 6, remaining participants received CP-690,550 5 mg or 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O4">
            <title>Adalimumab</title>
            <description>Adalimumab 40 mg injection subcutaneously once every other week along with placebo matched to CP-690,550 5 mg tablet orally twice daily up to Month 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Global Assessment (PtGA) of Arthritis Pain at Baseline, Month 1, 3 and 6</title>
          <description>Participants answered: &quot;Considering all the ways your arthritis affects you, how are you feeling today?&quot; Participants responded by using a 0 - 100 mm VAS, where 0 mm = very well and 100 mm = very poorly.</description>
          <population>FAS: all randomized participants who received at least 1 dose of study drug and had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). n=number of participants evaluable at specific time points for each arm group, respectively.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="199"/>
                <count group_id="O3" value="106"/>
                <count group_id="O4" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=201, 199, 106, 201)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.86" spread="21.38"/>
                    <measurement group_id="O2" value="56.55" spread="23.83"/>
                    <measurement group_id="O3" value="54.46" spread="21.27"/>
                    <measurement group_id="O4" value="57.22" spread="22.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 1 (n=194, 196, 105, 197)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.85" spread="23.02"/>
                    <measurement group_id="O2" value="36.61" spread="23.51"/>
                    <measurement group_id="O3" value="50.70" spread="24.24"/>
                    <measurement group_id="O4" value="39.32" spread="23.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 (n=188, 185, 99, 190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.56" spread="23.81"/>
                    <measurement group_id="O2" value="31.25" spread="22.23"/>
                    <measurement group_id="O3" value="49.84" spread="22.45"/>
                    <measurement group_id="O4" value="36.97" spread="25.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (n=174, 181, 46, 180)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.79" spread="25.56"/>
                    <measurement group_id="O2" value="29.74" spread="22.41"/>
                    <measurement group_id="O3" value="37.76" spread="20.86"/>
                    <measurement group_id="O4" value="33.50" spread="21.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Global Assessment (PtGA) of Arthritis Pain at Month 9 and 12</title>
        <description>Participants answered: &quot;Considering all the ways your arthritis affects you, how are you feeling today?&quot; Participants responded by using a 0 - 100 mm VAS, where 0 mm = very well and 100 mm = very poorly.</description>
        <time_frame>Month 9, 12</time_frame>
        <population>FAS: all randomized participants who received at least 1 dose of study drug and had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). N=participants evaluable for this measure. n=number of participants evaluable at specific time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Then CP-690,550 5 mg</title>
            <description>Placebo matched to CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week, for 3 to 6 months. Response was assessed at Month 3 and participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts from baseline, received CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12. At Month 6, remaining participants advanced to CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, Then CP-690,550 10 mg</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week, for 3 to 6 months. Response was assessed at Month 3 and participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts from baseline, received CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12. At Month 6, remaining participants advanced to CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O5">
            <title>Adalimumab</title>
            <description>Adalimumab 40 mg injection subcutaneously once every other week along with placebo matched to CP-690,550 5 mg tablet orally twice daily up to Month 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Global Assessment (PtGA) of Arthritis Pain at Month 9 and 12</title>
          <description>Participants answered: &quot;Considering all the ways your arthritis affects you, how are you feeling today?&quot; Participants responded by using a 0 - 100 mm VAS, where 0 mm = very well and 100 mm = very poorly.</description>
          <population>FAS: all randomized participants who received at least 1 dose of study drug and had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). N=participants evaluable for this measure. n=number of participants evaluable at specific time points for each arm group, respectively.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="167"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="41"/>
                <count group_id="O5" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 9 (n=158, 167, 49, 41, 171)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.39" spread="22.31"/>
                    <measurement group_id="O2" value="29.47" spread="21.99"/>
                    <measurement group_id="O3" value="31.78" spread="20.75"/>
                    <measurement group_id="O4" value="30.00" spread="20.31"/>
                    <measurement group_id="O5" value="34.38" spread="24.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (n=149, 150, 49, 37, 160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.86" spread="22.44"/>
                    <measurement group_id="O2" value="27.70" spread="22.09"/>
                    <measurement group_id="O3" value="30.78" spread="17.65"/>
                    <measurement group_id="O4" value="29.70" spread="20.69"/>
                    <measurement group_id="O5" value="30.33" spread="24.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Physician Global Assessment (PGA) of Arthritis Pain at Baseline, Month 1, 3 and 6</title>
        <description>Physician global assessment of arthritis was measured on a 0 to 100 mm VAS, where 0 mm = very good and 100 mm = very bad.</description>
        <time_frame>Baseline, Month 1, 3, 6</time_frame>
        <population>FAS: all randomized participants who received at least 1 dose of study drug and had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). N=participants evaluable for this measure. n=number of participants evaluable at specific time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week for 3 to 6 months. Response was assessed at Month 3 and participants who failed to achieve at least 20% reduction from baseline in both swollen and tender joint counts, received CP-690,550 5 mg or 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12. At Month 6, remaining participants received CP-690,550 5 mg or 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O4">
            <title>Adalimumab</title>
            <description>Adalimumab 40 mg injection subcutaneously once every other week along with placebo matched to CP-690,550 5 mg tablet orally twice daily up to Month 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Physician Global Assessment (PGA) of Arthritis Pain at Baseline, Month 1, 3 and 6</title>
          <description>Physician global assessment of arthritis was measured on a 0 to 100 mm VAS, where 0 mm = very good and 100 mm = very bad.</description>
          <population>FAS: all randomized participants who received at least 1 dose of study drug and had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). N=participants evaluable for this measure. n=number of participants evaluable at specific time points for each arm group, respectively.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="199"/>
                <count group_id="O2" value="199"/>
                <count group_id="O3" value="106"/>
                <count group_id="O4" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=199, 199, 106, 201)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.92" spread="16.77"/>
                    <measurement group_id="O2" value="59.56" spread="16.70"/>
                    <measurement group_id="O3" value="60.28" spread="16.55"/>
                    <measurement group_id="O4" value="58.64" spread="15.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 1 (n=193, 195, 106, 197)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.90" spread="18.56"/>
                    <measurement group_id="O2" value="36.16" spread="19.27"/>
                    <measurement group_id="O3" value="50.73" spread="22.08"/>
                    <measurement group_id="O4" value="38.81" spread="20.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 (n=186, 185, 99, 189)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.28" spread="20.71"/>
                    <measurement group_id="O2" value="29.91" spread="21.04"/>
                    <measurement group_id="O3" value="45.12" spread="22.77"/>
                    <measurement group_id="O4" value="32.40" spread="21.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (n=174, 180, 46, 178)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.97" spread="19.26"/>
                    <measurement group_id="O2" value="24.46" spread="19.78"/>
                    <measurement group_id="O3" value="29.76" spread="20.43"/>
                    <measurement group_id="O4" value="27.77" spread="18.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Physician Global Assessment (PGA) of Arthritis Pain at Month 9 and 12</title>
        <description>Physician Global Assessment of Arthritis was measured on a 0 to 100 mm VAS, where 0 mm = very good and 100 mm = very bad.</description>
        <time_frame>Month 9, 12</time_frame>
        <population>FAS: all randomized participants who received at least 1 dose of study drug and had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). N=participants evaluable for this measure. n=number of participants evaluable at specific time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Then CP-690,550 5 mg</title>
            <description>Placebo matched to CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week, for 3 to 6 months. Response was assessed at Month 3 and participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts from baseline, received CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12. At Month 6, remaining participants advanced to CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, Then CP-690,550 10 mg</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week, for 3 to 6 months. Response was assessed at Month 3 and participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts from baseline, received CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12. At Month 6, remaining participants advanced to CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O5">
            <title>Adalimumab</title>
            <description>Adalimumab 40 mg injection subcutaneously once every other week along with placebo matched to CP-690,550 5 mg tablet orally twice daily up to Month 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Physician Global Assessment (PGA) of Arthritis Pain at Month 9 and 12</title>
          <description>Physician Global Assessment of Arthritis was measured on a 0 to 100 mm VAS, where 0 mm = very good and 100 mm = very bad.</description>
          <population>FAS: all randomized participants who received at least 1 dose of study drug and had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). N=participants evaluable for this measure. n=number of participants evaluable at specific time points for each arm group, respectively.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="160"/>
                <count group_id="O2" value="167"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="41"/>
                <count group_id="O5" value="170"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 9 (n=160, 167, 49, 41, 170)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.93" spread="16.20"/>
                    <measurement group_id="O2" value="21.92" spread="17.87"/>
                    <measurement group_id="O3" value="25.82" spread="20.32"/>
                    <measurement group_id="O4" value="23.78" spread="15.54"/>
                    <measurement group_id="O5" value="25.45" spread="19.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (n=149, 150, 48, 38, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.67" spread="16.18"/>
                    <measurement group_id="O2" value="18.87" spread="16.05"/>
                    <measurement group_id="O3" value="19.77" spread="13.88"/>
                    <measurement group_id="O4" value="20.68" spread="14.51"/>
                    <measurement group_id="O5" value="20.44" spread="16.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>36-Item Short-Form Health Survey (SF-36) at Baseline, Month 1, 3 and 6</title>
        <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and was reported as 2 summary scores; Physical Component Score and Mental Component Score. Total score range for the summary scores = 0-100 where higher scores represented higher level of functioning.</description>
        <time_frame>Baseline, Month 1, 3, 6</time_frame>
        <population>FAS: all randomized participants who received at least 1 dose of study drug and had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). n=number of participants evaluable at specific time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week for 3 to 6 months. Response was assessed at Month 3 and participants who failed to achieve at least 20% reduction from baseline in both swollen and tender joint counts, received CP-690,550 5 mg or 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12. At Month 6, remaining participants received CP-690,550 5 mg or 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O4">
            <title>Adalimumab</title>
            <description>Adalimumab 40 mg injection subcutaneously once every other week along with placebo matched to CP-690,550 5 mg tablet orally twice daily up to Month 12.</description>
          </group>
        </group_list>
        <measure>
          <title>36-Item Short-Form Health Survey (SF-36) at Baseline, Month 1, 3 and 6</title>
          <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and was reported as 2 summary scores; Physical Component Score and Mental Component Score. Total score range for the summary scores = 0-100 where higher scores represented higher level of functioning.</description>
          <population>FAS: all randomized participants who received at least 1 dose of study drug and had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). n=number of participants evaluable at specific time points for each arm group, respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="199"/>
                <count group_id="O3" value="106"/>
                <count group_id="O4" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: Physical functioning (n=201,199,106,201)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.02" spread="9.48"/>
                    <measurement group_id="O2" value="31.06" spread="9.52"/>
                    <measurement group_id="O3" value="32.23" spread="9.43"/>
                    <measurement group_id="O4" value="31.74" spread="8.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Role physical (n=201,199,106,201)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.00" spread="9.11"/>
                    <measurement group_id="O2" value="33.54" spread="9.12"/>
                    <measurement group_id="O3" value="34.70" spread="8.01"/>
                    <measurement group_id="O4" value="34.79" spread="8.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Social functioning (n=201,199,106,201)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.15" spread="10.76"/>
                    <measurement group_id="O2" value="36.27" spread="11.59"/>
                    <measurement group_id="O3" value="39.36" spread="11.17"/>
                    <measurement group_id="O4" value="36.23" spread="11.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Bodily pain (n=201,199,106,201)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.42" spread="7.51"/>
                    <measurement group_id="O2" value="33.29" spread="7.42"/>
                    <measurement group_id="O3" value="34.53" spread="6.57"/>
                    <measurement group_id="O4" value="33.14" spread="7.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Mental health (n=201,199,106,201)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.04" spread="11.42"/>
                    <measurement group_id="O2" value="39.15" spread="11.19"/>
                    <measurement group_id="O3" value="41.11" spread="10.51"/>
                    <measurement group_id="O4" value="39.64" spread="11.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Role emotional (n=201,199,106,201)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.15" spread="12.49"/>
                    <measurement group_id="O2" value="34.11" spread="12.63"/>
                    <measurement group_id="O3" value="37.32" spread="11.97"/>
                    <measurement group_id="O4" value="35.54" spread="12.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Vitality (n=201,199,106,201)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.62" spread="9.23"/>
                    <measurement group_id="O2" value="40.79" spread="9.36"/>
                    <measurement group_id="O3" value="42.67" spread="8.85"/>
                    <measurement group_id="O4" value="39.95" spread="9.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: General health (n=201,199,106,201)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.22" spread="8.95"/>
                    <measurement group_id="O2" value="35.81" spread="8.93"/>
                    <measurement group_id="O3" value="36.29" spread="8.38"/>
                    <measurement group_id="O4" value="35.18" spread="7.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:Mental component (n=201,199,106,201)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.82" spread="11.68"/>
                    <measurement group_id="O2" value="40.21" spread="11.14"/>
                    <measurement group_id="O3" value="43.29" spread="10.58"/>
                    <measurement group_id="O4" value="40.58" spread="11.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Physical component (n=201,199,106,201)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.10" spread="7.69"/>
                    <measurement group_id="O2" value="32.62" spread="7.78"/>
                    <measurement group_id="O3" value="33.02" spread="6.23"/>
                    <measurement group_id="O4" value="32.74" spread="6.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 1: Physical functioning (n=194,196,106,198)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.29" spread="9.94"/>
                    <measurement group_id="O2" value="35.23" spread="10.57"/>
                    <measurement group_id="O3" value="34.00" spread="9.68"/>
                    <measurement group_id="O4" value="35.38" spread="9.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 1: Role physical (n=194,196,106,198)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.19" spread="9.34"/>
                    <measurement group_id="O2" value="38.45" spread="10.01"/>
                    <measurement group_id="O3" value="36.79" spread="9.39"/>
                    <measurement group_id="O4" value="38.37" spread="9.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 1: Social functioning (n=194,196,106,198)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.77" spread="10.53"/>
                    <measurement group_id="O2" value="42.22" spread="10.64"/>
                    <measurement group_id="O3" value="41.74" spread="10.72"/>
                    <measurement group_id="O4" value="40.98" spread="10.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 1: Bodily pain (n=194,196,106,198)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.14" spread="8.54"/>
                    <measurement group_id="O2" value="40.73" spread="8.46"/>
                    <measurement group_id="O3" value="36.18" spread="7.52"/>
                    <measurement group_id="O4" value="39.58" spread="8.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 1: Mental health (n=194,196,106,198)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.31" spread="10.30"/>
                    <measurement group_id="O2" value="43.35" spread="11.13"/>
                    <measurement group_id="O3" value="41.79" spread="10.91"/>
                    <measurement group_id="O4" value="42.83" spread="10.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 1: Role emotional (n=194,196,106,198)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.29" spread="12.54"/>
                    <measurement group_id="O2" value="38.64" spread="12.05"/>
                    <measurement group_id="O3" value="38.18" spread="11.89"/>
                    <measurement group_id="O4" value="39.10" spread="11.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 1: Vitality (n=194,196,106,198)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.24" spread="9.33"/>
                    <measurement group_id="O2" value="46.99" spread="9.58"/>
                    <measurement group_id="O3" value="43.71" spread="8.74"/>
                    <measurement group_id="O4" value="44.44" spread="10.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 1: General health (n=194,196,106,198)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.53" spread="9.24"/>
                    <measurement group_id="O2" value="39.98" spread="9.16"/>
                    <measurement group_id="O3" value="37.41" spread="8.61"/>
                    <measurement group_id="O4" value="38.35" spread="8.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 1: Mental component (n=194,196,106,198)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.56" spread="10.60"/>
                    <measurement group_id="O2" value="44.92" spread="11.21"/>
                    <measurement group_id="O3" value="44.03" spread="11.04"/>
                    <measurement group_id="O4" value="44.05" spread="10.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 1: Physical component (n=194,196,106,198)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.50" spread="7.99"/>
                    <measurement group_id="O2" value="37.86" spread="8.11"/>
                    <measurement group_id="O3" value="35.01" spread="7.36"/>
                    <measurement group_id="O4" value="37.08" spread="7.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: Physical functioning (n=187,185,99,190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.11" spread="10.39"/>
                    <measurement group_id="O2" value="38.49" spread="11.12"/>
                    <measurement group_id="O3" value="34.77" spread="8.92"/>
                    <measurement group_id="O4" value="36.56" spread="10.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: Role physical (n=188,185,99,190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.79" spread="9.55"/>
                    <measurement group_id="O2" value="40.93" spread="10.40"/>
                    <measurement group_id="O3" value="37.25" spread="8.88"/>
                    <measurement group_id="O4" value="39.51" spread="8.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: Social functioning (n=188,185,99,190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.59" spread="11.04"/>
                    <measurement group_id="O2" value="44.34" spread="11.00"/>
                    <measurement group_id="O3" value="41.41" spread="10.08"/>
                    <measurement group_id="O4" value="40.84" spread="10.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: Bodily pain (n=187,185,99,190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.08" spread="9.15"/>
                    <measurement group_id="O2" value="43.09" spread="9.58"/>
                    <measurement group_id="O3" value="37.05" spread="7.91"/>
                    <measurement group_id="O4" value="40.60" spread="9.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: Mental health (n=188,185,99,190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.43" spread="11.02"/>
                    <measurement group_id="O2" value="44.79" spread="11.25"/>
                    <measurement group_id="O3" value="42.44" spread="10.04"/>
                    <measurement group_id="O4" value="43.05" spread="10.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: Role emotional (n=188,185,99,190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.74" spread="12.56"/>
                    <measurement group_id="O2" value="41.76" spread="12.66"/>
                    <measurement group_id="O3" value="38.59" spread="12.42"/>
                    <measurement group_id="O4" value="39.24" spread="11.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: Vitality (n=188,185,99,190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.63" spread="9.91"/>
                    <measurement group_id="O2" value="48.09" spread="10.79"/>
                    <measurement group_id="O3" value="44.06" spread="9.22"/>
                    <measurement group_id="O4" value="45.57" spread="9.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: General health (n=188,185,99,189)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.15" spread="9.52"/>
                    <measurement group_id="O2" value="41.35" spread="8.93"/>
                    <measurement group_id="O3" value="37.51" spread="8.08"/>
                    <measurement group_id="O4" value="39.33" spread="9.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: Mental component (n=187,185,99,189)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.31" spread="11.47"/>
                    <measurement group_id="O2" value="46.49" spread="11.45"/>
                    <measurement group_id="O3" value="44.20" spread="10.65"/>
                    <measurement group_id="O4" value="43.90" spread="10.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: Physical component (n=187,185,99,189)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.57" spread="8.76"/>
                    <measurement group_id="O2" value="40.30" spread="8.94"/>
                    <measurement group_id="O3" value="35.59" spread="7.33"/>
                    <measurement group_id="O4" value="38.58" spread="8.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: Physical functioning (n=173,181,46,179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.31" spread="10.92"/>
                    <measurement group_id="O2" value="38.56" spread="11.35"/>
                    <measurement group_id="O3" value="37.00" spread="8.99"/>
                    <measurement group_id="O4" value="37.29" spread="10.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: Role physical (n=173,181,46,179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.42" spread="10.03"/>
                    <measurement group_id="O2" value="41.29" spread="9.73"/>
                    <measurement group_id="O3" value="38.62" spread="7.95"/>
                    <measurement group_id="O4" value="39.99" spread="9.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: Social functioning (n=173,181,46,180)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.85" spread="11.17"/>
                    <measurement group_id="O2" value="43.98" spread="11.30"/>
                    <measurement group_id="O3" value="42.49" spread="9.92"/>
                    <measurement group_id="O4" value="42.36" spread="10.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: Bodily pain (n=173,181,46,180)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.79" spread="9.41"/>
                    <measurement group_id="O2" value="43.63" spread="9.31"/>
                    <measurement group_id="O3" value="39.79" spread="8.05"/>
                    <measurement group_id="O4" value="41.59" spread="8.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: Mental health (n=173,181,46,180)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.31" spread="11.29"/>
                    <measurement group_id="O2" value="45.32" spread="11.43"/>
                    <measurement group_id="O3" value="41.21" spread="11.70"/>
                    <measurement group_id="O4" value="43.13" spread="11.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: Role emotional (n=173,181, 46,179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.78" spread="12.03"/>
                    <measurement group_id="O2" value="40.68" spread="11.77"/>
                    <measurement group_id="O3" value="39.22" spread="11.82"/>
                    <measurement group_id="O4" value="39.54" spread="11.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: Vitality (n=173,181,46,180)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.35" spread="10.37"/>
                    <measurement group_id="O2" value="48.66" spread="10.08"/>
                    <measurement group_id="O3" value="45.06" spread="9.36"/>
                    <measurement group_id="O4" value="45.93" spread="9.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: General health (n=173,180,46,180)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.53" spread="9.44"/>
                    <measurement group_id="O2" value="41.95" spread="8.89"/>
                    <measurement group_id="O3" value="39.03" spread="9.30"/>
                    <measurement group_id="O4" value="39.91" spread="8.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: Mental component (n=173,180,46,179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.44" spread="11.19"/>
                    <measurement group_id="O2" value="46.14" spread="11.43"/>
                    <measurement group_id="O3" value="43.43" spread="10.60"/>
                    <measurement group_id="O4" value="44.24" spread="11.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: Physical component (n=173,180,46,179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.45" spread="9.29"/>
                    <measurement group_id="O2" value="40.86" spread="8.71"/>
                    <measurement group_id="O3" value="38.44" spread="6.67"/>
                    <measurement group_id="O4" value="39.36" spread="8.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>36-Item Short-Form Health Survey (SF-36) at Month 9 and 12</title>
        <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and was reported as 2 summary scores; Physical Component Score and Mental Component Score. Total score range for the summary scores = 0-100 where higher scores represented higher level of functioning.</description>
        <time_frame>Month 9, 12</time_frame>
        <population>FAS: all randomized participants who received at least 1 dose of study drug and had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). N=participants evaluable for this measure. n=number of participants evaluable at specific time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Then CP-690,550 5 mg</title>
            <description>Placebo matched to CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week, for 3 to 6 months. Response was assessed at Month 3 and participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts from baseline, received CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12. At Month 6, remaining participants advanced to CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, Then CP-690,550 10 mg</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week, for 3 to 6 months. Response was assessed at Month 3 and participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts from baseline, received CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12. At Month 6, remaining participants advanced to CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O5">
            <title>Adalimumab</title>
            <description>Adalimumab 40 mg injection subcutaneously once every other week along with placebo matched to CP-690,550 5 mg tablet orally twice daily up to Month 12.</description>
          </group>
        </group_list>
        <measure>
          <title>36-Item Short-Form Health Survey (SF-36) at Month 9 and 12</title>
          <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning) and was reported as 2 summary scores; Physical Component Score and Mental Component Score. Total score range for the summary scores = 0-100 where higher scores represented higher level of functioning.</description>
          <population>FAS: all randomized participants who received at least 1 dose of study drug and had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). N=participants evaluable for this measure. n=number of participants evaluable at specific time points for each arm group, respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="159"/>
                <count group_id="O2" value="167"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="41"/>
                <count group_id="O5" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 9: Physical functioning(n=158,167,49,41,171)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.77" spread="10.29"/>
                    <measurement group_id="O2" value="38.74" spread="11.31"/>
                    <measurement group_id="O3" value="38.94" spread="9.81"/>
                    <measurement group_id="O4" value="38.59" spread="10.08"/>
                    <measurement group_id="O5" value="38.75" spread="10.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9: Role physical (n=159,167,49,41,171)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.66" spread="9.62"/>
                    <measurement group_id="O2" value="40.55" spread="10.15"/>
                    <measurement group_id="O3" value="41.77" spread="8.36"/>
                    <measurement group_id="O4" value="39.75" spread="9.20"/>
                    <measurement group_id="O5" value="41.12" spread="9.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9: Social functioning (n=159,167,49,41,171)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.52" spread="10.65"/>
                    <measurement group_id="O2" value="44.42" spread="9.96"/>
                    <measurement group_id="O3" value="44.55" spread="9.82"/>
                    <measurement group_id="O4" value="42.76" spread="9.78"/>
                    <measurement group_id="O5" value="42.03" spread="11.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9: Bodily pain (n=159,166,49,41,171)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.45" spread="9.02"/>
                    <measurement group_id="O2" value="42.75" spread="9.50"/>
                    <measurement group_id="O3" value="44.68" spread="8.86"/>
                    <measurement group_id="O4" value="42.26" spread="7.77"/>
                    <measurement group_id="O5" value="41.81" spread="9.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9: Mental health (n=159,166,49,41,171)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.47" spread="10.27"/>
                    <measurement group_id="O2" value="45.42" spread="10.44"/>
                    <measurement group_id="O3" value="44.83" spread="10.70"/>
                    <measurement group_id="O4" value="43.70" spread="10.16"/>
                    <measurement group_id="O5" value="43.44" spread="12.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9: Role emotional (n=159,167,49,41,171)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.98" spread="11.99"/>
                    <measurement group_id="O2" value="40.58" spread="12.07"/>
                    <measurement group_id="O3" value="39.84" spread="11.40"/>
                    <measurement group_id="O4" value="41.46" spread="11.81"/>
                    <measurement group_id="O5" value="40.07" spread="12.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9: Vitality (n=159,166,49,41,171)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.76" spread="9.51"/>
                    <measurement group_id="O2" value="48.69" spread="9.68"/>
                    <measurement group_id="O3" value="47.80" spread="8.94"/>
                    <measurement group_id="O4" value="46.41" spread="10.03"/>
                    <measurement group_id="O5" value="46.11" spread="10.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9: General health (n=159,166,49,41,171)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.15" spread="9.79"/>
                    <measurement group_id="O2" value="41.34" spread="9.20"/>
                    <measurement group_id="O3" value="41.39" spread="8.54"/>
                    <measurement group_id="O4" value="40.57" spread="9.34"/>
                    <measurement group_id="O5" value="40.12" spread="9.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month9:Mental component (n=158,165,49,41,171)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.79" spread="10.76"/>
                    <measurement group_id="O2" value="46.55" spread="10.52"/>
                    <measurement group_id="O3" value="45.31" spread="9.75"/>
                    <measurement group_id="O4" value="45.23" spread="11.22"/>
                    <measurement group_id="O5" value="44.08" spread="11.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9: Physical component (n=158,165,49,41,171)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.55" spread="8.57"/>
                    <measurement group_id="O2" value="40.32" spread="9.44"/>
                    <measurement group_id="O3" value="41.65" spread="8.20"/>
                    <measurement group_id="O4" value="39.73" spread="7.73"/>
                    <measurement group_id="O5" value="40.35" spread="8.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12:Physical functioning(n=149,149,49,38,160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.16" spread="10.25"/>
                    <measurement group_id="O2" value="40.34" spread="11.59"/>
                    <measurement group_id="O3" value="39.24" spread="10.07"/>
                    <measurement group_id="O4" value="40.42" spread="9.84"/>
                    <measurement group_id="O5" value="39.21" spread="10.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12: Role physical (n=150,150,49,38,160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.15" spread="9.35"/>
                    <measurement group_id="O2" value="42.34" spread="10.32"/>
                    <measurement group_id="O3" value="40.16" spread="8.73"/>
                    <measurement group_id="O4" value="41.18" spread="9.30"/>
                    <measurement group_id="O5" value="41.07" spread="9.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12: Social functioning (n=150,150,49,38,160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.14" spread="10.46"/>
                    <measurement group_id="O2" value="44.07" spread="10.44"/>
                    <measurement group_id="O3" value="43.78" spread="9.97"/>
                    <measurement group_id="O4" value="44.94" spread="9.78"/>
                    <measurement group_id="O5" value="42.96" spread="10.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12: Bodily pain (n=150,150,49,38,160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.44" spread="9.48"/>
                    <measurement group_id="O2" value="44.02" spread="10.02"/>
                    <measurement group_id="O3" value="43.90" spread="8.28"/>
                    <measurement group_id="O4" value="43.18" spread="7.76"/>
                    <measurement group_id="O5" value="42.73" spread="9.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12: Mental health (n=150,149,49,38,159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.83" spread="10.02"/>
                    <measurement group_id="O2" value="45.06" spread="10.49"/>
                    <measurement group_id="O3" value="44.09" spread="9.20"/>
                    <measurement group_id="O4" value="45.28" spread="10.94"/>
                    <measurement group_id="O5" value="44.23" spread="10.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12:Role emotional (n=150,150,49,38,159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.18" spread="11.46"/>
                    <measurement group_id="O2" value="42.25" spread="11.68"/>
                    <measurement group_id="O3" value="40.23" spread="10.79"/>
                    <measurement group_id="O4" value="41.03" spread="12.67"/>
                    <measurement group_id="O5" value="39.89" spread="11.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12: Vitality (n=150,149,49,38,159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.60" spread="9.01"/>
                    <measurement group_id="O2" value="49.12" spread="9.95"/>
                    <measurement group_id="O3" value="47.31" spread="9.13"/>
                    <measurement group_id="O4" value="48.17" spread="9.36"/>
                    <measurement group_id="O5" value="46.27" spread="9.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12:General health (n=150,150,49,38,160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.07" spread="9.85"/>
                    <measurement group_id="O2" value="42.33" spread="9.05"/>
                    <measurement group_id="O3" value="40.47" spread="9.44"/>
                    <measurement group_id="O4" value="40.77" spread="8.31"/>
                    <measurement group_id="O5" value="40.40" spread="9.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12:Mental component (n=149,149,49,38,158)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.02" spread="10.14"/>
                    <measurement group_id="O2" value="46.29" spread="10.56"/>
                    <measurement group_id="O3" value="45.02" spread="9.29"/>
                    <measurement group_id="O4" value="46.12" spread="11.75"/>
                    <measurement group_id="O5" value="44.42" spread="10.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12: Physical component(n=149,149,49,38,158)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.44" spread="8.81"/>
                    <measurement group_id="O2" value="41.96" spread="9.40"/>
                    <measurement group_id="O3" value="40.82" spread="8.01"/>
                    <measurement group_id="O4" value="41.12" spread="6.49"/>
                    <measurement group_id="O5" value="40.72" spread="8.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT)-Fatigue Scale at Baseline, Month 1, 3 and 6</title>
        <description>FACIT-Fatigue scale is a 13-item questionnaire. Participant scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as 4 minus the participant's response. The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). A higher score reflected an improvement in the participant's health status.</description>
        <time_frame>Baseline, Month 1, 3, 6</time_frame>
        <population>FAS: all randomized participants who received at least 1 dose of study drug and had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). n=number of participants evaluable at specific time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week for 3 to 6 months. Response was assessed at Month 3 and participants who failed to achieve at least 20% reduction from baseline in both swollen and tender joint counts, received CP-690,550 5 mg or 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12. At Month 6, remaining participants received CP-690,550 5 mg or 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O4">
            <title>Adalimumab</title>
            <description>Adalimumab 40 mg injection subcutaneously once every other week along with placebo matched to CP-690,550 5 mg tablet orally twice daily up to Month 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT)-Fatigue Scale at Baseline, Month 1, 3 and 6</title>
          <description>FACIT-Fatigue scale is a 13-item questionnaire. Participant scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as 4 minus the participant's response. The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). A higher score reflected an improvement in the participant's health status.</description>
          <population>FAS: all randomized participants who received at least 1 dose of study drug and had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). n=number of participants evaluable at specific time points for each arm group, respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="199"/>
                <count group_id="O3" value="106"/>
                <count group_id="O4" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=201, 199, 106, 201)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.18" spread="10.48"/>
                    <measurement group_id="O2" value="28.56" spread="10.84"/>
                    <measurement group_id="O3" value="30.49" spread="10.23"/>
                    <measurement group_id="O4" value="27.95" spread="10.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 1 (n=192, 196, 106, 198)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.54" spread="9.94"/>
                    <measurement group_id="O2" value="33.95" spread="10.54"/>
                    <measurement group_id="O3" value="31.66" spread="10.09"/>
                    <measurement group_id="O4" value="31.94" spread="10.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 (n=187, 185, 99, 190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.86" spread="10.18"/>
                    <measurement group_id="O2" value="35.12" spread="11.07"/>
                    <measurement group_id="O3" value="30.96" spread="10.21"/>
                    <measurement group_id="O4" value="32.72" spread="10.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (n=173, 181, 46, 180)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.58" spread="10.53"/>
                    <measurement group_id="O2" value="36.09" spread="10.07"/>
                    <measurement group_id="O3" value="32.37" spread="8.92"/>
                    <measurement group_id="O4" value="33.69" spread="10.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT)-Fatigue Scale at Month 12</title>
        <description>FACIT-Fatigue scale is a 13-item questionnaire. Participant scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as 4 minus the participant's response. The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). A higher score reflected an improvement in the participant's health status.</description>
        <time_frame>Month 12</time_frame>
        <population>FAS: all randomized participants who received at least 1 dose of study drug and had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). N=participants evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Then CP-690,550 5 mg</title>
            <description>Placebo matched to CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week, for 3 to 6 months. Response was assessed at Month 3 and participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts from baseline, received CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12. At Month 6, remaining participants advanced to CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, Then CP-690,550 10 mg</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week, for 3 to 6 months. Response was assessed at Month 3 and participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts from baseline, received CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12. At Month 6, remaining participants advanced to CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O5">
            <title>Adalimumab</title>
            <description>Adalimumab 40 mg injection subcutaneously once every other week along with placebo matched to CP-690,550 5 mg tablet orally twice daily up to Month 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT)-Fatigue Scale at Month 12</title>
          <description>FACIT-Fatigue scale is a 13-item questionnaire. Participant scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as 4 minus the participant's response. The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). A higher score reflected an improvement in the participant's health status.</description>
          <population>FAS: all randomized participants who received at least 1 dose of study drug and had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). N=participants evaluable for this measure.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
                <count group_id="O2" value="151"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="38"/>
                <count group_id="O5" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.76" spread="9.53"/>
                    <measurement group_id="O2" value="37.53" spread="10.41"/>
                    <measurement group_id="O3" value="36.71" spread="7.81"/>
                    <measurement group_id="O4" value="35.71" spread="9.65"/>
                    <measurement group_id="O5" value="34.30" spread="9.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Medical Outcomes Study-Sleep Scale (MOS-SS) at Baseline, Month 1, 3 and 6</title>
        <description>Participant-rated questionnaire to assess key constructs of sleep over the past week. Consists of a 12-item based on 7 sub scales: sleep disturbance (SD), snoring (Sno), awakened short of breath (ASOB) or with headache, sleep adequacy (Ade), and somnolence (Som) (range:0-100); sleep quantity (Qua)(range:0-24), and optimal (Opt) sleep (yes: 1, no: 0) and nine item index measures of sleep disturbance were constructed to provide composite scores: sleep problem summary (SPS) and overall sleep problems (OSP). Except sleep adequacy, optimal sleep and quantity, higher scores=greater impairment. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range* 100); total score range: 0 to 100; higher score = greater intensity of attribute.</description>
        <time_frame>Baseline, Month 1, 3, 6</time_frame>
        <population>FAS: all randomized participants who received at least 1 dose of study drug and had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). N=participants evaluable for this measure. n=number of participants evaluable at specific time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week for 3 to 6 months. Response was assessed at Month 3 and participants who failed to achieve at least 20% reduction from baseline in both swollen and tender joint counts, received CP-690,550 5 mg or 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12. At Month 6, remaining participants received CP-690,550 5 mg or 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O4">
            <title>Adalimumab</title>
            <description>Adalimumab 40 mg injection subcutaneously once every other week along with placebo matched to CP-690,550 5 mg tablet orally twice daily up to Month 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Medical Outcomes Study-Sleep Scale (MOS-SS) at Baseline, Month 1, 3 and 6</title>
          <description>Participant-rated questionnaire to assess key constructs of sleep over the past week. Consists of a 12-item based on 7 sub scales: sleep disturbance (SD), snoring (Sno), awakened short of breath (ASOB) or with headache, sleep adequacy (Ade), and somnolence (Som) (range:0-100); sleep quantity (Qua)(range:0-24), and optimal (Opt) sleep (yes: 1, no: 0) and nine item index measures of sleep disturbance were constructed to provide composite scores: sleep problem summary (SPS) and overall sleep problems (OSP). Except sleep adequacy, optimal sleep and quantity, higher scores=greater impairment. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range* 100); total score range: 0 to 100; higher score = greater intensity of attribute.</description>
          <population>FAS: all randomized participants who received at least 1 dose of study drug and had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). N=participants evaluable for this measure. n=number of participants evaluable at specific time points for each arm group, respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="199"/>
                <count group_id="O2" value="198"/>
                <count group_id="O3" value="105"/>
                <count group_id="O4" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: SPS (n=199, 198, 105, 200)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.13" spread="20.58"/>
                    <measurement group_id="O2" value="40.20" spread="19.48"/>
                    <measurement group_id="O3" value="39.14" spread="19.04"/>
                    <measurement group_id="O4" value="40.90" spread="19.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: OSP (n=199, 198, 105, 200)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.24" spread="19.91"/>
                    <measurement group_id="O2" value="42.27" spread="19.32"/>
                    <measurement group_id="O3" value="41.27" spread="19.47"/>
                    <measurement group_id="O4" value="43.12" spread="19.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Ade (n=200, 198, 105, 200)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.95" spread="27.92"/>
                    <measurement group_id="O2" value="44.04" spread="28.21"/>
                    <measurement group_id="O3" value="47.43" spread="26.06"/>
                    <measurement group_id="O4" value="44.25" spread="27.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: ASOB (n=200, 198, 105, 200)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.10" spread="24.91"/>
                    <measurement group_id="O2" value="15.96" spread="21.70"/>
                    <measurement group_id="O3" value="18.67" spread="24.54"/>
                    <measurement group_id="O4" value="20.00" spread="24.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: SD (n=200, 198, 105, 200)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.46" spread="26.30"/>
                    <measurement group_id="O2" value="44.67" spread="25.96"/>
                    <measurement group_id="O3" value="43.95" spread="27.40"/>
                    <measurement group_id="O4" value="46.55" spread="26.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Qua (n=200, 198, 104, 199)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.46" spread="1.36"/>
                    <measurement group_id="O2" value="6.61" spread="1.70"/>
                    <measurement group_id="O3" value="6.70" spread="1.51"/>
                    <measurement group_id="O4" value="6.65" spread="1.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Sno (n=198, 197, 105, 199)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.06" spread="31.78"/>
                    <measurement group_id="O2" value="34.62" spread="31.71"/>
                    <measurement group_id="O3" value="30.10" spread="28.16"/>
                    <measurement group_id="O4" value="34.77" spread="30.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Som (n=199, 198, 105, 199)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.52" spread="21.22"/>
                    <measurement group_id="O2" value="35.66" spread="22.28"/>
                    <measurement group_id="O3" value="36.70" spread="20.55"/>
                    <measurement group_id="O4" value="33.47" spread="19.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 1: SPS (n=194, 195, 105, 198)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.25" spread="19.19"/>
                    <measurement group_id="O2" value="34.03" spread="18.74"/>
                    <measurement group_id="O3" value="37.62" spread="18.83"/>
                    <measurement group_id="O4" value="38.16" spread="20.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 1: OSP (n=194, 195, 105, 198)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.70" spread="18.13"/>
                    <measurement group_id="O2" value="34.81" spread="18.64"/>
                    <measurement group_id="O3" value="38.77" spread="18.45"/>
                    <measurement group_id="O4" value="39.18" spread="19.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 1: Ade (n=194, 195, 105, 198)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.97" spread="27.11"/>
                    <measurement group_id="O2" value="52.62" spread="27.62"/>
                    <measurement group_id="O3" value="49.81" spread="25.87"/>
                    <measurement group_id="O4" value="46.87" spread="27.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 1: ASOB (n=194, 195, 105, 198)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.35" spread="22.52"/>
                    <measurement group_id="O2" value="14.56" spread="20.13"/>
                    <measurement group_id="O3" value="19.81" spread="23.78"/>
                    <measurement group_id="O4" value="18.69" spread="25.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 1: SD (n=194, 195, 105, 198)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.52" spread="23.48"/>
                    <measurement group_id="O2" value="35.46" spread="24.25"/>
                    <measurement group_id="O3" value="40.43" spread="26.13"/>
                    <measurement group_id="O4" value="39.41" spread="25.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 1: Qua (n=193, 195, 105, 197)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.70" spread="1.38"/>
                    <measurement group_id="O2" value="6.97" spread="1.49"/>
                    <measurement group_id="O3" value="6.74" spread="1.49"/>
                    <measurement group_id="O4" value="6.89" spread="1.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 1: Sno (n=194, 193, 104, 196)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.08" spread="32.53"/>
                    <measurement group_id="O2" value="34.30" spread="29.56"/>
                    <measurement group_id="O3" value="31.35" spread="27.13"/>
                    <measurement group_id="O4" value="32.76" spread="28.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 1: Som (n=194, 195, 105, 198)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.68" spread="21.26"/>
                    <measurement group_id="O2" value="31.04" spread="22.02"/>
                    <measurement group_id="O3" value="33.90" spread="21.80"/>
                    <measurement group_id="O4" value="33.91" spread="19.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: SPS (n=186, 185, 99, 190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.39" spread="18.66"/>
                    <measurement group_id="O2" value="32.86" spread="20.91"/>
                    <measurement group_id="O3" value="37.54" spread="19.18"/>
                    <measurement group_id="O4" value="37.21" spread="20.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: OSP (n=186, 185, 99, 190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.74" spread="18.30"/>
                    <measurement group_id="O2" value="33.44" spread="20.23"/>
                    <measurement group_id="O3" value="38.55" spread="18.97"/>
                    <measurement group_id="O4" value="38.32" spread="20.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: Ade (n=187, 185, 99, 190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.59" spread="27.67"/>
                    <measurement group_id="O2" value="53.24" spread="28.90"/>
                    <measurement group_id="O3" value="48.99" spread="28.16"/>
                    <measurement group_id="O4" value="49.21" spread="28.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: ASOB (n=187, 185, 99, 190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.18" spread="22.12"/>
                    <measurement group_id="O2" value="14.81" spread="20.62"/>
                    <measurement group_id="O3" value="18.59" spread="20.85"/>
                    <measurement group_id="O4" value="18.42" spread="24.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: SD (n=186, 185, 99, 190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.93" spread="24.29"/>
                    <measurement group_id="O2" value="32.86" spread="25.10"/>
                    <measurement group_id="O3" value="38.66" spread="26.24"/>
                    <measurement group_id="O4" value="39.95" spread="25.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: Qua (n=188, 185, 99, 190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.82" spread="1.32"/>
                    <measurement group_id="O2" value="7.03" spread="1.45"/>
                    <measurement group_id="O3" value="6.51" spread="1.56"/>
                    <measurement group_id="O4" value="6.83" spread="1.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: Sno (n=186, 184, 99, 189)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.66" spread="30.78"/>
                    <measurement group_id="O2" value="34.35" spread="30.06"/>
                    <measurement group_id="O3" value="30.10" spread="22.92"/>
                    <measurement group_id="O4" value="34.60" spread="27.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: Som (n=187, 185, 99, 190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.41" spread="19.66"/>
                    <measurement group_id="O2" value="30.74" spread="22.65"/>
                    <measurement group_id="O3" value="36.50" spread="20.10"/>
                    <measurement group_id="O4" value="31.05" spread="20.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: SPS (n=173, 181, 46, 179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.66" spread="18.60"/>
                    <measurement group_id="O2" value="31.79" spread="18.64"/>
                    <measurement group_id="O3" value="36.52" spread="19.89"/>
                    <measurement group_id="O4" value="36.31" spread="19.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: OSP (n=173, 181, 46, 179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.28" spread="17.93"/>
                    <measurement group_id="O2" value="32.46" spread="18.50"/>
                    <measurement group_id="O3" value="36.87" spread="18.51"/>
                    <measurement group_id="O4" value="36.73" spread="19.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: Ade (n=173, 181, 46, 179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.12" spread="28.85"/>
                    <measurement group_id="O2" value="53.76" spread="27.87"/>
                    <measurement group_id="O3" value="50.00" spread="26.83"/>
                    <measurement group_id="O4" value="50.22" spread="27.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: ASOB (n=173, 181, 46, 179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.65" spread="22.00"/>
                    <measurement group_id="O2" value="13.48" spread="20.21"/>
                    <measurement group_id="O3" value="16.52" spread="20.79"/>
                    <measurement group_id="O4" value="19.22" spread="22.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: SD (n=173, 181, 46, 179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.95" spread="23.76"/>
                    <measurement group_id="O2" value="32.00" spread="24.30"/>
                    <measurement group_id="O3" value="37.31" spread="24.73"/>
                    <measurement group_id="O4" value="36.39" spread="24.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: Qua (n=173, 181, 45, 178)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.86" spread="1.18"/>
                    <measurement group_id="O2" value="7.10" spread="1.60"/>
                    <measurement group_id="O3" value="6.71" spread="1.50"/>
                    <measurement group_id="O4" value="6.81" spread="1.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: Sno (n=171, 180, 46, 179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.46" spread="31.43"/>
                    <measurement group_id="O2" value="35.00" spread="29.13"/>
                    <measurement group_id="O3" value="23.91" spread="23.33"/>
                    <measurement group_id="O4" value="33.18" spread="27.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: Som (n=173, 181, 46, 179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.17" spread="17.55"/>
                    <measurement group_id="O2" value="30.39" spread="22.37"/>
                    <measurement group_id="O3" value="33.62" spread="17.72"/>
                    <measurement group_id="O4" value="31.84" spread="20.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Medical Outcomes Study-Sleep Scale (MOS-SS) at Month 12</title>
        <description>Participant-rated questionnaire to assess key constructs of sleep over the past week. Consists of a 12-item based on 7 sub scales: sleep disturbance (SD), snoring (Sno), awakened short of breath (ASOB) or with headache, sleep adequacy (Ade), and somnolence (Som) (range:0-100); sleep quantity (Qua)(range:0-24), and optimal (Opt) sleep (yes: 1, no: 0) and nine item index measures of sleep disturbance were constructed to provide composite scores: sleep problem summary (SPS) and overall sleep problems (OSP). Except sleep adequacy, optimal sleep and quantity, higher scores=greater impairment. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range* 100); total score range: 0 to 100; higher score = greater intensity of attribute.</description>
        <time_frame>Month 12</time_frame>
        <population>FAS: all randomized participants who received at least 1 dose of study drug and had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). N=participants evaluable for this measure. n=number of participants evaluable at specific time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Then CP-690,550 5 mg</title>
            <description>Placebo matched to CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week, for 3 to 6 months. Response was assessed at Month 3 and participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts from baseline, received CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12. At Month 6, remaining participants advanced to CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, Then CP-690,550 10 mg</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week, for 3 to 6 months. Response was assessed at Month 3 and participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts from baseline, received CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12. At Month 6, remaining participants advanced to CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O5">
            <title>Adalimumab</title>
            <description>Adalimumab 40 mg injection subcutaneously once every other week along with placebo matched to CP-690,550 5 mg tablet orally twice daily up to Month 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Medical Outcomes Study-Sleep Scale (MOS-SS) at Month 12</title>
          <description>Participant-rated questionnaire to assess key constructs of sleep over the past week. Consists of a 12-item based on 7 sub scales: sleep disturbance (SD), snoring (Sno), awakened short of breath (ASOB) or with headache, sleep adequacy (Ade), and somnolence (Som) (range:0-100); sleep quantity (Qua)(range:0-24), and optimal (Opt) sleep (yes: 1, no: 0) and nine item index measures of sleep disturbance were constructed to provide composite scores: sleep problem summary (SPS) and overall sleep problems (OSP). Except sleep adequacy, optimal sleep and quantity, higher scores=greater impairment. Scores are transformed (actual raw score minus lowest possible score divided by possible raw score range* 100); total score range: 0 to 100; higher score = greater intensity of attribute.</description>
          <population>FAS: all randomized participants who received at least 1 dose of study drug and had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). N=participants evaluable for this measure. n=number of participants evaluable at specific time points for each arm group, respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="150"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SPS (n=148, 150, 49, 37, 159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.62" spread="18.58"/>
                    <measurement group_id="O2" value="30.64" spread="18.42"/>
                    <measurement group_id="O3" value="34.69" spread="19.10"/>
                    <measurement group_id="O4" value="34.68" spread="21.32"/>
                    <measurement group_id="O5" value="35.72" spread="20.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OSP (n=148, 150, 49, 37, 158)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.86" spread="17.87"/>
                    <measurement group_id="O2" value="31.49" spread="17.90"/>
                    <measurement group_id="O3" value="36.00" spread="17.63"/>
                    <measurement group_id="O4" value="35.38" spread="20.40"/>
                    <measurement group_id="O5" value="36.52" spread="19.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ade (n=149, 150, 49, 37, 159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.21" spread="26.96"/>
                    <measurement group_id="O2" value="57.20" spread="28.48"/>
                    <measurement group_id="O3" value="54.29" spread="27.84"/>
                    <measurement group_id="O4" value="50.00" spread="30.18"/>
                    <measurement group_id="O5" value="49.81" spread="27.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ASOB (n=149, 150, 49, 37, 159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.78" spread="19.74"/>
                    <measurement group_id="O2" value="14.13" spread="20.67"/>
                    <measurement group_id="O3" value="21.22" spread="22.14"/>
                    <measurement group_id="O4" value="18.38" spread="18.49"/>
                    <measurement group_id="O5" value="17.48" spread="21.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SD (n=149, 150, 49, 37, 159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.82" spread="23.95"/>
                    <measurement group_id="O2" value="32.32" spread="22.41"/>
                    <measurement group_id="O3" value="37.12" spread="23.55"/>
                    <measurement group_id="O4" value="34.86" spread="23.94"/>
                    <measurement group_id="O5" value="37.36" spread="25.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Qua (n=148, 150, 49, 37, 158)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.78" spread="1.19"/>
                    <measurement group_id="O2" value="7.03" spread="1.47"/>
                    <measurement group_id="O3" value="6.86" spread="1.34"/>
                    <measurement group_id="O4" value="6.84" spread="1.34"/>
                    <measurement group_id="O5" value="6.72" spread="1.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sno (n=148, 150, 48, 37, 159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.78" spread="29.95"/>
                    <measurement group_id="O2" value="30.53" spread="27.29"/>
                    <measurement group_id="O3" value="27.50" spread="22.83"/>
                    <measurement group_id="O4" value="32.43" spread="26.81"/>
                    <measurement group_id="O5" value="34.47" spread="30.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Som (n=148, 150, 49, 37, 158)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.41" spread="18.95"/>
                    <measurement group_id="O2" value="27.07" spread="19.36"/>
                    <measurement group_id="O3" value="32.38" spread="17.53"/>
                    <measurement group_id="O4" value="29.37" spread="22.25"/>
                    <measurement group_id="O5" value="30.00" spread="21.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Optimal Sleep Assessed Using Medical Outcomes Study-Sleep Scale (MOS-SS) at Baseline, Month 1, 3 and 6</title>
        <description>MOS-SS: participant-rated 12 item questionnaire to assess constructs of sleep over past week. It included 7 subscales: sleep disturbance, snoring, awakened short of breath, sleep adequacy, somnolence, sleep quantity and optimal sleep. Participants responded whether their sleep was optimal or not by choosing yes or no. Number of participants with optimal sleep are reported.</description>
        <time_frame>Baseline, Month 1, 3, 6</time_frame>
        <population>FAS: all randomized participants who received at least 1 dose of study drug and had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). n=number of participants evaluable at specific time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week for 3 to 6 months. Response was assessed at Month 3 and participants who failed to achieve at least 20% reduction from baseline in both swollen and tender joint counts, received CP-690,550 5 mg or 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12. At Month 6, remaining participants received CP-690,550 5 mg or 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O4">
            <title>Adalimumab</title>
            <description>Adalimumab 40 mg injection subcutaneously once every other week along with placebo matched to CP-690,550 5 mg tablet orally twice daily up to Month 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Optimal Sleep Assessed Using Medical Outcomes Study-Sleep Scale (MOS-SS) at Baseline, Month 1, 3 and 6</title>
          <description>MOS-SS: participant-rated 12 item questionnaire to assess constructs of sleep over past week. It included 7 subscales: sleep disturbance, snoring, awakened short of breath, sleep adequacy, somnolence, sleep quantity and optimal sleep. Participants responded whether their sleep was optimal or not by choosing yes or no. Number of participants with optimal sleep are reported.</description>
          <population>FAS: all randomized participants who received at least 1 dose of study drug and had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). n=number of participants evaluable at specific time points for each arm group, respectively.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="199"/>
                <count group_id="O3" value="106"/>
                <count group_id="O4" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=201, 199, 106, 201)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                    <measurement group_id="O2" value="94"/>
                    <measurement group_id="O3" value="49"/>
                    <measurement group_id="O4" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 1 (n=194, 196, 106, 198)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="107"/>
                    <measurement group_id="O3" value="55"/>
                    <measurement group_id="O4" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 (n=188, 185, 99, 190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="110"/>
                    <measurement group_id="O3" value="37"/>
                    <measurement group_id="O4" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (n=174, 181, 94, 182)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="46"/>
                    <measurement group_id="O4" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Optimal Sleep Assessed Using Medical Outcomes Study-Sleep Scale (MOS-SS) at Month 12</title>
        <description>MOS-SS: participant-rated 12 item questionnaire to assess constructs of sleep over past week. It included 7 subscales: sleep disturbance, snoring, awakened short of breath, sleep adequacy, somnolence, sleep quantity and optimal sleep. Participants responded whether their sleep was optimal or not by choosing yes or no. Number of participants with optimal sleep are reported.</description>
        <time_frame>Month 12</time_frame>
        <population>FAS: all randomized participants who received at least 1 dose of study drug and had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). N=participants evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Then CP-690,550 5 mg</title>
            <description>Placebo matched to CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week, for 3 to 6 months. Response was assessed at Month 3 and participants who failed to achieve a minimum improvement of at least 20 percent (%) reduction in both swollen and tender joint counts from baseline, received CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12. At Month 6, remaining participants advanced to CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, Then CP-690,550 10 mg</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week, for 3 to 6 months. Response was assessed at Month 3 and participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts from baseline, received CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12. At Month 6, remaining participants advanced to CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O5">
            <title>Adalimumab</title>
            <description>Adalimumab 40 mg injection subcutaneously once every other week along with placebo matched to CP-690,550 5 mg tablet orally twice daily up to Month 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Optimal Sleep Assessed Using Medical Outcomes Study-Sleep Scale (MOS-SS) at Month 12</title>
          <description>MOS-SS: participant-rated 12 item questionnaire to assess constructs of sleep over past week. It included 7 subscales: sleep disturbance, snoring, awakened short of breath, sleep adequacy, somnolence, sleep quantity and optimal sleep. Participants responded whether their sleep was optimal or not by choosing yes or no. Number of participants with optimal sleep are reported.</description>
          <population>FAS: all randomized participants who received at least 1 dose of study drug and had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). N=participants evaluable for this measure.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
                <count group_id="O2" value="151"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="38"/>
                <count group_id="O5" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="84"/>
                    <measurement group_id="O3" value="28"/>
                    <measurement group_id="O4" value="19"/>
                    <measurement group_id="O5" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Euro Quality of Life-5 Dimension (EQ-5D) Health State Profile Utility Score at Baseline, Month 1, 3 and 6</title>
        <description>EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (&quot;confined to bed&quot;). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.</description>
        <time_frame>Baseline, Month 1, 3, 6</time_frame>
        <population>FAS: all randomized participants who received at least 1 dose of study drug and had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). N=participants evaluable for this measure. n=number of participants evaluable at specific time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week for 3 to 6 months. Response was assessed at Month 3 and participants who failed to achieve at least 20% reduction from baseline in both swollen and tender joint counts, received CP-690,550 5 mg or 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12. At Month 6, remaining participants received CP-690,550 5 mg or 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O4">
            <title>Adalimumab</title>
            <description>Adalimumab 40 mg injection subcutaneously once every other week along with placebo matched to CP-690,550 5 mg tablet orally twice daily up to Month 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Euro Quality of Life-5 Dimension (EQ-5D) Health State Profile Utility Score at Baseline, Month 1, 3 and 6</title>
          <description>EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (&quot;confined to bed&quot;). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.</description>
          <population>FAS: all randomized participants who received at least 1 dose of study drug and had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). N=participants evaluable for this measure. n=number of participants evaluable at specific time points for each arm group, respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
                <count group_id="O2" value="199"/>
                <count group_id="O3" value="106"/>
                <count group_id="O4" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=200, 199, 106, 201)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.43" spread="0.32"/>
                    <measurement group_id="O2" value="0.43" spread="0.32"/>
                    <measurement group_id="O3" value="0.50" spread="0.28"/>
                    <measurement group_id="O4" value="0.45" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 1 (n=192, 195, 106, 198)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.61" spread="0.23"/>
                    <measurement group_id="O2" value="0.60" spread="0.25"/>
                    <measurement group_id="O3" value="0.56" spread="0.25"/>
                    <measurement group_id="O4" value="0.58" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 (n=187, 184, 99, 189)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.62" spread="0.28"/>
                    <measurement group_id="O2" value="0.64" spread="0.28"/>
                    <measurement group_id="O3" value="0.55" spread="0.27"/>
                    <measurement group_id="O4" value="0.61" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (n=172, 180, 46, 178)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.66" spread="0.26"/>
                    <measurement group_id="O2" value="0.65" spread="0.25"/>
                    <measurement group_id="O3" value="0.58" spread="0.28"/>
                    <measurement group_id="O4" value="0.64" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Euro Quality of Life-5 Dimension (EQ-5D) Health State Profile Utility Score at Month 12</title>
        <description>EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (&quot;confined to bed&quot;). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.</description>
        <time_frame>Month 12</time_frame>
        <population>FAS: all randomized participants who received at least 1 dose of study drug and had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). N=participants evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Then CP-690,550 5 mg</title>
            <description>Placebo matched to CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week, for 3 to 6 months. Response was assessed at Month 3 and participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts from baseline, received CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12. At Month 6, remaining participants advanced to CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, Then CP-690,550 10 mg</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week, for 3 to 6 months. Response was assessed at Month 3 and participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts from baseline, received CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12. At Month 6, remaining participants advanced to CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O5">
            <title>Adalimumab</title>
            <description>Adalimumab 40 mg injection subcutaneously once every other week along with placebo matched to CP-690,550 5 mg tablet orally twice daily up to Month 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Euro Quality of Life-5 Dimension (EQ-5D) Health State Profile Utility Score at Month 12</title>
          <description>EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (&quot;confined to bed&quot;). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.</description>
          <population>FAS: all randomized participants who received at least 1 dose of study drug and had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). N=participants evaluable for this measure.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="151"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="38"/>
                <count group_id="O5" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.69" spread="0.22"/>
                    <measurement group_id="O2" value="0.69" spread="0.22"/>
                    <measurement group_id="O3" value="0.68" spread="0.20"/>
                    <measurement group_id="O4" value="0.66" spread="0.19"/>
                    <measurement group_id="O5" value="0.66" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Work Limitations Questionnaire (WLQ) Score at Month 3 and 6</title>
        <description>WLQ: participant-reported 25-item scale to evaluate degree to which health problems interfere with an ability to perform job roles along 4 dimensions: 5-items Time Management scale (TMS); 6-items Physical Demands scale (PDS); 9-items Mental-Interpersonal Demands Scale (MIDS); 5-items Output Demands scale (ODS). All the scales ranged from 0 (limited none of the time) to 100 (limited all of the time). Work Loss Index (WLI), which represented percentage of lost work over time period relative to a normative population, was derived (total score: 0 [no loss] to 100 [complete loss of work]).</description>
        <time_frame>Month 3, 6</time_frame>
        <population>FAS: all randomized participants who received at least 1 dose of study drug, had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). N=participants evaluable for this measure. n=number of participants evaluable at specific time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week for 3 to 6 months. Response was assessed at Month 3 and participants who failed to achieve at least 20% reduction from baseline in both swollen and tender joint counts, received CP-690,550 5 mg or 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12. At Month 6, remaining participants received CP-690,550 5 mg or 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O4">
            <title>Adalimumab</title>
            <description>Adalimumab 40 mg injection subcutaneously once every other week along with placebo matched to CP-690,550 5 mg tablet orally twice daily up to Month 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Work Limitations Questionnaire (WLQ) Score at Month 3 and 6</title>
          <description>WLQ: participant-reported 25-item scale to evaluate degree to which health problems interfere with an ability to perform job roles along 4 dimensions: 5-items Time Management scale (TMS); 6-items Physical Demands scale (PDS); 9-items Mental-Interpersonal Demands Scale (MIDS); 5-items Output Demands scale (ODS). All the scales ranged from 0 (limited none of the time) to 100 (limited all of the time). Work Loss Index (WLI), which represented percentage of lost work over time period relative to a normative population, was derived (total score: 0 [no loss] to 100 [complete loss of work]).</description>
          <population>FAS: all randomized participants who received at least 1 dose of study drug, had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). N=participants evaluable for this measure. n=number of participants evaluable at specific time points for each arm group, respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="42"/>
                <count group_id="O4" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: TMS (n=79, 77, 40, 76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.46" spread="23.42"/>
                    <measurement group_id="O2" value="42.09" spread="28.98"/>
                    <measurement group_id="O3" value="37.65" spread="23.69"/>
                    <measurement group_id="O4" value="46.43" spread="25.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: PDS (n=85, 76, 40, 77)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.99" spread="23.16"/>
                    <measurement group_id="O2" value="52.14" spread="24.22"/>
                    <measurement group_id="O3" value="53.24" spread="23.62"/>
                    <measurement group_id="O4" value="44.51" spread="21.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: MIDS (n=82, 79, 41, 77)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.80" spread="22.80"/>
                    <measurement group_id="O2" value="27.30" spread="22.32"/>
                    <measurement group_id="O3" value="24.85" spread="28.33"/>
                    <measurement group_id="O4" value="28.45" spread="23.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: ODS (n=80, 74, 40, 77)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.34" spread="26.55"/>
                    <measurement group_id="O2" value="37.29" spread="28.16"/>
                    <measurement group_id="O3" value="29.28" spread="26.41"/>
                    <measurement group_id="O4" value="36.82" spread="22.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: WLI (n=85, 81, 42, 81)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.76" spread="5.34"/>
                    <measurement group_id="O2" value="9.85" spread="5.67"/>
                    <measurement group_id="O3" value="8.83" spread="5.90"/>
                    <measurement group_id="O4" value="9.92" spread="5.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: TMS (n=74, 68, 40, 70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.31" spread="25.50"/>
                    <measurement group_id="O2" value="21.97" spread="25.52"/>
                    <measurement group_id="O3" value="34.26" spread="26.40"/>
                    <measurement group_id="O4" value="35.73" spread="28.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: PDS (n=77, 72, 39, 76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.03" spread="26.21"/>
                    <measurement group_id="O2" value="47.04" spread="33.97"/>
                    <measurement group_id="O3" value="55.57" spread="27.38"/>
                    <measurement group_id="O4" value="54.38" spread="28.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: MIDS (n=78, 72, 41, 73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.45" spread="22.03"/>
                    <measurement group_id="O2" value="15.14" spread="20.53"/>
                    <measurement group_id="O3" value="23.20" spread="26.04"/>
                    <measurement group_id="O4" value="22.64" spread="21.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: ODS (n=75, 70, 39, 76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.64" spread="23.61"/>
                    <measurement group_id="O2" value="19.31" spread="23.89"/>
                    <measurement group_id="O3" value="27.44" spread="25.18"/>
                    <measurement group_id="O4" value="26.57" spread="22.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: WLI (n=80, 74, 41, 78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.89" spread="5.12"/>
                    <measurement group_id="O2" value="5.92" spread="5.17"/>
                    <measurement group_id="O3" value="8.39" spread="5.73"/>
                    <measurement group_id="O4" value="8.23" spread="5.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: PDS (n=66, 65, 15, 71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.62" spread="30.05"/>
                    <measurement group_id="O2" value="53.57" spread="36.13"/>
                    <measurement group_id="O3" value="55.03" spread="29.84"/>
                    <measurement group_id="O4" value="52.17" spread="28.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: TMS (n=68, 65, 16, 67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.87" spread="26.81"/>
                    <measurement group_id="O2" value="21.30" spread="27.67"/>
                    <measurement group_id="O3" value="24.53" spread="24.19"/>
                    <measurement group_id="O4" value="29.70" spread="25.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: MIDS (n=70, 68, 16, 71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.50" spread="21.18"/>
                    <measurement group_id="O2" value="12.87" spread="22.77"/>
                    <measurement group_id="O3" value="18.26" spread="23.15"/>
                    <measurement group_id="O4" value="22.61" spread="22.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: ODS (n=67, 67, 16, 69)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.18" spread="25.53"/>
                    <measurement group_id="O2" value="16.44" spread="23.79"/>
                    <measurement group_id="O3" value="19.69" spread="20.77"/>
                    <measurement group_id="O4" value="25.82" spread="22.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: WLI (n= 70, 69, 16, 73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.32" spread="5.47"/>
                    <measurement group_id="O2" value="5.69" spread="5.54"/>
                    <measurement group_id="O3" value="6.89" spread="4.90"/>
                    <measurement group_id="O4" value="7.84" spread="5.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Work Limitations Questionnaire (WLQ) Score at Baseline and Month 12</title>
        <description>WLQ: participant-reported 25-item scale to evaluate degree to which health problems interfere with an ability to perform job roles along 4 dimensions: 5-items Time Management scale (TMS); 6-items Physical Demands scale (PDS); 9-items Mental-Interpersonal Demands Scale (MIDS); 5-items Output Demands scale (ODS). All the scales ranged from 0 (limited none of the time) to 100 (limited all of the time). Work Loss Index (WLI), which represented percentage of lost work over time period relative to a normative population, was derived (total score: 0 [no loss] to 100 [complete loss of work]).</description>
        <time_frame>Baseline, Month 12</time_frame>
        <population>FAS: all randomized participants who received at least 1 dose of study drug and had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). N=participants evaluable for this measure. n=number of participants evaluable at specific time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Then CP-690,550 5 mg</title>
            <description>Placebo matched to CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week, for 3 to 6 months. Response was assessed at Month 3 and participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts from baseline, received CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12. At Month 6, remaining participants advanced to CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, Then CP-690,550 10 mg</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week, for 3 to 6 months. Response was assessed at Month 3 and participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts from baseline, received CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12. At Month 6, remaining participants advanced to CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O5">
            <title>Adalimumab</title>
            <description>Adalimumab 40 mg injection subcutaneously once every other week along with placebo matched to CP-690,550 5 mg tablet orally twice daily up to Month 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Work Limitations Questionnaire (WLQ) Score at Baseline and Month 12</title>
          <description>WLQ: participant-reported 25-item scale to evaluate degree to which health problems interfere with an ability to perform job roles along 4 dimensions: 5-items Time Management scale (TMS); 6-items Physical Demands scale (PDS); 9-items Mental-Interpersonal Demands Scale (MIDS); 5-items Output Demands scale (ODS). All the scales ranged from 0 (limited none of the time) to 100 (limited all of the time). Work Loss Index (WLI), which represented percentage of lost work over time period relative to a normative population, was derived (total score: 0 [no loss] to 100 [complete loss of work]).</description>
          <population>FAS: all randomized participants who received at least 1 dose of study drug and had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). N=participants evaluable for this measure. n=number of participants evaluable at specific time points for each arm group, respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TMS (n=55, 53, 20, 14, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.59" spread="25.10"/>
                    <measurement group_id="O2" value="20.77" spread="28.68"/>
                    <measurement group_id="O3" value="32.69" spread="29.07"/>
                    <measurement group_id="O4" value="28.75" spread="28.26"/>
                    <measurement group_id="O5" value="26.57" spread="26.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PDS (n=55, 52, 18, 14, 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.35" spread="32.96"/>
                    <measurement group_id="O2" value="55.69" spread="38.22"/>
                    <measurement group_id="O3" value="51.81" spread="32.57"/>
                    <measurement group_id="O4" value="59.02" spread="36.59"/>
                    <measurement group_id="O5" value="50.41" spread="33.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MIDS (n=55, 51, 21, 14, 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.72" spread="19.96"/>
                    <measurement group_id="O2" value="13.96" spread="23.76"/>
                    <measurement group_id="O3" value="21.46" spread="27.11"/>
                    <measurement group_id="O4" value="19.44" spread="24.29"/>
                    <measurement group_id="O5" value="17.99" spread="20.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ODS (n=57, 50, 19, 14, 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.51" spread="23.13"/>
                    <measurement group_id="O2" value="17.35" spread="27.77"/>
                    <measurement group_id="O3" value="27.11" spread="27.29"/>
                    <measurement group_id="O4" value="25.36" spread="29.64"/>
                    <measurement group_id="O5" value="21.55" spread="22.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WLI (n=57, 55, 21, 14, 60)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.61" spread="5.07"/>
                    <measurement group_id="O2" value="5.78" spread="5.59"/>
                    <measurement group_id="O3" value="7.75" spread="6.53"/>
                    <measurement group_id="O4" value="8.06" spread="6.01"/>
                    <measurement group_id="O5" value="6.85" spread="5.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Work Productivity and Healthcare Resource Utilization (HCRU) at Baseline, Month 3 and 6</title>
        <description>Rheumatoid Arthritis (RA)-HCRU assessed healthcare usage during last 3 months for direct, indirect medical cost domains. Direct cost: any RA/non-RA related medical/non-medical (NM) practitioner visit, nursing home, hospital, surgery, emergency room (ER) treatment, diagnostic tests, over-night stay, home healthcare (HC) services, aids/devices used. Indirect costs associated with functional disability: employment status, willingness to work, work disability due to RA, sick leave, part time work, ability to perform chores, chores done by family/friends/housekeeper. Assessment was based on 0 to 2-point scale; higher score indicated higher medical cost.</description>
        <time_frame>Baseline, Month 3, 6</time_frame>
        <population>FAS: all randomized participants who received at least 1 dose of study drug and had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). N=participants evaluable for this measure. n=number of participants evaluable at specific time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week for 3 to 6 months. Response was assessed at Month 3 and participants who failed to achieve at least 20% reduction from baseline in both swollen and tender joint counts, received CP-690,550 5 mg or 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12. At Month 6, remaining participants received CP-690,550 5 mg or 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O4">
            <title>Adalimumab</title>
            <description>Adalimumab 40 mg injection subcutaneously once every other week along with placebo matched to CP-690,550 5 mg tablet orally twice daily up to Month 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Work Productivity and Healthcare Resource Utilization (HCRU) at Baseline, Month 3 and 6</title>
          <description>Rheumatoid Arthritis (RA)-HCRU assessed healthcare usage during last 3 months for direct, indirect medical cost domains. Direct cost: any RA/non-RA related medical/non-medical (NM) practitioner visit, nursing home, hospital, surgery, emergency room (ER) treatment, diagnostic tests, over-night stay, home healthcare (HC) services, aids/devices used. Indirect costs associated with functional disability: employment status, willingness to work, work disability due to RA, sick leave, part time work, ability to perform chores, chores done by family/friends/housekeeper. Assessment was based on 0 to 2-point scale; higher score indicated higher medical cost.</description>
          <population>FAS: all randomized participants who received at least 1 dose of study drug and had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). N=participants evaluable for this measure. n=number of participants evaluable at specific time points for each arm group, respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="201"/>
                <count group_id="O2" value="199"/>
                <count group_id="O3" value="106"/>
                <count group_id="O4" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: Seen any doctor (n=201, 199, 106, 201)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.16" spread="0.37"/>
                    <measurement group_id="O2" value="1.13" spread="0.34"/>
                    <measurement group_id="O3" value="1.15" spread="0.36"/>
                    <measurement group_id="O4" value="1.15" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Treated in ER (n=201, 199, 106, 201)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.95" spread="0.23"/>
                    <measurement group_id="O2" value="1.93" spread="0.26"/>
                    <measurement group_id="O3" value="1.93" spread="0.25"/>
                    <measurement group_id="O4" value="1.94" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Admitted overnight stay (n=11,14,6,12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.45" spread="0.82"/>
                    <measurement group_id="O2" value="0.21" spread="0.43"/>
                    <measurement group_id="O3" value="0.17" spread="0.41"/>
                    <measurement group_id="O4" value="0.08" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Hospitalization (n=201, 199, 106, 201)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.94" spread="0.24"/>
                    <measurement group_id="O2" value="1.97" spread="0.17"/>
                    <measurement group_id="O3" value="1.93" spread="0.25"/>
                    <measurement group_id="O4" value="1.95" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Outpatient surgeries (n=200,199,106,201)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.96" spread="0.20"/>
                    <measurement group_id="O2" value="1.97" spread="0.17"/>
                    <measurement group_id="O3" value="1.98" spread="0.14"/>
                    <measurement group_id="O4" value="1.97" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Diagnostic tests (n=200,199,106,200)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.81" spread="0.39"/>
                    <measurement group_id="O2" value="1.83" spread="0.37"/>
                    <measurement group_id="O3" value="1.82" spread="0.39"/>
                    <measurement group_id="O4" value="1.82" spread="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: In nursing home (n=201, 199, 106, 201)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.99" spread="0.12"/>
                    <measurement group_id="O2" value="2.00" spread="0.00"/>
                    <measurement group_id="O3" value="2.00" spread="0.00"/>
                    <measurement group_id="O4" value="1.98" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Home HC services (n=201, 198, 106, 201)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.99" spread="0.10"/>
                    <measurement group_id="O2" value="1.99" spread="0.10"/>
                    <measurement group_id="O3" value="1.99" spread="0.10"/>
                    <measurement group_id="O4" value="1.99" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:Required aids/devices (n=201,199,106,201)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.92" spread="0.28"/>
                    <measurement group_id="O2" value="1.86" spread="0.35"/>
                    <measurement group_id="O3" value="1.92" spread="0.28"/>
                    <measurement group_id="O4" value="1.91" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Seen NM practitioner (n=201,199,106,201)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.99" spread="0.12"/>
                    <measurement group_id="O2" value="1.97" spread="0.17"/>
                    <measurement group_id="O3" value="1.98" spread="0.14"/>
                    <measurement group_id="O4" value="1.97" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Currently employed (n=201,199,106,201)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.64" spread="0.48"/>
                    <measurement group_id="O2" value="1.65" spread="0.48"/>
                    <measurement group_id="O3" value="1.64" spread="0.48"/>
                    <measurement group_id="O4" value="1.65" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Feel well enough to work (n=73,83,39,81)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.90" spread="0.30"/>
                    <measurement group_id="O2" value="1.89" spread="0.31"/>
                    <measurement group_id="O3" value="1.82" spread="0.39"/>
                    <measurement group_id="O4" value="1.80" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Retired (n=80,88,45,89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.41" spread="0.50"/>
                    <measurement group_id="O2" value="1.41" spread="0.49"/>
                    <measurement group_id="O3" value="1.40" spread="0.50"/>
                    <measurement group_id="O4" value="1.39" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Lost job/retired early(n=66,82,39,81)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" spread="0.50"/>
                    <measurement group_id="O2" value="1.70" spread="0.46"/>
                    <measurement group_id="O3" value="1.74" spread="0.44"/>
                    <measurement group_id="O4" value="1.57" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Unable to work due to RA (n=76,84,40,78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.36" spread="0.48"/>
                    <measurement group_id="O2" value="1.37" spread="0.49"/>
                    <measurement group_id="O3" value="1.45" spread="0.50"/>
                    <measurement group_id="O4" value="1.37" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Work disabled due to RA (n=66,82,40,79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.56" spread="0.50"/>
                    <measurement group_id="O2" value="1.70" spread="0.46"/>
                    <measurement group_id="O3" value="1.70" spread="0.46"/>
                    <measurement group_id="O4" value="1.65" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Sick leave due to RA (n=167,166,92,167)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.85" spread="0.36"/>
                    <measurement group_id="O2" value="1.86" spread="0.35"/>
                    <measurement group_id="O3" value="1.84" spread="0.37"/>
                    <measurement group_id="O4" value="1.83" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Part time work (n=169,166,92,167)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.92" spread="0.27"/>
                    <measurement group_id="O2" value="1.92" spread="0.27"/>
                    <measurement group_id="O3" value="1.93" spread="0.25"/>
                    <measurement group_id="O4" value="1.94" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Performed paid work(n=169,166,91,167)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.69" spread="0.46"/>
                    <measurement group_id="O2" value="1.70" spread="0.46"/>
                    <measurement group_id="O3" value="1.66" spread="0.48"/>
                    <measurement group_id="O4" value="1.67" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Unable to do chores (n=201,199,105,198)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.41" spread="0.49"/>
                    <measurement group_id="O2" value="1.46" spread="0.50"/>
                    <measurement group_id="O3" value="1.53" spread="0.50"/>
                    <measurement group_id="O4" value="1.41" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Chores by housekeeper(n=201,199,106,201)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.89" spread="0.32"/>
                    <measurement group_id="O2" value="1.90" spread="0.29"/>
                    <measurement group_id="O3" value="1.93" spread="0.25"/>
                    <measurement group_id="O4" value="1.91" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Chores by family (n=200,199,106,201)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" spread="0.50"/>
                    <measurement group_id="O2" value="1.48" spread="0.50"/>
                    <measurement group_id="O3" value="1.62" spread="0.49"/>
                    <measurement group_id="O4" value="1.51" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: Seen any doctor (n=186,185,99,190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.27" spread="0.45"/>
                    <measurement group_id="O2" value="1.28" spread="0.45"/>
                    <measurement group_id="O3" value="1.22" spread="0.42"/>
                    <measurement group_id="O4" value="1.29" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: Treated in ER (n=186,185,99,190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.96" spread="0.20"/>
                    <measurement group_id="O2" value="1.96" spread="0.19"/>
                    <measurement group_id="O3" value="1.96" spread="0.20"/>
                    <measurement group_id="O4" value="1.95" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: Admitted overnight stay (n=8,8,4,9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" spread="0.46"/>
                    <measurement group_id="O2" value="0.88" spread="0.99"/>
                    <measurement group_id="O3" value="0.00" spread="0.00"/>
                    <measurement group_id="O4" value="0.22" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: Hospitalization (n=185,185,99,190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.98" spread="0.15"/>
                    <measurement group_id="O2" value="1.97" spread="0.16"/>
                    <measurement group_id="O3" value="1.99" spread="0.10"/>
                    <measurement group_id="O4" value="1.98" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: Outpatient surgeries (n=185,185,99,190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.98" spread="0.13"/>
                    <measurement group_id="O2" value="1.98" spread="0.15"/>
                    <measurement group_id="O3" value="1.96" spread="0.20"/>
                    <measurement group_id="O4" value="1.97" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: Diagnostic tests (n=184,185,99,190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.90" spread="0.30"/>
                    <measurement group_id="O2" value="1.87" spread="0.34"/>
                    <measurement group_id="O3" value="1.91" spread="0.29"/>
                    <measurement group_id="O4" value="1.89" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: In nursing home (n=185,185,99,190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.99" spread="0.07"/>
                    <measurement group_id="O2" value="2.00" spread="0.00"/>
                    <measurement group_id="O3" value="2.00" spread="0.00"/>
                    <measurement group_id="O4" value="1.99" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: Home HC services (n=184,185,99,190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.99" spread="0.07"/>
                    <measurement group_id="O2" value="2.00" spread="0.00"/>
                    <measurement group_id="O3" value="2.00" spread="0.00"/>
                    <measurement group_id="O4" value="2.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: Required aids/devices (n=185,185,99,190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.94" spread="0.25"/>
                    <measurement group_id="O2" value="1.91" spread="0.29"/>
                    <measurement group_id="O3" value="1.92" spread="0.27"/>
                    <measurement group_id="O4" value="1.92" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: Seen NM practitioner (n=185,185,99,190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.97" spread="0.16"/>
                    <measurement group_id="O2" value="2.00" spread="0.00"/>
                    <measurement group_id="O3" value="1.98" spread="0.14"/>
                    <measurement group_id="O4" value="1.98" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: Currently employed (n=185,185,99,190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.62" spread="0.49"/>
                    <measurement group_id="O2" value="1.64" spread="0.48"/>
                    <measurement group_id="O3" value="1.63" spread="0.49"/>
                    <measurement group_id="O4" value="1.64" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: Feel well enough to work (n=74,79,41,80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.70" spread="0.46"/>
                    <measurement group_id="O2" value="1.73" spread="0.44"/>
                    <measurement group_id="O3" value="1.93" spread="0.26"/>
                    <measurement group_id="O4" value="1.74" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: Retired (n=80,86,47,86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.39" spread="0.49"/>
                    <measurement group_id="O2" value="1.34" spread="0.48"/>
                    <measurement group_id="O3" value="1.38" spread="0.49"/>
                    <measurement group_id="O4" value="1.38" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: Lost job/retired early(n=73,78,40,79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.55" spread="0.50"/>
                    <measurement group_id="O2" value="1.59" spread="0.50"/>
                    <measurement group_id="O3" value="1.75" spread="0.44"/>
                    <measurement group_id="O4" value="1.65" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: Unable to work due to RA (n=76,83,44,77)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.42" spread="0.50"/>
                    <measurement group_id="O2" value="1.46" spread="0.50"/>
                    <measurement group_id="O3" value="1.45" spread="0.50"/>
                    <measurement group_id="O4" value="1.58" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: Work disabled due to RA (n=71,82,41,73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.63" spread="0.49"/>
                    <measurement group_id="O2" value="1.68" spread="0.47"/>
                    <measurement group_id="O3" value="1.61" spread="0.49"/>
                    <measurement group_id="O4" value="1.74" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: Sick leave due to RA (n=153,146,85,157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.93" spread="0.26"/>
                    <measurement group_id="O2" value="1.94" spread="0.24"/>
                    <measurement group_id="O3" value="1.81" spread="0.39"/>
                    <measurement group_id="O4" value="1.90" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: Part time work (n=153,145,85,155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.95" spread="0.21"/>
                    <measurement group_id="O2" value="1.97" spread="0.16"/>
                    <measurement group_id="O3" value="1.94" spread="0.24"/>
                    <measurement group_id="O4" value="1.94" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: Performed paid work(n=153,145,85,157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.73" spread="0.45"/>
                    <measurement group_id="O2" value="1.81" spread="0.39"/>
                    <measurement group_id="O3" value="1.68" spread="0.47"/>
                    <measurement group_id="O4" value="1.70" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: Unable to do chores(n=182,182,99,189)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.62" spread="0.49"/>
                    <measurement group_id="O2" value="1.71" spread="0.46"/>
                    <measurement group_id="O3" value="1.59" spread="0.50"/>
                    <measurement group_id="O4" value="1.66" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: Chores by housekeeper (n=184,183,99,190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.91" spread="0.29"/>
                    <measurement group_id="O2" value="1.94" spread="0.24"/>
                    <measurement group_id="O3" value="1.93" spread="0.26"/>
                    <measurement group_id="O4" value="1.94" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: Chores by family (n=183,183,99,190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.67" spread="0.47"/>
                    <measurement group_id="O2" value="1.74" spread="0.44"/>
                    <measurement group_id="O3" value="1.66" spread="0.48"/>
                    <measurement group_id="O4" value="1.68" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: Seen any doctor (n=173,180,45,179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.25" spread="0.43"/>
                    <measurement group_id="O2" value="1.28" spread="0.45"/>
                    <measurement group_id="O3" value="1.27" spread="0.45"/>
                    <measurement group_id="O4" value="1.31" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: Treated in ER (n=173,180,46,179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.93" spread="0.25"/>
                    <measurement group_id="O2" value="1.97" spread="0.18"/>
                    <measurement group_id="O3" value="1.91" spread="0.28"/>
                    <measurement group_id="O4" value="1.98" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: Admitted overnight stay (n=12,6,4,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.58" spread="0.67"/>
                    <measurement group_id="O2" value="0.17" spread="0.41"/>
                    <measurement group_id="O3" value="0.00" spread="0.00"/>
                    <measurement group_id="O4" value="0.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: Hospitalization (n=172,180,46,179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.95" spread="0.22"/>
                    <measurement group_id="O2" value="1.97" spread="0.16"/>
                    <measurement group_id="O3" value="1.96" spread="0.21"/>
                    <measurement group_id="O4" value="1.99" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: Outpatient surgeries (n=173,180,46,178)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.98" spread="0.15"/>
                    <measurement group_id="O2" value="1.96" spread="0.19"/>
                    <measurement group_id="O3" value="1.98" spread="0.15"/>
                    <measurement group_id="O4" value="1.99" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: Diagnostic tests (n=173,180,46,178)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.87" spread="0.33"/>
                    <measurement group_id="O2" value="1.86" spread="0.35"/>
                    <measurement group_id="O3" value="1.89" spread="0.31"/>
                    <measurement group_id="O4" value="1.89" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: In nursing home (n=173,180,46,178)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.99" spread="0.11"/>
                    <measurement group_id="O2" value="2.00" spread="0.00"/>
                    <measurement group_id="O3" value="2.00" spread="0.00"/>
                    <measurement group_id="O4" value="2.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: Home HC services (n=173,180,46,177)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.99" spread="0.11"/>
                    <measurement group_id="O2" value="1.99" spread="0.11"/>
                    <measurement group_id="O3" value="2.00" spread="0.00"/>
                    <measurement group_id="O4" value="2.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: Required aids/devices (n=173,180,46,178)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.91" spread="0.28"/>
                    <measurement group_id="O2" value="1.91" spread="0.29"/>
                    <measurement group_id="O3" value="1.87" spread="0.34"/>
                    <measurement group_id="O4" value="1.92" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: Seen NM practitioner (n=173,180,45,178)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" spread="0.00"/>
                    <measurement group_id="O2" value="1.98" spread="0.13"/>
                    <measurement group_id="O3" value="2.00" spread="0.00"/>
                    <measurement group_id="O4" value="1.99" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: Currently employed (n=173,180,46,179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.62" spread="0.49"/>
                    <measurement group_id="O2" value="1.66" spread="0.48"/>
                    <measurement group_id="O3" value="1.63" spread="0.49"/>
                    <measurement group_id="O4" value="1.63" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: Feel well enough to work (72,81,23,76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.75" spread="0.44"/>
                    <measurement group_id="O2" value="1.77" spread="0.43"/>
                    <measurement group_id="O3" value="1.83" spread="0.39"/>
                    <measurement group_id="O4" value="1.71" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: Retired (n=77,87,22,82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.32" spread="0.47"/>
                    <measurement group_id="O2" value="1.30" spread="0.46"/>
                    <measurement group_id="O3" value="1.32" spread="0.48"/>
                    <measurement group_id="O4" value="1.35" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: Lost job/retired early (n=70,82,22,72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.57" spread="0.50"/>
                    <measurement group_id="O2" value="1.66" spread="0.48"/>
                    <measurement group_id="O3" value="1.68" spread="0.48"/>
                    <measurement group_id="O4" value="1.67" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: Unable to work due to RA (n=73,83,23,74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.51" spread="0.50"/>
                    <measurement group_id="O2" value="1.54" spread="0.50"/>
                    <measurement group_id="O3" value="1.48" spread="0.51"/>
                    <measurement group_id="O4" value="1.57" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: Work disabled due to RA (n=67,80,22,72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.72" spread="0.45"/>
                    <measurement group_id="O2" value="1.70" spread="0.46"/>
                    <measurement group_id="O3" value="1.73" spread="0.46"/>
                    <measurement group_id="O4" value="1.72" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: Sick leave due to RA (n=138,134,38,144)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.93" spread="0.25"/>
                    <measurement group_id="O2" value="1.93" spread="0.25"/>
                    <measurement group_id="O3" value="1.92" spread="0.27"/>
                    <measurement group_id="O4" value="1.94" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: Part time work (n=135,134,37,142)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.94" spread="0.24"/>
                    <measurement group_id="O2" value="1.96" spread="0.21"/>
                    <measurement group_id="O3" value="1.97" spread="0.16"/>
                    <measurement group_id="O4" value="1.95" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: Performed paid work (n=136,136,38,142)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.75" spread="0.43"/>
                    <measurement group_id="O2" value="1.80" spread="0.40"/>
                    <measurement group_id="O3" value="1.74" spread="0.45"/>
                    <measurement group_id="O4" value="1.76" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: Unable to do chores(n=171,178,45,175)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.70" spread="0.46"/>
                    <measurement group_id="O2" value="1.74" spread="0.44"/>
                    <measurement group_id="O3" value="1.62" spread="0.49"/>
                    <measurement group_id="O4" value="1.67" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: Chores by housekeeper (n=172,180,45,180)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.92" spread="0.27"/>
                    <measurement group_id="O2" value="1.94" spread="0.23"/>
                    <measurement group_id="O3" value="1.93" spread="0.25"/>
                    <measurement group_id="O4" value="1.96" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: Chores by family (n=172,180,46,180)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.72" spread="0.45"/>
                    <measurement group_id="O2" value="1.74" spread="0.44"/>
                    <measurement group_id="O3" value="1.67" spread="0.47"/>
                    <measurement group_id="O4" value="1.71" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Work Productivity and Healthcare Resource Utilization (HCRU) at Month 12</title>
        <description>RA-HCRU assessed healthcare usage during last 3 months for direct, indirect medical cost domains. Direct cost: visit to doctor, NM practitioner, nursing home, hospital, surgery, ER treatment, diagnostic tests, over-night stay, home HC services, and aids/devices used. Indirect costs associated with functional disability: employment status, willingness to work, work disability due to RA, sick leave, part time work, ability to perform chores, chores done by family/friends/housekeeper. Assessment was based on 0 to 2-point scale; higher score indicated higher medical cost.</description>
        <time_frame>Month 12</time_frame>
        <population>FAS: all randomized participants who received at least 1 dose of study drug and had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). N=participants evaluable for this measure. n=number of participants evaluable at specific time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Then CP-690,550 5 mg</title>
            <description>Placebo matched to CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week, for 3 to 6 months. Response was assessed at Month 3 and participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts from baseline, received CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12. At Month 6, remaining participants advanced to CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, Then CP-690,550 10 mg</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week, for 3 to 6 months. Response was assessed at Month 3 and participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts from baseline, received CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12. At Month 6, remaining participants advanced to CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O5">
            <title>Adalimumab</title>
            <description>Adalimumab 40 mg injection subcutaneously once every other week along with placebo matched to CP-690,550 5 mg tablet orally twice daily up to Month 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Work Productivity and Healthcare Resource Utilization (HCRU) at Month 12</title>
          <description>RA-HCRU assessed healthcare usage during last 3 months for direct, indirect medical cost domains. Direct cost: visit to doctor, NM practitioner, nursing home, hospital, surgery, ER treatment, diagnostic tests, over-night stay, home HC services, and aids/devices used. Indirect costs associated with functional disability: employment status, willingness to work, work disability due to RA, sick leave, part time work, ability to perform chores, chores done by family/friends/housekeeper. Assessment was based on 0 to 2-point scale; higher score indicated higher medical cost.</description>
          <population>FAS: all randomized participants who received at least 1 dose of study drug and had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). N=participants evaluable for this measure. n=number of participants evaluable at specific time points for each arm group, respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="151"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="38"/>
                <count group_id="O5" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Seen any doctor (n=148,151,49,38,160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.31" spread="0.46"/>
                    <measurement group_id="O2" value="1.27" spread="0.45"/>
                    <measurement group_id="O3" value="1.24" spread="0.43"/>
                    <measurement group_id="O4" value="1.24" spread="0.43"/>
                    <measurement group_id="O5" value="1.23" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treated in ER (n=149,151,49,38,160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.98" spread="0.14"/>
                    <measurement group_id="O2" value="1.97" spread="0.18"/>
                    <measurement group_id="O3" value="2.00" spread="0.00"/>
                    <measurement group_id="O4" value="1.97" spread="0.16"/>
                    <measurement group_id="O5" value="1.96" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Admitted overnight stay (n=3,5,0,1,6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.33" spread="0.58"/>
                    <measurement group_id="O2" value="0.20" spread="0.45"/>
                    <measurement group_id="O3" value="NA">Data not available as no participant was evaluable for the treatment arm at the given time point.</measurement>
                    <measurement group_id="O4" value="0.00">Standard deviation was not estimable since only 1 participant was evaluable.</measurement>
                    <measurement group_id="O5" value="0.17" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hospitalization (n=148,151,49,38,160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.98" spread="0.14"/>
                    <measurement group_id="O2" value="1.97" spread="0.18"/>
                    <measurement group_id="O3" value="1.98" spread="0.14"/>
                    <measurement group_id="O4" value="1.97" spread="0.16"/>
                    <measurement group_id="O5" value="1.98" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Outpatient surgeries (n=148,151,49,38,160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.97" spread="0.18"/>
                    <measurement group_id="O2" value="1.99" spread="0.11"/>
                    <measurement group_id="O3" value="2.00" spread="0.00"/>
                    <measurement group_id="O4" value="1.95" spread="0.23"/>
                    <measurement group_id="O5" value="1.97" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diagnostic tests (n=149,151,49,38,159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.94" spread="0.24"/>
                    <measurement group_id="O2" value="1.87" spread="0.33"/>
                    <measurement group_id="O3" value="1.88" spread="0.33"/>
                    <measurement group_id="O4" value="1.84" spread="0.37"/>
                    <measurement group_id="O5" value="1.86" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>In nursing home (n=149,151,49,38,159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.99" spread="0.12"/>
                    <measurement group_id="O2" value="2.00" spread="0.00"/>
                    <measurement group_id="O3" value="2.00" spread="0.00"/>
                    <measurement group_id="O4" value="2.00" spread="0.00"/>
                    <measurement group_id="O5" value="1.99" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Home HC services (n=148,151,49,38,159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" spread="0.00"/>
                    <measurement group_id="O2" value="2.00" spread="0.00"/>
                    <measurement group_id="O3" value="2.00" spread="0.00"/>
                    <measurement group_id="O4" value="2.00" spread="0.00"/>
                    <measurement group_id="O5" value="1.99" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Required aids/devices (n=148,151,49,38,160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.93" spread="0.26"/>
                    <measurement group_id="O2" value="1.92" spread="0.27"/>
                    <measurement group_id="O3" value="1.94" spread="0.24"/>
                    <measurement group_id="O4" value="1.92" spread="0.27"/>
                    <measurement group_id="O5" value="1.91" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seen NM practitioner(n=149,151,49,38,160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.98" spread="0.14"/>
                    <measurement group_id="O2" value="1.97" spread="0.16"/>
                    <measurement group_id="O3" value="1.98" spread="0.14"/>
                    <measurement group_id="O4" value="1.95" spread="0.23"/>
                    <measurement group_id="O5" value="2.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently employed (n=148,151,49,38,160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.59" spread="0.49"/>
                    <measurement group_id="O2" value="1.68" spread="0.47"/>
                    <measurement group_id="O3" value="1.61" spread="0.49"/>
                    <measurement group_id="O4" value="1.61" spread="0.50"/>
                    <measurement group_id="O5" value="1.64" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Feel well enough to work (n=61,79,19,19,76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.72" spread="0.45"/>
                    <measurement group_id="O2" value="1.75" spread="0.44"/>
                    <measurement group_id="O3" value="1.84" spread="0.37"/>
                    <measurement group_id="O4" value="1.84" spread="0.37"/>
                    <measurement group_id="O5" value="1.68" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Retired (n=64,84,21,19,80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.25" spread="0.44"/>
                    <measurement group_id="O2" value="1.31" spread="0.47"/>
                    <measurement group_id="O3" value="1.19" spread="0.40"/>
                    <measurement group_id="O4" value="1.53" spread="0.51"/>
                    <measurement group_id="O5" value="1.35" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lost job/retired early (n=58,75,19,18,75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.53" spread="0.50"/>
                    <measurement group_id="O2" value="1.72" spread="0.45"/>
                    <measurement group_id="O3" value="1.68" spread="0.48"/>
                    <measurement group_id="O4" value="1.78" spread="0.43"/>
                    <measurement group_id="O5" value="1.67" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unable to work due to RA (n=59,77,19,19,77)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.56" spread="0.50"/>
                    <measurement group_id="O2" value="1.61" spread="0.49"/>
                    <measurement group_id="O3" value="1.58" spread="0.51"/>
                    <measurement group_id="O4" value="1.58" spread="0.51"/>
                    <measurement group_id="O5" value="1.57" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Work disabled due to RA (n=58,76,19,18,75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.64" spread="0.48"/>
                    <measurement group_id="O2" value="1.75" spread="0.44"/>
                    <measurement group_id="O3" value="1.79" spread="0.42"/>
                    <measurement group_id="O4" value="1.67" spread="0.49"/>
                    <measurement group_id="O5" value="1.67" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sick leave due to RA (n=118,112,37,30,124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.96" spread="0.20"/>
                    <measurement group_id="O2" value="1.96" spread="0.19"/>
                    <measurement group_id="O3" value="1.95" spread="0.23"/>
                    <measurement group_id="O4" value="2.00" spread="0.00"/>
                    <measurement group_id="O5" value="1.97" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part time work (n=117,112,37,30,123)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.95" spread="0.22"/>
                    <measurement group_id="O2" value="1.99" spread="0.09"/>
                    <measurement group_id="O3" value="2.00" spread="0.00"/>
                    <measurement group_id="O4" value="2.00" spread="0.00"/>
                    <measurement group_id="O5" value="1.99" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Performed paid work (n=118,114,37,31,123)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.83" spread="0.38"/>
                    <measurement group_id="O2" value="1.82" spread="0.39"/>
                    <measurement group_id="O3" value="1.78" spread="0.42"/>
                    <measurement group_id="O4" value="1.71" spread="0.46"/>
                    <measurement group_id="O5" value="1.82" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unable to do chores (n=146,150,47,38,154)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.81" spread="0.40"/>
                    <measurement group_id="O2" value="1.75" spread="0.44"/>
                    <measurement group_id="O3" value="1.79" spread="0.41"/>
                    <measurement group_id="O4" value="1.84" spread="0.37"/>
                    <measurement group_id="O5" value="1.73" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chores by housekeeper (n=148,151,49,38,160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.94" spread="0.24"/>
                    <measurement group_id="O2" value="1.97" spread="0.16"/>
                    <measurement group_id="O3" value="1.96" spread="0.20"/>
                    <measurement group_id="O4" value="1.95" spread="0.23"/>
                    <measurement group_id="O5" value="1.93" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chores by family (n=145,151,49,38,160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.76" spread="0.43"/>
                    <measurement group_id="O2" value="1.80" spread="0.40"/>
                    <measurement group_id="O3" value="1.84" spread="0.37"/>
                    <measurement group_id="O4" value="1.71" spread="0.46"/>
                    <measurement group_id="O5" value="1.71" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Events Including Visits, Surgeries, Tests or Devices as Assessed Using RA-HCRU at Baseline, Month 3 and 6</title>
        <description>RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains. Any RA/non-RA related number of events including visits to doctor, non-medical practitioner, hospital ER treatment, hospitalizations, number of surgeries, diagnostic tests, and devices/aids used were reported.</description>
        <time_frame>Baseline, Month 3, 6</time_frame>
        <population>FAS: all randomized participants who received at least 1 dose of study drug and had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). N=participants evaluable for this measure. n=number of participants evaluable at specific time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week for 3 to 6 months. Response was assessed at Month 3 and participants who failed to achieve at least 20% reduction from baseline in both swollen and tender joint counts, received CP-690,550 5 mg or 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12. At Month 6, remaining participants received CP-690,550 5 mg or 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O4">
            <title>Adalimumab</title>
            <description>Adalimumab 40 mg injection subcutaneously once every other week along with placebo matched to CP-690,550 5 mg tablet orally twice daily up to Month 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Events Including Visits, Surgeries, Tests or Devices as Assessed Using RA-HCRU at Baseline, Month 3 and 6</title>
          <description>RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains. Any RA/non-RA related number of events including visits to doctor, non-medical practitioner, hospital ER treatment, hospitalizations, number of surgeries, diagnostic tests, and devices/aids used were reported.</description>
          <population>FAS: all randomized participants who received at least 1 dose of study drug and had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). N=participants evaluable for this measure. n=number of participants evaluable at specific time points for each arm group, respectively.</population>
          <units>events</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="174"/>
                <count group_id="O3" value="90"/>
                <count group_id="O4" value="172"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: Doctor visits (n=168,174,90,172)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.26" spread="3.51"/>
                    <measurement group_id="O2" value="4.06" spread="3.57"/>
                    <measurement group_id="O3" value="4.50" spread="5.32"/>
                    <measurement group_id="O4" value="3.87" spread="3.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: NM practitioners visits (n=3,6,2,6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.33" spread="0.58"/>
                    <measurement group_id="O2" value="3.00" spread="1.79"/>
                    <measurement group_id="O3" value="4.50" spread="4.95"/>
                    <measurement group_id="O4" value="10.00" spread="10.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Hospital ER visits (n=12,14,7,12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.08" spread="0.51"/>
                    <measurement group_id="O2" value="1.93" spread="1.59"/>
                    <measurement group_id="O3" value="1.57" spread="0.79"/>
                    <measurement group_id="O4" value="1.58" spread="1.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Number visits hospitalized(n=11,5,7,11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.82" spread="5.71"/>
                    <measurement group_id="O2" value="1.00" spread="0.00"/>
                    <measurement group_id="O3" value="1.00" spread="0.00"/>
                    <measurement group_id="O4" value="1.27" spread="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:Number of outpatient surgeries(n=8,6,2,7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.13" spread="0.35"/>
                    <measurement group_id="O2" value="1.33" spread="0.82"/>
                    <measurement group_id="O3" value="1.00" spread="0.00"/>
                    <measurement group_id="O4" value="2.57" spread="4.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:Non-study diagnostic tests(n=37,33,19,36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.73" spread="1.04"/>
                    <measurement group_id="O2" value="1.79" spread="1.17"/>
                    <measurement group_id="O3" value="1.21" spread="0.54"/>
                    <measurement group_id="O4" value="1.64" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:RA related doctor visit(n=169,175,91,172)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.33" spread="1.03"/>
                    <measurement group_id="O2" value="1.17" spread="0.70"/>
                    <measurement group_id="O3" value="1.26" spread="0.81"/>
                    <measurement group_id="O4" value="1.19" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: RA related ER visit (n=11,14,6,12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.64" spread="0.81"/>
                    <measurement group_id="O2" value="0.64" spread="0.74"/>
                    <measurement group_id="O3" value="0.17" spread="0.41"/>
                    <measurement group_id="O4" value="0.25" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: RA diagnostic tests (n=38,33,19,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50" spread="0.76"/>
                    <measurement group_id="O2" value="0.55" spread="0.62"/>
                    <measurement group_id="O3" value="0.47" spread="0.61"/>
                    <measurement group_id="O4" value="0.84" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: RA related hospitalization (n=11,6,7,11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.91" spread="0.83"/>
                    <measurement group_id="O2" value="0.67" spread="0.52"/>
                    <measurement group_id="O3" value="0.57" spread="0.79"/>
                    <measurement group_id="O4" value="0.82" spread="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: RA related outpatient surgery(n=7,6,3,7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.43" spread="0.79"/>
                    <measurement group_id="O2" value="0.33" spread="0.82"/>
                    <measurement group_id="O3" value="0.33" spread="0.58"/>
                    <measurement group_id="O4" value="0.43" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: RA related NM visit (n=3,6,2,6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.67" spread="0.58"/>
                    <measurement group_id="O2" value="0.50" spread="0.84"/>
                    <measurement group_id="O3" value="1.00" spread="0.00"/>
                    <measurement group_id="O4" value="1.00" spread="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: Doctor visits (n=136,138,78,136)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.62" spread="4.25"/>
                    <measurement group_id="O2" value="2.86" spread="2.99"/>
                    <measurement group_id="O3" value="3.27" spread="3.93"/>
                    <measurement group_id="O4" value="3.05" spread="2.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: NM practitioners visits (n=5,0,2,2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.40" spread="0.89"/>
                    <measurement group_id="O2" value="NA">Data not available as no participant was evaluable for the treatment arm at the given time point.</measurement>
                    <measurement group_id="O3" value="17.00" spread="21.21"/>
                    <measurement group_id="O4" value="7.50" spread="9.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: Hospital ER visits (n=8,8,4,10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.38" spread="0.74"/>
                    <measurement group_id="O2" value="1.00" spread="0.00"/>
                    <measurement group_id="O3" value="1.75" spread="1.50"/>
                    <measurement group_id="O4" value="1.90" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: Number visits hospitalized (n=4,6,1,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" spread="1.00"/>
                    <measurement group_id="O2" value="1.00" spread="0.00"/>
                    <measurement group_id="O3" value="1.00">Standard deviation was not estimable since only 1 participant was evaluable.</measurement>
                    <measurement group_id="O4" value="1.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: Number of outpatient surgeries(n=3,4,4,6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.67" spread="0.58"/>
                    <measurement group_id="O2" value="1.00" spread="0.00"/>
                    <measurement group_id="O3" value="1.00" spread="0.00"/>
                    <measurement group_id="O4" value="1.33" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: Non-study diagnostic tests (n=18,23,9,20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.72" spread="1.41"/>
                    <measurement group_id="O2" value="1.52" spread="0.79"/>
                    <measurement group_id="O3" value="1.56" spread="0.88"/>
                    <measurement group_id="O4" value="1.45" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: RA related doctor visit(n=136,138,78,136)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.91" spread="0.75"/>
                    <measurement group_id="O2" value="0.92" spread="0.67"/>
                    <measurement group_id="O3" value="0.90" spread="0.71"/>
                    <measurement group_id="O4" value="0.93" spread="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: RA related ER visit (n=8,8,4,9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" spread="0.46"/>
                    <measurement group_id="O2" value="0.50" spread="0.76"/>
                    <measurement group_id="O3" value="0.00" spread="0.00"/>
                    <measurement group_id="O4" value="0.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: RA-diagnostic tests (n=19,24,9,21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" spread="0.32"/>
                    <measurement group_id="O2" value="0.21" spread="0.51"/>
                    <measurement group_id="O3" value="0.11" spread="0.33"/>
                    <measurement group_id="O4" value="0.24" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: RA related hospitalization (n=4,6,1,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.17" spread="0.41"/>
                    <measurement group_id="O3" value="0.00">Standard deviation was not estimable since only 1 participant were evaluable.</measurement>
                    <measurement group_id="O4" value="0.67" spread="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: RA related outpatient surgery (n=3,4,4,6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.25" spread="0.50"/>
                    <measurement group_id="O3" value="0.25" spread="0.50"/>
                    <measurement group_id="O4" value="0.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: RA related NM visit (n=5,0,2,2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.60" spread="0.89"/>
                    <measurement group_id="O2" value="NA">Data not available as no participant was evaluable for the treatment arm at the given time point.</measurement>
                    <measurement group_id="O3" value="1.50" spread="0.71"/>
                    <measurement group_id="O4" value="0.50" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: Doctor visits (n=132,131,33,128)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.30" spread="4.17"/>
                    <measurement group_id="O2" value="2.86" spread="4.23"/>
                    <measurement group_id="O3" value="2.52" spread="1.91"/>
                    <measurement group_id="O4" value="2.73" spread="2.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: NM practitioners visits (n=1,3,0,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00">Standard deviation was not estimable since only 1 participant was evaluable.</measurement>
                    <measurement group_id="O2" value="2.67" spread="2.89"/>
                    <measurement group_id="O3" value="NA">Data not available as no participant was evaluable for the treatment arm at the given time point.</measurement>
                    <measurement group_id="O4" value="14.00">Standard deviation was not estimable since only 1 participant was evaluable.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: Hospital ER visits (n=12,6,4,4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.08" spread="0.29"/>
                    <measurement group_id="O2" value="1.17" spread="0.41"/>
                    <measurement group_id="O3" value="1.00" spread="0.00"/>
                    <measurement group_id="O4" value="1.75" spread="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: Number visits hospitalized (n=9,5,2,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" spread="0.00"/>
                    <measurement group_id="O2" value="1.00" spread="0.00"/>
                    <measurement group_id="O3" value="1.00" spread="0.00"/>
                    <measurement group_id="O4" value="1.00">Standard deviation was not estimable since only 1 participant was evaluable.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: Number of outpatient surgeries(n=4,7,1,2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.25" spread="0.50"/>
                    <measurement group_id="O2" value="1.14" spread="0.38"/>
                    <measurement group_id="O3" value="1.00">Standard deviation was not estimable since only 1 participant was evaluable.</measurement>
                    <measurement group_id="O4" value="1.50" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: Non-study diagnostic tests (n=21,25,5,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.33" spread="3.89"/>
                    <measurement group_id="O2" value="1.96" spread="1.31"/>
                    <measurement group_id="O3" value="1.80" spread="0.45"/>
                    <measurement group_id="O4" value="1.53" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: RA related doctor visit(n=132,131,33,129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.81" spread="0.63"/>
                    <measurement group_id="O2" value="0.96" spread="0.74"/>
                    <measurement group_id="O3" value="0.88" spread="0.86"/>
                    <measurement group_id="O4" value="1.00" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: RA related ER visit (n=12,6,4,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" spread="0.62"/>
                    <measurement group_id="O2" value="0.67" spread="0.82"/>
                    <measurement group_id="O3" value="0.00" spread="0.00"/>
                    <measurement group_id="O4" value="0.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: RA-diagnostic tests (n=21,25,5,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" spread="0.50"/>
                    <measurement group_id="O2" value="0.16" spread="0.37"/>
                    <measurement group_id="O3" value="0.20" spread="0.45"/>
                    <measurement group_id="O4" value="0.11" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: RA related hospitalization (n=9,5,2,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22" spread="0.67"/>
                    <measurement group_id="O2" value="0.40" spread="0.89"/>
                    <measurement group_id="O3" value="0.00" spread="0.00"/>
                    <measurement group_id="O4" value="0.00">Standard deviation was not estimable since only 1 participant were evaluable.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: RA related outpatient surgery (n=4,7,1,2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.43" spread="0.79"/>
                    <measurement group_id="O3" value="0.00">Standard deviation was not estimable since only 1 participant were evaluable.</measurement>
                    <measurement group_id="O4" value="1.00" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: RA related NM visit (n=1,3,0,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00">Standard deviation was not estimable since only 1 participant were evaluable.</measurement>
                    <measurement group_id="O2" value="0.67" spread="1.15"/>
                    <measurement group_id="O3" value="NA">Data not available as no participant was evaluable for the treatment arm at the given time point.</measurement>
                    <measurement group_id="O4" value="0.00">Standard deviation was not estimable as only 1 participant was evaluable.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Events Including Visits, Surgeries, Tests or Devices as Assessed Using RA-HCRU at Month 12</title>
        <description>RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains. Any RA/non-RA related number of events including visits to doctor, non-medical practitioner, hospital ER treatment, hospitalizations, number of surgeries, diagnostic tests, and devices/aids used were reported.</description>
        <time_frame>Month 12</time_frame>
        <population>FAS: all randomized participants who received at least 1 dose of study drug and had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). N=participants evaluable for this measure. n=number of participants evaluable at specific time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Then CP-690,550 5 mg</title>
            <description>Placebo matched to CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week, for 3 to 6 months. Response was assessed at Month 3 and participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts from baseline, received CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12. At Month 6, remaining participants advanced to CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, Then CP-690,550 10 mg</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week, for 3 to 6 months. Response was assessed at Month 3 and participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts from baseline, received CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12. At Month 6, remaining participants advanced to CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O5">
            <title>Adalimumab</title>
            <description>Adalimumab 40 mg injection subcutaneously once every other week along with placebo matched to CP-690,550 5 mg tablet orally twice daily up to Month 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Events Including Visits, Surgeries, Tests or Devices as Assessed Using RA-HCRU at Month 12</title>
          <description>RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains. Any RA/non-RA related number of events including visits to doctor, non-medical practitioner, hospital ER treatment, hospitalizations, number of surgeries, diagnostic tests, and devices/aids used were reported.</description>
          <population>FAS: all randomized participants who received at least 1 dose of study drug and had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). N=participants evaluable for this measure. n=number of participants evaluable at specific time points for each arm group, respectively.</population>
          <units>events</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="111"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Doctor visit (n=102,111,37,30,125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.73" spread="2.78"/>
                    <measurement group_id="O2" value="2.80" spread="2.46"/>
                    <measurement group_id="O3" value="3.92" spread="5.97"/>
                    <measurement group_id="O4" value="3.50" spread="3.34"/>
                    <measurement group_id="O5" value="2.94" spread="3.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NM practitioners visits (n=3,4,1,2,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.67" spread="11.72"/>
                    <measurement group_id="O2" value="9.75" spread="10.97"/>
                    <measurement group_id="O3" value="192.00">Standard deviation was not estimable since only 1 participant was evaluable.</measurement>
                    <measurement group_id="O4" value="10.50" spread="6.36"/>
                    <measurement group_id="O5" value="NA">Data not available as no participant was evaluable for the treatment arm at the given time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hospital ER visits (n=3,5,0,1,6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" spread="0.00"/>
                    <measurement group_id="O2" value="2.40" spread="1.34"/>
                    <measurement group_id="O3" value="NA">Data not available as no participant was evaluable for the treatment arm at the given time point.</measurement>
                    <measurement group_id="O4" value="3.00">Standard deviation was not estimable since only 1 participant was evaluable.</measurement>
                    <measurement group_id="O5" value="1.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of visits hospitalized (n=3,5,1,1,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" spread="0.00"/>
                    <measurement group_id="O2" value="1.00" spread="0.00"/>
                    <measurement group_id="O3" value="1.00">Standard deviation was not estimable since only 1 participant was evaluable.</measurement>
                    <measurement group_id="O4" value="1.00">Standard deviation was not estimable since only 1 participant was evaluable.</measurement>
                    <measurement group_id="O5" value="1.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of outpatient surgeries (n=5,2,0,2,5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.40" spread="0.89"/>
                    <measurement group_id="O2" value="1.50" spread="0.71"/>
                    <measurement group_id="O3" value="NA">Data not available as no participant was evaluable for the treatment arm at the given time point.</measurement>
                    <measurement group_id="O4" value="1.00" spread="0.00"/>
                    <measurement group_id="O5" value="2.20" spread="2.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-study diagnostic tests (n=8,19,6,6,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.13" spread="0.35"/>
                    <measurement group_id="O2" value="1.95" spread="1.31"/>
                    <measurement group_id="O3" value="3.17" spread="2.64"/>
                    <measurement group_id="O4" value="1.33" spread="0.82"/>
                    <measurement group_id="O5" value="1.64" spread="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RA related doctor visit (n=104,111,37,30,125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.82" spread="0.59"/>
                    <measurement group_id="O2" value="0.93" spread="0.57"/>
                    <measurement group_id="O3" value="0.89" spread="0.52"/>
                    <measurement group_id="O4" value="0.87" spread="0.68"/>
                    <measurement group_id="O5" value="0.84" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RA related ER visits (n=3,5,0,1,6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.33" spread="0.58"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                    <measurement group_id="O3" value="NA">Data not available as no participant was evaluable for the treatment arm at the given time point.</measurement>
                    <measurement group_id="O4" value="0.00">Standard deviation was not estimable since only 1 participant was evaluable.</measurement>
                    <measurement group_id="O5" value="0.17" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RA-diagnostic tests (n=9,19,6,6,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" spread="0.33"/>
                    <measurement group_id="O2" value="0.21" spread="0.42"/>
                    <measurement group_id="O3" value="0.17" spread="0.41"/>
                    <measurement group_id="O4" value="0.00" spread="0.00"/>
                    <measurement group_id="O5" value="0.05" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RA related hospitalization (n=3,5,1,1,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                    <measurement group_id="O3" value="0.00">Standard deviation was not estimable since only 1 participant were evaluable.</measurement>
                    <measurement group_id="O4" value="0.00">Standard deviation was not estimable since only 1 participant were evaluable.</measurement>
                    <measurement group_id="O5" value="0.67" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RA related outpatient surgery (n=5,2,0,2,5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                    <measurement group_id="O3" value="NA">Data not available as no participant was evaluable for the treatment arm at the given time point.</measurement>
                    <measurement group_id="O4" value="0.00" spread="0.00"/>
                    <measurement group_id="O5" value="0.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RA related NM visits (n=3,4,1,2,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                    <measurement group_id="O2" value="0.50" spread="1.00"/>
                    <measurement group_id="O3" value="0.00">Standard deviation was not estimable as only 1 participant was evaluable.</measurement>
                    <measurement group_id="O4" value="0.00" spread="0.00"/>
                    <measurement group_id="O5" value="NA">Data not available as no participant was evaluable for the treatment arm at the given time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days as Assessed Using RA-HCRU at Baseline, Month 3 and 6</title>
        <description>RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains. Any RA or non-RA related number of days spent in hospital, nursing home, aids/devices used, on sick leave, work per week, performed part time work, performed paid work, chores done by housekeeper and chores done by family/friends.</description>
        <time_frame>Baseline, Month 3, 6</time_frame>
        <population>FAS: all randomized participants who received at least 1 dose of study drug and had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). N=participants evaluable for this measure. n=number of participants evaluable at specific time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week for 3 to 6 months. Response was assessed at Month 3 and participants who failed to achieve at least 20% reduction from baseline in both swollen and tender joint counts, received CP-690,550 5 mg or 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12. At Month 6, remaining participants received CP-690,550 5 mg or 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O4">
            <title>Adalimumab</title>
            <description>Adalimumab 40 mg injection subcutaneously once every other week along with placebo matched to CP-690,550 5 mg tablet orally twice daily up to Month 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days as Assessed Using RA-HCRU at Baseline, Month 3 and 6</title>
          <description>RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains. Any RA or non-RA related number of days spent in hospital, nursing home, aids/devices used, on sick leave, work per week, performed part time work, performed paid work, chores done by housekeeper and chores done by family/friends.</description>
          <population>FAS: all randomized participants who received at least 1 dose of study drug and had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). N=participants evaluable for this measure. n=number of participants evaluable at specific time points for each arm group, respectively.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: Hospital length of stay (n=11,6,7,11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.64" spread="12.91"/>
                    <measurement group_id="O2" value="10.83" spread="9.89"/>
                    <measurement group_id="O3" value="13.43" spread="9.78"/>
                    <measurement group_id="O4" value="12.82" spread="10.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Days in nursing home (n=3,0,0,4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.33" spread="17.56"/>
                    <measurement group_id="O2" value="NA">Data not available as no participant was evaluable for the treatment arm at the given time point.</measurement>
                    <measurement group_id="O3" value="NA">Data not available as no participant was evaluable for the treatment arm at the given time point.</measurement>
                    <measurement group_id="O4" value="14.25" spread="9.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Days devices/aids used (n=17,28,8,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133.88" spread="111.17"/>
                    <measurement group_id="O2" value="67.32" spread="61.88"/>
                    <measurement group_id="O3" value="172.75" spread="94.28"/>
                    <measurement group_id="O4" value="66.13" spread="65.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Days of work per week (n=71,69,38,70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.94" spread="1.18"/>
                    <measurement group_id="O2" value="4.80" spread="1.05"/>
                    <measurement group_id="O3" value="4.95" spread="0.98"/>
                    <measurement group_id="O4" value="5.01" spread="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Chores by housekeeper (n=23,19,6,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.57" spread="25.73"/>
                    <measurement group_id="O2" value="14.95" spread="27.24"/>
                    <measurement group_id="O3" value="38.83" spread="41.44"/>
                    <measurement group_id="O4" value="6.94" spread="6.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Chores by family (n=101,102,39,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.06" spread="29.27"/>
                    <measurement group_id="O2" value="26.57" spread="31.02"/>
                    <measurement group_id="O3" value="26.95" spread="32.87"/>
                    <measurement group_id="O4" value="29.80" spread="32.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Days on sick leave (n=24,24,15,29)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.58" spread="27.78"/>
                    <measurement group_id="O2" value="16.33" spread="27.21"/>
                    <measurement group_id="O3" value="29.60" spread="34.88"/>
                    <measurement group_id="O4" value="16.31" spread="26.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Days of part time work (n=13,13,6,10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.31" spread="18.94"/>
                    <measurement group_id="O2" value="25.31" spread="61.19"/>
                    <measurement group_id="O3" value="5.33" spread="3.44"/>
                    <measurement group_id="O4" value="18.50" spread="26.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Paid work, bothered by RA(n=51,47,31,53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.10" spread="27.47"/>
                    <measurement group_id="O2" value="29.45" spread="31.37"/>
                    <measurement group_id="O3" value="28.74" spread="28.76"/>
                    <measurement group_id="O4" value="42.74" spread="31.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: RA related devices/aids (n=17,28,9,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.76" spread="1.15"/>
                    <measurement group_id="O2" value="1.39" spread="0.69"/>
                    <measurement group_id="O3" value="2.33" spread="1.66"/>
                    <measurement group_id="O4" value="1.65" spread="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: Hospital length of stay (n=4,6,1,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.25" spread="4.03"/>
                    <measurement group_id="O2" value="10.00" spread="10.75"/>
                    <measurement group_id="O3" value="2.00">Standard deviation was not estimable since only 1 participant was evaluable.</measurement>
                    <measurement group_id="O4" value="10.33" spread="8.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: Days in nursing home (n=0,0,0,2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data not available as no participant was evaluable for the treatment arm at the given time point.</measurement>
                    <measurement group_id="O2" value="NA">Data not available as no participant was evaluable for the treatment arm at the given time point.</measurement>
                    <measurement group_id="O3" value="NA">Data not available as no participant was evaluable for the treatment arm at the given time point.</measurement>
                    <measurement group_id="O4" value="17.50" spread="4.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: Days devices/aids used (n=11,17,6,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117.91" spread="112.91"/>
                    <measurement group_id="O2" value="60.41" spread="88.79"/>
                    <measurement group_id="O3" value="163.83" spread="153.63"/>
                    <measurement group_id="O4" value="91.80" spread="95.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: Days of work per week (n=70,66,38,68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.83" spread="0.95"/>
                    <measurement group_id="O2" value="4.68" spread="1.18"/>
                    <measurement group_id="O3" value="4.95" spread="0.80"/>
                    <measurement group_id="O4" value="4.75" spread="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: Chores by housekeeper (n=17,11,7,12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.59" spread="23.15"/>
                    <measurement group_id="O2" value="6.00" spread="8.63"/>
                    <measurement group_id="O3" value="8.00" spread="12.54"/>
                    <measurement group_id="O4" value="10.50" spread="16.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: Chores by family (n=60,47,34,58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.10" spread="32.38"/>
                    <measurement group_id="O2" value="18.32" spread="24.03"/>
                    <measurement group_id="O3" value="24.97" spread="31.72"/>
                    <measurement group_id="O4" value="25.41" spread="30.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: Days on sick leave (n=11,9,17,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.27" spread="33.73"/>
                    <measurement group_id="O2" value="18.44" spread="29.37"/>
                    <measurement group_id="O3" value="27.12" spread="31.42"/>
                    <measurement group_id="O4" value="5.13" spread="4.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: Days of part time work (n=7,4,6,10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.29" spread="13.76"/>
                    <measurement group_id="O2" value="25.50" spread="27.77"/>
                    <measurement group_id="O3" value="5.50" spread="3.27"/>
                    <measurement group_id="O4" value="14.90" spread="27.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: Paid work, bothered by RA (n=39,28,28,44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.08" spread="21.77"/>
                    <measurement group_id="O2" value="26.57" spread="32.41"/>
                    <measurement group_id="O3" value="19.93" spread="20.79"/>
                    <measurement group_id="O4" value="33.61" spread="30.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: RA related devices/aids (n=12,17,8,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.75" spread="1.22"/>
                    <measurement group_id="O2" value="1.12" spread="1.36"/>
                    <measurement group_id="O3" value="2.38" spread="1.60"/>
                    <measurement group_id="O4" value="1.81" spread="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: Hospital length of stay (n=9,5,2,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.00" spread="8.20"/>
                    <measurement group_id="O2" value="12.80" spread="16.71"/>
                    <measurement group_id="O3" value="8.50" spread="2.12"/>
                    <measurement group_id="O4" value="6.00">Standard deviation was not estimable since only 1 participant was evaluable.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: Days in nursing home (n=2,0,0,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.00" spread="18.38"/>
                    <measurement group_id="O2" value="NA">Data not available as no participant was evaluable for the treatment arm at the given time point.</measurement>
                    <measurement group_id="O3" value="NA">Data not available as no participant was evaluable for the treatment arm at the given time point.</measurement>
                    <measurement group_id="O4" value="NA">Data not available as no participant was evaluable for the treatment arm at the given time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: Days devices/aids used (n=14,16,5,14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102.29" spread="115.01"/>
                    <measurement group_id="O2" value="126.25" spread="134.08"/>
                    <measurement group_id="O3" value="80.20" spread="73.45"/>
                    <measurement group_id="O4" value="94.21" spread="76.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: Days of work per week (n=65,61,17,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.94" spread="0.85"/>
                    <measurement group_id="O2" value="4.70" spread="1.09"/>
                    <measurement group_id="O3" value="5.35" spread="0.93"/>
                    <measurement group_id="O4" value="4.95" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: Chores by housekeeper (n=11,10,3,7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.73" spread="8.25"/>
                    <measurement group_id="O2" value="15.80" spread="22.73"/>
                    <measurement group_id="O3" value="44.00" spread="42.57"/>
                    <measurement group_id="O4" value="7.29" spread="3.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: Chores by family (n=46,46,15,50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.59" spread="16.95"/>
                    <measurement group_id="O2" value="29.09" spread="35.16"/>
                    <measurement group_id="O3" value="35.53" spread="39.39"/>
                    <measurement group_id="O4" value="22.64" spread="29.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: Days on sick leave (n=7,9,3,9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.57" spread="41.48"/>
                    <measurement group_id="O2" value="12.44" spread="14.60"/>
                    <measurement group_id="O3" value="3.00" spread="2.00"/>
                    <measurement group_id="O4" value="8.67" spread="13.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: Days of part time work (n=7,6,1,7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.57" spread="6.80"/>
                    <measurement group_id="O2" value="24.67" spread="33.07"/>
                    <measurement group_id="O3" value="4.00">Standard deviation was not estimable since only 1 participant was evaluable.</measurement>
                    <measurement group_id="O4" value="9.29" spread="8.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: Paid work, bothered by RA (n=31,25,10,33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.71" spread="18.47"/>
                    <measurement group_id="O2" value="20.40" spread="25.93"/>
                    <measurement group_id="O3" value="11.00" spread="9.13"/>
                    <measurement group_id="O4" value="24.55" spread="26.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: RA related devices/aids (n=15,16,6,14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" spread="1.73"/>
                    <measurement group_id="O2" value="1.56" spread="1.46"/>
                    <measurement group_id="O3" value="2.17" spread="1.83"/>
                    <measurement group_id="O4" value="2.07" spread="1.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days as Assessed Using RA-HCRU at Month 12</title>
        <description>RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains. Any RA or non-RA related number of days spent in hospital, nursing home, aids/devices used, on sick leave, work per week, performed part time work, performed paid work, chores done by housekeeper and chores done by family/friends.</description>
        <time_frame>Month 12</time_frame>
        <population>FAS: all randomized participants who received at least 1 dose of study drug, had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). N=participants evaluable for this measure. n=number of participants evaluable at specific time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Then CP-690,550 5 mg</title>
            <description>Placebo matched to CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week, for 3 to 6 months. Response was assessed at Month 3 and participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts from baseline, received CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12. At Month 6, remaining participants advanced to CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, Then CP-690,550 10 mg</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week, for 3 to 6 months. Response was assessed at Month 3 and participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts from baseline, received CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12. At Month 6, remaining participants advanced to CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O5">
            <title>Adalimumab</title>
            <description>Adalimumab 40 mg injection subcutaneously once every other week along with placebo matched to CP-690,550 5 mg tablet orally twice daily up to Month 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days as Assessed Using RA-HCRU at Month 12</title>
          <description>RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains. Any RA or non-RA related number of days spent in hospital, nursing home, aids/devices used, on sick leave, work per week, performed part time work, performed paid work, chores done by housekeeper and chores done by family/friends.</description>
          <population>FAS: all randomized participants who received at least 1 dose of study drug, had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). N=participants evaluable for this measure. n=number of participants evaluable at specific time points for each arm group, respectively.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="15"/>
                <count group_id="O5" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hospital length of stay (n=3,5,1,1,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.00" spread="6.93"/>
                    <measurement group_id="O2" value="5.60" spread="2.70"/>
                    <measurement group_id="O3" value="15.00">Standard deviation was not estimable since only 1 participant was evaluable.</measurement>
                    <measurement group_id="O4" value="1.00">Standard deviation was not estimable since only 1 participant was evaluable.</measurement>
                    <measurement group_id="O5" value="15.33" spread="4.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days in nursing home (n=2,0,0,0,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.50" spread="4.95"/>
                    <measurement group_id="O2" value="NA">Data not available as no participant was evaluable for the treatment arm at the given time point.</measurement>
                    <measurement group_id="O3" value="NA">Data not available as no participant was evaluable for the treatment arm at the given time point.</measurement>
                    <measurement group_id="O4" value="NA">Data not available as no participant was evaluable for the treatment arm at the given time point.</measurement>
                    <measurement group_id="O5" value="10.00">Standard deviation was not estimable since only 1 participant was evaluable.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days devices/aids used (n=11,12,3,2,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144.55" spread="258.85"/>
                    <measurement group_id="O2" value="51.75" spread="41.51"/>
                    <measurement group_id="O3" value="163.67" spread="173.70"/>
                    <measurement group_id="O4" value="321.50" spread="327.39"/>
                    <measurement group_id="O5" value="79.33" spread="74.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days of work per week (n=60,49,19,15,58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.83" spread="1.04"/>
                    <measurement group_id="O2" value="5.04" spread="0.93"/>
                    <measurement group_id="O3" value="5.16" spread="0.90"/>
                    <measurement group_id="O4" value="4.93" spread="0.70"/>
                    <measurement group_id="O5" value="4.95" spread="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chores by housekeeper (n=9,4,1,2,10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.44" spread="3.40"/>
                    <measurement group_id="O2" value="7.75" spread="5.06"/>
                    <measurement group_id="O3" value="90.00">Standard deviation was not estimable since only 1 participant was evaluable.</measurement>
                    <measurement group_id="O4" value="24.00" spread="16.97"/>
                    <measurement group_id="O5" value="4.90" spread="3.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chores by family (n=35,30,8,10,45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.06" spread="27.84"/>
                    <measurement group_id="O2" value="13.13" spread="12.28"/>
                    <measurement group_id="O3" value="51.88" spread="40.91"/>
                    <measurement group_id="O4" value="28.40" spread="33.88"/>
                    <measurement group_id="O5" value="23.49" spread="28.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days on sick leave (n=5,3,2,0,4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.40" spread="11.41"/>
                    <measurement group_id="O2" value="36.00" spread="45.97"/>
                    <measurement group_id="O3" value="50.00" spread="56.57"/>
                    <measurement group_id="O4" value="NA">Data not available as no participant was evaluable for the treatment arm at the given time point.</measurement>
                    <measurement group_id="O5" value="18.25" spread="14.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days of part time work (n=6,1,0,0,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.33" spread="12.55"/>
                    <measurement group_id="O2" value="33.00">Standard deviation was not estimable since only 1 participant was evaluable.</measurement>
                    <measurement group_id="O3" value="NA">Data not available as no participant was evaluable for the treatment arm at the given time point.</measurement>
                    <measurement group_id="O4" value="NA">Data not available as no participant was evaluable for the treatment arm at the given time point.</measurement>
                    <measurement group_id="O5" value="30.00">Standard deviation was not estimable since only 1 participant was evaluable.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Paid work, bothered by RA (n=20,20,7,9,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.10" spread="30.75"/>
                    <measurement group_id="O2" value="20.40" spread="27.90"/>
                    <measurement group_id="O3" value="11.43" spread="8.60"/>
                    <measurement group_id="O4" value="12.33" spread="12.32"/>
                    <measurement group_id="O5" value="22.86" spread="24.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RA related devices/aids used (n=11,12,3,3,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.18" spread="2.79"/>
                    <measurement group_id="O2" value="0.75" spread="0.62"/>
                    <measurement group_id="O3" value="2.33" spread="1.53"/>
                    <measurement group_id="O4" value="3.00" spread="2.65"/>
                    <measurement group_id="O5" value="1.53" spread="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Hours Per Day as Assessed RA-HCRU at Baseline, Month 3 and 6</title>
        <description>RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains. Any RA or non-RA related number of hours spent per day for home healthcare services, chores done by housekeeper, chores done by family or friends, hours affected per day and average number of hours missed work per day were reported.</description>
        <time_frame>Baseline, Month 3, 6</time_frame>
        <population>FAS: all randomized participants who received at least 1 dose of study drug, had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). N=participants evaluable for this measure. n=number of participants evaluable at specific time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week for 3 to 6 months. Response was assessed at Month 3 and participants who failed to achieve at least 20% reduction from baseline in both swollen and tender joint counts, received CP-690,550 5 mg or 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12. At Month 6, remaining participants received CP-690,550 5 mg or 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O4">
            <title>Adalimumab</title>
            <description>Adalimumab 40 mg injection subcutaneously once every other week along with placebo matched to CP-690,550 5 mg tablet orally twice daily up to Month 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Hours Per Day as Assessed RA-HCRU at Baseline, Month 3 and 6</title>
          <description>RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains. Any RA or non-RA related number of hours spent per day for home healthcare services, chores done by housekeeper, chores done by family or friends, hours affected per day and average number of hours missed work per day were reported.</description>
          <population>FAS: all randomized participants who received at least 1 dose of study drug, had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). N=participants evaluable for this measure. n=number of participants evaluable at specific time points for each arm group, respectively.</population>
          <units>hours per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: Home HC services (n=2,2,1,2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00" spread="2.83"/>
                    <measurement group_id="O2" value="1.50" spread="0.71"/>
                    <measurement group_id="O3" value="2.00">Standard deviation was not estimable since only 1 participant was evaluable.</measurement>
                    <measurement group_id="O4" value="1.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Work done (n=72,69,38,70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.76" spread="2.40"/>
                    <measurement group_id="O2" value="7.54" spread="2.25"/>
                    <measurement group_id="O3" value="7.79" spread="1.76"/>
                    <measurement group_id="O4" value="8.16" spread="2.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Chores by housekeeper (n=22,19,7,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.23" spread="4.60"/>
                    <measurement group_id="O2" value="5.53" spread="5.36"/>
                    <measurement group_id="O3" value="8.00" spread="7.55"/>
                    <measurement group_id="O4" value="3.89" spread="2.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Chores by family (n=101,102,39,95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.24" spread="4.75"/>
                    <measurement group_id="O2" value="3.31" spread="2.76"/>
                    <measurement group_id="O3" value="4.21" spread="4.71"/>
                    <measurement group_id="O4" value="2.82" spread="1.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Missed work due to RA (n=13,13,6,10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.38" spread="7.22"/>
                    <measurement group_id="O2" value="5.00" spread="5.85"/>
                    <measurement group_id="O3" value="4.00" spread="1.26"/>
                    <measurement group_id="O4" value="4.00" spread="4.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: RA related home HC services (n=2,2,1,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50" spread="0.71"/>
                    <measurement group_id="O2" value="1.00" spread="0.00"/>
                    <measurement group_id="O3" value="1.00">Standard deviation was not estimable since only 1 participant was evaluable.</measurement>
                    <measurement group_id="O4" value="0.33" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: Home HC services (n=1,0,0,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00">Standard deviation was not estimable since only 1 participant was evaluable.</measurement>
                    <measurement group_id="O2" value="NA">Data not available as no participant was evaluable for the treatment arm at the given time point.</measurement>
                    <measurement group_id="O3" value="NA">Data not available as no participant was evaluable for the treatment arm at the given time point.</measurement>
                    <measurement group_id="O4" value="NA">Data not available as no participant was evaluable for the treatment arm at the given time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: Work done (n=70,66,38,68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.06" spread="3.59"/>
                    <measurement group_id="O2" value="7.53" spread="1.92"/>
                    <measurement group_id="O3" value="8.53" spread="5.62"/>
                    <measurement group_id="O4" value="8.38" spread="4.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: Chores by housekeeper (n=17,11,7,12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.00" spread="2.12"/>
                    <measurement group_id="O2" value="5.73" spread="2.61"/>
                    <measurement group_id="O3" value="5.00" spread="2.00"/>
                    <measurement group_id="O4" value="4.17" spread="1.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: Chores by family (n=59,46,34,59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.46" spread="3.67"/>
                    <measurement group_id="O2" value="3.28" spread="2.60"/>
                    <measurement group_id="O3" value="3.41" spread="2.72"/>
                    <measurement group_id="O4" value="3.68" spread="3.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: Missed work due to RA (n=7,4,6,9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.57" spread="5.03"/>
                    <measurement group_id="O2" value="20.75" spread="39.51"/>
                    <measurement group_id="O3" value="5.50" spread="5.01"/>
                    <measurement group_id="O4" value="3.56" spread="1.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3: RA related home HC services (n=1,0,0,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00">Standard deviation was not estimable since only 1 participant was evaluable.</measurement>
                    <measurement group_id="O2" value="NA">Data not available as no participant was evaluable for the treatment arm at the given time point.</measurement>
                    <measurement group_id="O3" value="NA">Data not available as no participant was evaluable for the treatment arm at the given time point.</measurement>
                    <measurement group_id="O4" value="NA">Data not available as no participant was evaluable for the treatment arm at the given time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: Home HC services (n=2,2,0,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.50" spread="2.12"/>
                    <measurement group_id="O2" value="16.00" spread="5.66"/>
                    <measurement group_id="O3" value="NA">Data not available as no participant was evaluable for the treatment arm at the given time point.</measurement>
                    <measurement group_id="O4" value="NA">Data not available as no participant was evaluable for the treatment arm at the given time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: Work done (n=65,61,17,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.35" spread="4.46"/>
                    <measurement group_id="O2" value="7.72" spread="2.24"/>
                    <measurement group_id="O3" value="9.71" spread="7.59"/>
                    <measurement group_id="O4" value="8.00" spread="4.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: Chores by housekeeper (n=11,10,3,7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.36" spread="2.58"/>
                    <measurement group_id="O2" value="5.40" spread="2.50"/>
                    <measurement group_id="O3" value="5.33" spread="1.53"/>
                    <measurement group_id="O4" value="6.29" spread="7.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: Chores by family (n=47,45,13,51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.30" spread="2.69"/>
                    <measurement group_id="O2" value="2.91" spread="2.00"/>
                    <measurement group_id="O3" value="3.69" spread="2.32"/>
                    <measurement group_id="O4" value="3.33" spread="3.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: Missed work due to RA (n=7,6,1,7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.57" spread="5.19"/>
                    <measurement group_id="O2" value="3.17" spread="2.32"/>
                    <measurement group_id="O3" value="5.00">Standard deviation was not estimable since only 1 participant was evaluable.</measurement>
                    <measurement group_id="O4" value="3.29" spread="1.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6: RA related home HC services (n=2,2,0,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" spread="1.41"/>
                    <measurement group_id="O2" value="0.50" spread="0.71"/>
                    <measurement group_id="O3" value="NA">Data not available as no participant was evaluable for the treatment arm at the given time point.</measurement>
                    <measurement group_id="O4" value="NA">Data not available as no participant was evaluable for the treatment arm at the given time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Hours Per Day as Assessed RA-HCRU at Month 12</title>
        <description>RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains. Any RA or non-RA related number of hours spent per day for home healthcare services, chores done by housekeeper, chores done by family or friends, hours affected per day and average number of hours missed work per day were reported.</description>
        <time_frame>Month 12</time_frame>
        <population>FAS: all randomized participants who received at least 1 dose of study drug and had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). N=participants evaluable for this measure. n=number of participants evaluable at specific time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Then CP-690,550 5 mg</title>
            <description>Placebo matched to CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week, for 3 to 6 months. Response was assessed at Month 3 and participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts from baseline, received CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12. At Month 6, remaining participants advanced to CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, Then CP-690,550 10 mg</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week, for 3 to 6 months. Response was assessed at Month 3 and participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts from baseline, received CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12. At Month 6, remaining participants advanced to CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O5">
            <title>Adalimumab</title>
            <description>Adalimumab 40 mg injection subcutaneously once every other week along with placebo matched to CP-690,550 5 mg tablet orally twice daily up to Month 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Hours Per Day as Assessed RA-HCRU at Month 12</title>
          <description>RA-HCRU assessed healthcare usage during previous 3 months for direct or indirect medical cost domains. Any RA or non-RA related number of hours spent per day for home healthcare services, chores done by housekeeper, chores done by family or friends, hours affected per day and average number of hours missed work per day were reported.</description>
          <population>FAS: all randomized participants who received at least 1 dose of study drug and had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). N=participants evaluable for this measure. n=number of participants evaluable at specific time points for each arm group, respectively.</population>
          <units>hours per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="15"/>
                <count group_id="O5" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Home HC services (n=0,0,0,0,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data not available as no participant was evaluable for the treatment arm at the given time point.</measurement>
                    <measurement group_id="O2" value="NA">Data not available as no participant was evaluable for the treatment arm at the given time point.</measurement>
                    <measurement group_id="O3" value="NA">Data not available as no participant was evaluable for the treatment arm at the given time point.</measurement>
                    <measurement group_id="O4" value="NA">Data not available as no participant was evaluable for the treatment arm at the given time point.</measurement>
                    <measurement group_id="O5" value="1.00">Standard deviation was not estimable since only 1 participant was evaluable.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Work done (n=60,49,19,15,58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.52" spread="2.27"/>
                    <measurement group_id="O2" value="7.82" spread="1.60"/>
                    <measurement group_id="O3" value="9.53" spread="7.65"/>
                    <measurement group_id="O4" value="7.73" spread="2.40"/>
                    <measurement group_id="O5" value="7.93" spread="3.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chores by housekeeper (n=8,4,1,2,10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.63" spread="3.16"/>
                    <measurement group_id="O2" value="4.75" spread="0.96"/>
                    <measurement group_id="O3" value="3.00">Standard deviation was not estimable since only 1 participant was evaluable.</measurement>
                    <measurement group_id="O4" value="6.00" spread="1.41"/>
                    <measurement group_id="O5" value="4.10" spread="2.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chores by family (n=34,30,8,10,44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.65" spread="1.95"/>
                    <measurement group_id="O2" value="4.00" spread="4.11"/>
                    <measurement group_id="O3" value="2.88" spread="2.17"/>
                    <measurement group_id="O4" value="2.70" spread="2.26"/>
                    <measurement group_id="O5" value="2.55" spread="1.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missed work due to RA (n=6,1,0,0,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" spread="1.67"/>
                    <measurement group_id="O2" value="4.00">Standard deviation was not estimable since only 1 participant was evaluable.</measurement>
                    <measurement group_id="O3" value="NA">Data not available as no participant was evaluable for the treatment arm at the given time point.</measurement>
                    <measurement group_id="O4" value="NA">Data not available as no participant was evaluable for the treatment arm at the given time point.</measurement>
                    <measurement group_id="O5" value="4.00">Standard deviation was not estimable since only 1 participant was evaluable.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RA related home HC services (n=0,0,0,0,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Data not available as no participant was evaluable for the treatment arm at the given time point.</measurement>
                    <measurement group_id="O2" value="NA">Data not available as no participant was evaluable for the treatment arm at the given time point.</measurement>
                    <measurement group_id="O3" value="NA">Data not available as no participant was evaluable for the treatment arm at the given time point.</measurement>
                    <measurement group_id="O4" value="NA">Data not available as no participant was evaluable for the treatment arm at the given time point.</measurement>
                    <measurement group_id="O5" value="1.00">Standard deviation was not estimable since only 1 participant was evaluable.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Work Performance in Past 3 Months on Days Bothered as Assessed Using RA-HCRU at Baseline, Month 3 and 6</title>
        <description>Work performance of participants on number of days bothered was based on 10-point scale, where higher score indicated lower work performance.</description>
        <time_frame>Baseline, Month 3, 6</time_frame>
        <population>FAS: all randomized participants who received at least 1 dose of study drug and had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). N=participants evaluable for this measure. n=number of participants evaluable at specific time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week for 3 to 6 months. Response was assessed at Month 3 and participants who failed to achieve at least 20% reduction from baseline in both swollen and tender joint counts, received CP-690,550 5 mg or 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12. At Month 6, remaining participants received CP-690,550 5 mg or 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O4">
            <title>Adalimumab</title>
            <description>Adalimumab 40 mg injection subcutaneously once every other week along with placebo matched to CP-690,550 5 mg tablet orally twice daily up to Month 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Work Performance in Past 3 Months on Days Bothered as Assessed Using RA-HCRU at Baseline, Month 3 and 6</title>
          <description>Work performance of participants on number of days bothered was based on 10-point scale, where higher score indicated lower work performance.</description>
          <population>FAS: all randomized participants who received at least 1 dose of study drug and had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). N=participants evaluable for this measure. n=number of participants evaluable at specific time points for each arm group, respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="141"/>
                <count group_id="O3" value="83"/>
                <count group_id="O4" value="142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=139,141,83,142)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.16" spread="3.05"/>
                    <measurement group_id="O2" value="4.16" spread="3.33"/>
                    <measurement group_id="O3" value="4.08" spread="3.32"/>
                    <measurement group_id="O4" value="4.19" spread="3.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 (n=137,129,76,139)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.68" spread="2.75"/>
                    <measurement group_id="O2" value="2.81" spread="2.89"/>
                    <measurement group_id="O3" value="3.38" spread="2.84"/>
                    <measurement group_id="O4" value="3.09" spread="2.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 (n=125,125,35,127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.31" spread="2.51"/>
                    <measurement group_id="O2" value="2.39" spread="2.84"/>
                    <measurement group_id="O3" value="2.17" spread="2.64"/>
                    <measurement group_id="O4" value="2.66" spread="2.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Work Performance in Past 3 Months on Days Bothered as Assessed Using RA-HCRU at Month 12</title>
        <description>Work performance of participants on number of days bothered was based on 10-point scale, where higher score indicated lower work performance.</description>
        <time_frame>Month 12</time_frame>
        <population>FAS: all randomized participants who received at least 1 dose of study drug and had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). n=number of participants evaluable at specific time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 5 mg</title>
            <description>CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 10 mg</title>
            <description>CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Then CP-690,550 5 mg</title>
            <description>Placebo matched to CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week, for 3 to 6 months. Response was assessed at Month 3 and participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts from baseline, received CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12. At Month 6, remaining participants advanced to CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, Then CP-690,550 10 mg</title>
            <description>Placebo matched to CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week, for 3 to 6 months. Response was assessed at Month 3 and participants who failed to achieve a minimum improvement of at least 20% reduction in both swollen and tender joint counts from baseline, received CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12. At Month 6, remaining participants advanced to CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
          </group>
          <group group_id="O5">
            <title>Adalimumab</title>
            <description>Adalimumab 40 mg injection subcutaneously once every other week along with placebo matched to CP-690,550 5 mg tablet orally twice daily up to Month 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Work Performance in Past 3 Months on Days Bothered as Assessed Using RA-HCRU at Month 12</title>
          <description>Work performance of participants on number of days bothered was based on 10-point scale, where higher score indicated lower work performance.</description>
          <population>FAS: all randomized participants who received at least 1 dose of study drug and had at least 1 post-baseline and baseline measurement (for change from baseline endpoint). n=number of participants evaluable at specific time points for each arm group, respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="101"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.18" spread="2.65"/>
                    <measurement group_id="O2" value="1.92" spread="2.50"/>
                    <measurement group_id="O3" value="2.69" spread="2.66"/>
                    <measurement group_id="O4" value="2.23" spread="3.02"/>
                    <measurement group_id="O5" value="1.93" spread="2.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline Through Month 12</time_frame>
      <desc>The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>CP-690,550 5 mg (Up To Month 3)</title>
          <description>CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 3.</description>
        </group>
        <group group_id="E2">
          <title>CP-690,550 10 mg (Up To Month 3)</title>
          <description>CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 3.</description>
        </group>
        <group group_id="E3">
          <title>Placebo (Up To Month 3)</title>
          <description>Placebo matched to CP-690,550 tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week for 3 months. Response was assessed at Month 3 and participants who failed to achieve at least 20% reduction from baseline in both swollen and tender joint counts, received CP-690,550 5 mg or 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12. At Month 6, remaining participants received CP-690,550 5 mg or 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
        </group>
        <group group_id="E4">
          <title>Adalimumab (Up To Month 3)</title>
          <description>Adalimumab 40 mg injection subcutaneously once every other week along with placebo matched to CP-690,550 5 mg tablet orally twice daily up to Month 3.</description>
        </group>
        <group group_id="E5">
          <title>CP-690,550 5 mg (Month 3 to 6)</title>
          <description>CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week from Month 3 to Month 6.</description>
        </group>
        <group group_id="E6">
          <title>CP-690,550 10 mg (Month 3 to 6)</title>
          <description>CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week from Month 3 to Month 6.</description>
        </group>
        <group group_id="E7">
          <title>Placebo (Month 3 to 6)</title>
          <description>Placebo matched to CP-690,550 tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week for 3 to 6 months. Response was assessed at Month 3 and participants who failed to achieve at least 20% reduction from baseline in both swollen and tender joint counts, received CP-690,550 5 mg or 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12. At Month 6, remaining participants received CP-690,550 5 mg or 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week up to Month 12.</description>
        </group>
        <group group_id="E8">
          <title>Adalimumab (Month 3 to 6)</title>
          <description>Adalimumab 40 mg injection subcutaneously once every other week along with placebo matched to CP-690,550 5 mg tablet orally twice daily from Month 3 to Month 6.</description>
        </group>
        <group group_id="E9">
          <title>CP-690,550 5 mg (Post Month 6)</title>
          <description>CP-690,550 5 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week from Month 6 to Month 12.</description>
        </group>
        <group group_id="E10">
          <title>CP-690,550 10 mg (Post Month 6)</title>
          <description>CP-690,550 10 mg tablet orally twice daily along with placebo matched to adalimumab 40 mg injection subcutaneously once every other week from Month 6 to Month 12.</description>
        </group>
        <group group_id="E11">
          <title>Adalimumab (Post Month 6)</title>
          <description>Adalimumab 40 mg injection subcutaneously once every other week along with placebo matched to CP-690,550 5 mg tablet orally twice daily from Month 6 to Month 12.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRAv13.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="11" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="10" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="7" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune thyroiditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anal polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Diverticular perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Salivary gland calculus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Peptic ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Labyrinthitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Sialoadenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Breast abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Clostridial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Gallbladder empyema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Lung abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Salpingo-oophoritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Scapula fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Tendon disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Hair follicle tumour benign</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Metastatic renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Ovarian germ cell teratoma benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Benign salivary gland neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Cervix carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Cholesteatoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Myelodysplastic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Neuroma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>IgA nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cervix disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Ovarian torsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Hydrothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Pulmonary sarcoidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Prurigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cholecystectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRAv13.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="50" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="18" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="36" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="44" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="24" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="7" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="10" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="6" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="8" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="5" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="9" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="6" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="5" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="7" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="201"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="232"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="260"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="253"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

